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Cancer remains one of the major causes of morbidity and mortality globally. Many novel and 
innovative approaches have been employed to develop new chemotherapeutic strategies, of 
which targeted therapies aim to identify a molecular lesion or dysregulated pathway that 
cancer cells are dependent on. Research in our laboratory and others identified the nuclear 
import protein, Karyopherin β1 (KPNB1), to be overexpressed in various cancers and that 
inhibiting its expression blocks the proliferation of cancer cells. However, little is known about 
the potential role of KPNB1 in other cancer cell phenotypes and inflammatory signalling 
pathways. The aim of this study was to investigate the anticancer and anti-inflammatory 
effects of inhibiting nuclear import via KPNB1 and to characterise the in vivo effect of the small 
molecule inhibitor of nuclear import, INI-43, on tumour formation. Using siRNA and a small 
molecule inhibitor, INI-43, to inhibit KPNB1 we found that cervical cancer cell migration and 
invasion was significantly reduced. The reduced motility of cancer cells was associated with a 
decrease in MMP-2 and -9 expression and an increase in TIMP-1 and -2 expression following 
INI-43 treatment. This corresponded with a decrease in MMP-9 gelatinase activity in KPNB1-
inhibited cervical cancer cells. Extended periods of KPNB1 inhibition lead to decreased 
proliferation and apoptosis.  
 
These changes in cancer cell biology when KPNB1 is inhibited may in part be due to its function 
as a nuclear transporter of transcription factors associated with cancer cell proliferation, 
migration and invasion. We therefore investigated the effects of KPNB1 inhibition on the 
nuclear localisation and transcriptional activity of key transcription factors; NFkB and AP-1, 
both having been implicated in many of the hallmarks of cancer. Immunofluorescent analysis 
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and nuclear/cytoplasmic fractionation assays showed that KPNB1 inhibition blocked the 
nuclear localisation of NFkB. Electromobility shift assays confirmed a reduced NFkB binding to 
an NFkB DNA-binding sequence in the nuclear extract of KPNB1-inhibited cells. Luciferase 
reporter assays containing NFkB and/or AP-1 consensus binding sites showed reduced 
transcriptional activity for both transcription factors following KPNB1 inhibition. Associated 
with these changes in NFkB and AP-1 activity was reduced inflammatory cytokines; IL-6, IL-1β, 
TNF-α and GM-CSF target gene expression.  
 
To further characterise the role of INI-43 as a potential chemotherapeutic, the effects on 
tumour growth and development were investigated in an ectopic xenograft mouse model. INI-
43 treatment significantly reduced tumour growth in mice and associated with the 
redistribution and reduction in KPNB1 levels. INI-43 treated tumours also showed altered 
morphological features including; better tissue differentiation and reduced inflammatory 
stromal infiltration, as well as reduced Ki-67 expression. The expression of extracellular matrix 
components and the cytoskeletal structure of cancer cells was analysed to further investigate 
the role of KPNB1 inhibition in tumour development. Inhibition of KPNB1 in cancer cells 
caused reduced expression of both collagen type IV and MMP-9. The redistribution of B-
catenin and F-actin suggested that INI-43 treatment caused a loss of mesenchymal features 
required for tumour progression.   
 
The nuclear transport system has been of particular interest in recent years for the 
development of targeted anticancer drugs. However, most studies have focused on nuclear 
export inhibitors with little known on the potential of nuclear import inhibitors as anticancer 
drugs. This study provides evidence that inhibiting the nuclear import protein, KPNB1, has 
anti-inflammatory and anticancer effects and shows promise as an anticancer approach 
requiring further investigation.  
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CHAPTER 1  
LITERATURE REVIEW 
            
 
1.1 Cancer burden 
 
Cancer remains one of the major causes of morbidity and mortality globally. The latest World 
Cancer Report of 2014 together with GLOBOCAN 2012 detail the global impact of cancer [1, 
2]. In 2012, 14.1 million new cancer cases were diagnosed with 8 million cancer-related 
deaths. It is predicted that this statistic will rise to over 20 million new annual cancer cases by 
2025. Cancer is a multi-factorial disease with an ageing and growing population contributing 
to the increased incidence and demographic distribution of cancer cases despite advances in 
prevention, diagnosis and therapy for cancer. Among the most common cancers globally 
including; lung, breast, prostate and colorectal and cervical cancer which is the fourth most 
common cancer among woman. Statistics for low to middle income countries however, show 
that cervical cancer is still often the most common cancer among woman. Risk factors for 
cancer include what are considered as “lifestyle choices” such as tobacco use, obesity, 
infections and sun exposure as well as non-modifiable risk factors including; familial genetic 
background, race or reproductive and hormonal history. Carcinogen exposure also includes; 
air/water pollution, foods, drugs or other consumer products. This adds to the challenge of 
developing cancer prevention strategies. Infection is considered a strong risk factor for 
specific cancers including cervical cancer. In Sub-Saharan Africa, 33% of cancer cases in 2008 
were attributable to infections which is the highest globally. In countries like South Africa 
infection with HIV can substantially increase the risk of virus-associated cancers due to 
immunosuppression. One such cancer is cervical cancer. HIV infection is known to increase 
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the risk of HPV-related neoplasias [3-6]. These statistics highlight the necessity for continued 
research in the field of oncology. Understanding cancer cell biology is essential for the 
development of rationally designed, targeted therapy and other preventative and therapeutic 
strategies. 
 
1.2 Conventional therapeutic strategies for cancer and their limitations  
 
Early treatment is the determining factor for patient survival. The success of such treatment 
may vary greatly depending on the type and stage of cancer, the patient’s age, health 
condition and medical history. The ultimate goal of treatment is cure but it also has 
advantages in palliation, prolonging survival and preventing metastasis. The current approach 




This form of cancer therapy is generally the first line of approach should the nature of the 
tumour allow for it. It involves surgically removing solid tumours and surrounding tissue to 
prevent possible dissemination. Surgery is normally performed in conjunction with 
chemotherapy and/or radiation therapy. This technique is limited to self-contained, solid 
tumours as it has little use for haematological cancers or disseminated tumours.  
 
ii) Chemotherapy 
Conventional cancer chemotherapeutics are targeted towards actively dividing cells. These 
drugs usually disrupt the cell cycle either in a phase-specific or non-specific manner but can 
also utilise other mechanisms of action.  The first type of chemotherapeutic drugs belonged 
to the class of alkylating agents and begun use in the early 1940’s. Alkylating agents act at any 
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stage in the cell cycle and cause irreparable DNA damage which leads to cell death. Several 
categories of compounds fall into this class including the metal salts such as Cisplatin [7].  Two 
other common classes of chemotherapeutics are; anti-metabolites and natural products. Anti-
metabolites are folic acid, pyrimidine and purine analogues; common components used in 
nucleic acid synthesis. These drugs normally cause cell death during S phase of the cell cycle 
when they are incorporated into RNA and DNA or inhibit enzyme function required for nucleic 
acid production. Methotrexate is a common example of an anti-folate while 5’-fluorouracil is 
a pyrimidine analogue [8]. Natural products include a range of taxanes, topoisomerase 
inhibitors and anthracyclines (antibiotics). The antibiotic, Doxorubicin, is among the most 
effective and commonly used chemotherapeutic agents against solid tumours [9]. While the 
goal of chemotherapy is to cure the cancer, prolong survival, provide palliation and 
radiosensitise cancer cells it is often at the cost of severe toxic side-effects. Many of the 
conventional chemotherapeutics are hydrophobic, requiring the use of solvents, which 
increases their toxicity [10]. Their cytotoxicity is also not selective for cancer cells and severe 
side-effects are not uncommon. These limitations including the development of drug 
resistance emphasises the need for more effective and specific chemotherapeutic strategies.   
 
iii) Radiation therapy 
This technique uses high-energy radiation such as X-rays, gamma rays and charged particles 
to shrink tumours and kill cancer cells by causing DNA damage [11]. Radiation therapy is often 
used in combination with surgery and/or chemotherapy. As with surgery this technique is also 
limited to solid tumours and is not particularly useful for haematological cancers and 
disseminated tumours. Although radiation therapy can be isolated to a specific region of tissue 





1.3 Developing new chemotherapeutic strategies 
 
Many novel and innovative approaches have been employed to develop new 
chemotherapeutic strategies against cancer cells. These approaches may not all seek to 
replace current strategies but also to incorporate them into combination therapies either with 
each other or with conventional chemotherapeutic approaches. The following areas of 
research; personalised medicine, targeted therapies and immunotherapy are making 
significant contributions to the field of chemotherapeutics in recent years. 
 
i) Personalised medicine  
Personalised medicine is also referred to as precision medicine or genomic medicine. This 
relatively new therapeutic strategy is generating a wealth of information with potential for 
cancer prevention and treatment. The first full genome sequence was obtained in 2003. 
Through sequencing the genome, it has been proposed that treatment decisions can be made 
on the tumours genetic signature rather than based on tumour tissue type or anatomical 
origin. The genetic makeup of individuals is unique and similarly for their tumours therefore 
it is predicted that personalising treatment may maximise efficiency while minimising toxicity 
[12]. Genetic alterations in genes associated with cancer such as; HER2 in breast cancer, KRAS 
in colorectal cancer and BCR-ABL in chronic myeloid leukaemia, highlight the value of genetic 
screening in treatment decision making [13-15]. The Personalized Oncogenomics Program 
which is run by The BC Cancer Agency started in 2012 and incorporates genomic sequencing 
into real-time treatment planning for a cohort of patients with late stage incurable cancers. 
This oncogenomics trial has to date enrolled 750 patients and has shown promise for this 
approach in future chemotherapeutic strategies [16].  The high cost associated with such an 





ii) Small molecules in targeted cancer therapy 
The Human Genome Project which enabled the sequencing of DNA has led to the advance of 
technology that can detect genomic, transcriptomic, proteomic and epigenetic alterations. 
This has aided in the development of targeted therapies with potential for great success. The 
basic approach of targeted therapy is to identify a molecular lesion or pathway that cancer 
cells are dependent on and develop an appropriate drug to inhibit its function. This process 
often takes advantage of the oncogenic addiction pathways in cancer. Targeted therapy 
received prominence in the late 1990’s with the introduction of the small molecule inhibitors; 
Imatinib targeting BCR-ABL in chronic myeloid leukaemia and Getfitinib targeting the EGF 
receptor in non-small cell lung cancer [17-19]. A variety of small molecule inhibitors have been 
approved by the FDA to date and include targets such as CD20 for non-Hodgkin’s lymphoma, 
EGFR for colorectal cancer, CD33 and CD52 for leukaemia and VEGF for colorectal and non-
small cell lung cancer [20].  The advantage with small molecules is their ability to target 
proteins located within the cellular compartment in addition to proteins on the surface of 
cancer cells.  
 
Transcription factors found to be overactive in cancer may also make potential targets for 
anticancer drugs. They were previously thought of as “undruggable” targets because of the 
relatively large interacting surface between the transcription factor and the DNA [21]. These 
proteins are activated through signal transduction pathways beginning with activation of a 
receptor by a ligand, a cascade of intracellular signalling leading to the translocation of the 
transcription factor into the nucleus where it can bind the DNA and initiate gene expression. 
Points of interception in these signalling pathways may include receptor-ligand binding, kinase 





















The major families considered as targetable transcription factors in cancer include 1) NFkB 
and AP-1 families, 2) STAT family and 3) Steroid receptors [22]. Further detail on NFkB and AP-
1 transcription factors and their contribution to cancer will be discussed in sections 1.6 and 
1.7. A feature essential for transcription factors is their translocation from the cytosol into the 
nucleus where they have function. Darnell (2002) proposed that inhibiting nuclear transport 
may be a reasonable target to inhibit several transcription factors that are overactive in cancer 
cells [23]. 
 
Figure 1.1: A generalised signal transduction pathway. Key reactions are summarised in the 




While targeting a single dysregulated protein has value in many cancers it may be less useful 
in cancers originating from carcinogen-induced genetic aberrations where there are multiple 
competing molecular signalling pathways. (e.g. tobacco-induced lung cancer or UV-induced 
melanoma). This emphasizes that in some cases more than one pathway needs to be targeted 
or a combination treatment strategy needs to be employed.  
 
iii) Immunotherapy 
The role of the immune system in preventing and controlling cancer has long been studied but 
only in the last two decades have there been new therapeutic strategies developed to use the 
immune system to target cancer tumours. Immunotherapy involves one of two strategies 
either targeting the tumour cells directly or activating the immune cells to in turn target the 
cancer cells. Targeting the tumour directly has been successfully achieved through the use of 
monoclonal antibodies. These monoclonal antibodies are designed to bind specific receptors 
or antigens on the surface of cancer cells, marking them for immune destruction. In 1997 the 
first monoclonal antibody, Rituximab, was used to treat lymphoma [24]. Since then many 
monoclonal antibodies have been approved by the FDA for the treatment of cancer. An 
example includes; Trastuzumab targeting the HER2 receptor in breast cancer [20]. This 
technology has the potential to conjugate radioisotopes or other cytotoxic molecules to the 
antibodies to achieve targeted delivery to the tumour and enhanced effectiveness [25-27]. 
New surface receptors and cancer-specific antigens are continually being discovered 
presenting opportunities for the design of new monoclonal antibodies as therapeutics.  
  
Therapies designed to activate the immune system include cancer vaccines, check point 
inhibitors and immune system boosters. Cancer vaccines aim to induce anti-tumour T-cells by 
immunising patients with either tumour-specific or tumour-associated antigens. To date only 
one cancer vaccine has been approved by the FDA. Sipuleucel-T used for the treatment of a 
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type of metastatic prostate cancer [28]. Nonetheless successful clinical trials using cancer 
vaccines still provides hope for their use as a therapeutic strategy.  A second strategy is to 
simply enhance the function of pre-existing anti-tumour T cells. The tumour develops several 
strategies to evade the host immune response and these are collectively known as immune 
check points. These immune check points can render endogenous anti-tumour T-cells 
ineffective [29]. Specific checkpoint inhibitors could override this immune evasion restoring 
function to these T-cells. Two successful checkpoint targets have been cytotoxic T-
lymphocyte-associated antigen 1 (CTLA-1) in patients with metastatic melanoma and the 
programmed death 1 (PD-1) pathway in patients with relapsed or refractory Hodgkin’s 
Lymphoma [30, 31]. Lastly immune system boosters can be used in the form of cytokines or 
immunomodulating drugs. Cytokines are naturally produced by cells of the immune system 
and modulate immune and inflammatory reactions within the body. The use of interferon 
alpha (IFN-α) and interleukin 2 (IL-2) have both been successful in the treatment of a small 
subset of melanoma patients [32]. The upregulation of a widespread T-cell response can 
unfortunately lead to non-specific side effects.    
 
1.4 Hallmarks of cancer 
 
The development of cancer is associated with an accumulation of genetic alterations leading 
to the gain of function of genes promoting cancer (oncogenes) and the loss of function of 
genes (tumour suppressor genes) preventing it. Hanahan and Weinberg (2000) initially 
described six essential alterations in cell physiology that together are responsible for 
malignant growth [33]. In a subsequent review, two additional hallmarks of cancer were 
added as well as two enabling factors critical for the development of cancer (Fig. 1.2) [34]. The 





















i) Sustaining proliferative signalling 
Possibly one of the most essential traits of cancer cells is the ability to sustain proliferation. In 
normal cells, growth signals are tightly controlled by mitogenic factors that instruct cells to 
move from a quiescent state to a proliferative one. Cancer cells lose their dependence on 
exogenous growth signals and are thought to produce their own which allows them to be in 
control of their own proliferative state. This process is mediated by various oncogenes.  
 
ii) Evading growth suppressors 
Antigrowth signals normally exist to counter balance the growth promoting signals. They can 
act by either forcing actively proliferating cells into a quiescent state or by permanently 
Figure 1.2: The Hallmarks of cancer including the acquired characteristics and enabling factors. 
From Hanahan and Weinberg, 2011. 
12 
 
relinquishing their proliferative potential. Cancer cells have to overcome these anti-
proliferative signals in order to succeed. Disruption of the retinoblastoma protein (pRb) or the 
tumour suppressor protein, p53, are most commonly responsible for the ability to evade anti-
growth signals.  
 
iii) Resisting cell death 
The carefully orchestrated cascade of events leading to cell death by apoptosis is essential for 
removing damaged cells. The alteration of tumour suppressor genes in cancer cells allows 
them to evade cell death.  
 
iv) Enabling replicative immortality 
The combined effects of self-sufficiency from growth signals, evading growth suppressors and 
resisting cell death lead to an unlimited ability of cancer cells to replicate.  This allows tumours 
to continue expanding beyond the confines of their environment.  
 
v) Activating invasion and metastasis 
Cancer cells acquire invasive properties in order to escape the confines of the primary site and 
occupy secondary locations. This is accomplished by epithelial-to-mesenchymal transition 
(EMT), a complex network of events that occurs in cancer cells at the invasive front of the 
tumour. The cells in this position receive stimuli from the surrounding microenvironment that 
drive these phenotypic changes. Epithelial cancer cells begin to lose their adherens junctions 
and expression of epithelial genes such as E-cadherin. While increasing the expression of 
mesenchymal genes such as vimentin and taking on a more spindle-shaped morphology. This 
is accompanied by the increased expression of matrix-degrading enzymes, enhancing motility, 
as well as a heightened resistance to apoptosis. Once cancer cells obtain these abilities they 
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are able to intravasate and disseminate to a secondary location leading to metastasis. 
Metastasis associates with a poor prognosis in many cancers.     
 
vi) Inducing angiogenesis 
As tumours grow their demand for nutrition and oxygen exceeds the supply and the growth 
of new blood vessels needs to be stimulated in order to compensate for this.   Cancer cells are 
capable of producing signals that induce angiogenesis.  
 
vii) Avoiding immune destruction 
Essentially cancer cells are not foreign to the human body. Although the immune system is on 
high alert for developing cancer cells they can produce various signals modulating the immune 
response and thereby escape detection and destruction.  
 
viii) Deregulating cellular energetics 
The development of chronic proliferation needs to be accompanied by an adjustment in 
energy metabolism to sustain the proliferative demands of these cells. Cancer cells favour 
glycolysis to be able to still produce for their biomass creation and meeting their energy needs 
under limited oxygen conditions.  
 
In addition to these hallmarks of cancer two enabling characteristics have been described 
which contribute to the acquisition of these hallmarks. These are tumour-promoting 
inflammation and genomic instability. The tumour microenvironment is infiltrated with host 
immune cells and while previously this was thought to play a role in tumour eradication in fact 
the opposite was true and a state of inflammation was found to fuel cancer initiation and 
progression. The development of genomic instability arises from an accumulation of random 
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mutations that confer an advantage in cancer cells by assisting in acquiring the cancer 
hallmarks.   
 
1.5 Inflammation and cancer 
 
Inflammation forms part of the innate immune response and acts typically in a normal host 
response to bacterial or viral infection as well as being critical in the process of wound healing. 
Tissue injury triggers a cascade of events involving the activation and recruitment of immune 
cells such as monocytes, neutrophils and eosinophils to the site of injury. Neutrophils are 
normally the first immune cells to enter the site of injury from the surrounding vasculature 
while macrophages, formed from monocytes in tissue, follow closely after. Macrophages are 
the main source of chemokines, cytokines and growth factors which severely influence the 
neighbouring tissue. Chemokines are responsible for the recruitment of specific immune 
effector cells and components, which dictate the progression of the inflammatory process. 
Cytokines can be pro-inflammatory or anti-inflammatory and maintain a critical balance in 
wound healing. Although wound healing and inflammation are normally self-limiting 
processes a disruption in the balance of pro-inflammatory and anti-inflammatory signals could 
result in a chronic inflammatory state [35].   
 
Inflammation was first linked to cancer in the 19th century when Virchow discovered 
leucocytes present in tumours [36]. In more recent years there has been extensive research 
investigating the connection between inflammation and cancer. A chronic inflammatory 
environment where there is sustained proliferation of cells, high concentrations of 
inflammatory cells, cytokines, chemokines, growth factors and DNA-damage promoting 
agents can potentially promote neoplastic formation [37]. Wound healing can fail to terminate 
when the highly susceptible proliferating cells sustain DNA damage or mutagenic assault and 
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continue growing in an inflammatory environment characteristic of a tumour. Invasive tumour 
growth mimics wound healing as neoplastic cells produce an array of cytokines and 
chemokines to attract leucocytes such as neutrophils, dendritic cells, macrophages, 
eosinophils, mast cells as well as lymphocytes [37]. Factors that result in chronic inflammation 
which have been linked to cancer include; Human Papilloma Virus infection and cervical 
cancer, inflammatory bowel disease and colon cancer and Helicobacter pylori infection and 
gastric cancer [38, 39]. Inflammatory components are also present in tumours not originating 
from inflammatory conditions. Although chronic inflammation may play an important role in 
the initiation of cancer, post-tumour inflammation has been associated with the maintenance 
of a pro-tumourigenic microenvironment. When tumours outgrow their nutrient supply they 
become necrotic in the centre which causes the release of pro-inflammatory mediators to 
promote neoangiogenesis, cancer cell survival and the recruitment of innate immune cells. 
The presence of pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α have been 
implicated in promoting tumour progression, migration and invasion [36, 40, 41]. Radiation 
and chemotherapy have also been known to initiate a tumour-associated inflammatory 
response. These treatments achieve this by causing necrotic cell death of the tumour cells and 
surrounding tissue which triggers the body’s natural immune response [42]. This reaction has 
been implicated in the resistance to anticancer treatments [43].  
 
1.5.1 Chemokines and cytokines associated with cancer development 
 
The tumour microenvironment contains various innate immune cells; macrophages, 
neutrophils, natural killer cells, dendritic cells and mast cells; T and B lymphocytes; cancer 
cells; cancer-associated fibroblasts and surrounding stromal factors. A network of 
communication occurs between these cells via the release of cytokines and chemokines or 
through direct contact to maintain and promote tumour growth and metastasis [34, 44]. 
16 
 
Tumour-associated macrophages (TAMs) have an important role in inflammation in neoplastic 
tissue. They play a dual role in the tumour microenvironment as they can kill tumour cells 
when activated by IL-2, IFN-γ and IL-12 but also produce a host of potent growth factors, 
cytokines and proteases that potentiate tumour progression [45]. Tumour cells have the 
ability to mimic immune cells by producing their own cytokines and chemokines and thereby 
controlling processes within the tumour microenvironment [46-48]. TAMs and tumour cells 
produce IL-10 which suppresses the anti-tumour response by cytotoxic T cells [37]. Stromal 
cells surrounding and integrating with the tumour site play an active role in tumorigenesis and 
contribute to metastasis by secreting matrix metalloproteases (MMPs). Inflammation at the 
tumour site is thought to sustain many hallmarks of cancer such as producing growth factors 
that sustain proliferation, survival factors that limit cells death, proangiogenic components, 
extracellular modifying enzymes promoting invasion and producing inductive signals which 
activate the epithelial-to-mesenchymal transition [34, 49]. Transcription factors such as NFkB 
and AP-1 are key regulators in the expression of chemokines and cytokines. Although an 
inflammatory response can be initiated in the absence of NFkB this is rarely the case [50]. 
 
The following section will discuss the role of key transcription factors, such as NFkB and AP-1, 
in inflammatory signalling and cancer.  
 
1.6 The Nuclear factor kappa B (NFkB) signalling pathway 
 
Nuclear factor kappa B was first identified as a regulator of κB light chain expression in mature 
B lymphocytes. Induction of NFkB activity by exogenous stimuli was shown in various cell types 
through stimulation with lipopolysaccharide (LPS), cyclohexamide and phorbol esters [51, 52].  
NFkB is expressed in most cell types and many genes have NFkB binding sites in their promoter 
or enhancer regions. The broad spectrum of NFkB activity requires tight regulation. Signalling 
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through the NFkB pathway allows cells to respond to environmental change and is therefore 
critical for their survival [53]. Pahl (1999) reviewed an extensive list of NFkB activators. 
Common activators include; cytokines (IL-1, TNF-α), products of infection (LPS, dsRNA), 
antigen receptors (TCR, BCR), genotoxic stress (UV, γ-radiation) as well as therapeutically used 
drugs (Cisplatin, Tamoxifen, Doxorubicin) [54].  
 
In mammals the NFkB family consists of five proteins; p65 (RelA), RelB, c-Rel, p105/p50 
(NFkB1) and p100/p52 (NFkB2). A combination of these proteins form 15 different 
homodimeric and heterodimeric complexes of which the p65/p50 heterodimer is the most 
abundant. Signalling by NFkB occurs through two distinct pathways namely the classical and 
alternative pathways. The classical pathway results in the activation of the p65/p50 dimer that 
initiates the transcription of inflammatory mediators and inhibitors of apoptosis. This pathway 
is activated in an innate immune response by a variety of inflammatory signals including IL-1β 
and TNF-α which bind to their respective receptors on the surface of the cell. This leads to the 
recruitment and activation of the IKK complex which then phosphorylates the inhibitor of κB 
(IκB) leading to its degradation by the proteasome. The p65/p50 subunits are released and 
transported into the nucleus via specific nuclear importers where it induces transcriptional 
activation (Fig. 1.3) [23, 55]. IκB interacts with both the p65 and p50 proteins in their 
dimerized form to mask the nuclear localisation sequence (NLS) thereby causing their 





















While the classical NFkB activation pathway is important for inflammatory signalling, the 
alternative pathway plays a more significant role in the adaptive immune response [55]. This 
pathway is activated by B-cell activation factor (BAF), CD40 and lymphotoxin β-receptor (LTβR) 
leading to the activation of IKKα by the NFkB-inducing kinase (NIK). IKKα then phosphorylates 
p100 leading to the polyubiquitination of p100 and subsequent proteasomal processing to 
p52. RelB then dimerizes with p52 and together they are transported into the nucleus to 
initiate transcriptional activation [57]. Apart from the phosphorylation and ubiquitination of 
IκB and IKK complexes, protein modifications of the subunits which include phosphorylation, 
ubiquitination and acetylation also play a role in tightly regulating NFkB signalling.  
Autoregulatory feedback loops also exist as IκBα and p105 are target genes of NFkB. In an 
unstimulated state NFkB proteins remain inactivated and retained in the cytoplasm however, 
Figure 1.3: The Classical NFkB signaling pathway. The signaling pathway resulting in the activation of 





constitutively active NFkB has been found in mature B cells, macrophages, neurons, vascular 
smooth muscle cells as well as in many tumours [53].  
 
1.6.1 NFkB: The link between inflammation and cancer 
 
In addition to the pro- and anti-inflammatory roles of NFkB, there is substantial evidence in 
the literature suggesting that NFkB has a key tumour-promoting role in cancer. The first clue 
that NFkB was linked to cancer was apparent with the cloning of p105/p50 and later RelA and 
the observation of the close relation to the avian viral oncoprotein v-Rel and its cellular 
homolog c-Rel [58]. The p100/p52 gene has also been found to be rearranged in B-cell and T-
cell lymphomas which gave rise to a truncated p100 protein devoid of its native IκB-like 
activity [59]. To date, no mutations in the IκB-NFĸB system have been identified in other 
cancers but rather the increased presence of activated nuclear NFĸB has been associated with 
an increase in inflammation promoting carcinogenesis. The increased activity of NFkB 
observed in cancer may be due to mutations in genes coding for upstream signalling proteins 
that feed the NFkB pathway or the exposure to pro-inflammatory stimuli within the tumour 
microenvironment [57, 60-63].  
 
NFkB is most commonly associated with innate immunity, mediating the inflammatory 
response. There are however, several other cellular processes where NFkB plays a critical role. 
It is involved in the promotion of cell proliferation and suppression of cell death. NFkB controls 
the expression of key cell cycle regulatory genes: cyclin D1, D2 and D3; cyclin E1; c-myc and 
CDK 2, 4 and 6. It also regulates growth signals like GM-CSF and IL-6 [64, 65]. A study by 
Jourdan et al. (2007) showed that the inhibition of IKKβ resulted in a block in cell cycle 
progression in multiple myeloma [66]. While NFkB also induces expression of genes encoding 
anti-apoptotic molecules thereby supressing cell death pathways and further promoting 
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growth [67]. Resistance to apoptosis in human cancer cell lines is potentially linked to 
activation of NFkB because subsequent inhibition of NFkB allowed apoptosis to be triggered 
more easily [64]. Failure of chemotherapeutics has been associated with NFkB-induced 
apoptotic resistance [68]. The progression of localised tumours to metastatic cancer involves 
changes in the relationship between cancer cells and the extracellular matrix favouring 
migration and invasion. Classical NFkB activation has been implicated in epithelial-to-
mesenchymal transition (EMT), a process leading to invasion and metastasis. Inhibition of 
NFkB was able to reverse EMT in mesenchymal cells [69]. NFkB is also implicated in metastasis 
through the expression of various matrix-modifying enzymes (MMP-2/-9) and adhesion 
proteins (VCAM-1, ICAM-1) [70-73]. As the tumour expands and the demand for nutritional 
resources outweigh the supply, new blood vessels are required. Angiogenesis is largely 
triggered by NFkB signalling. NFkB inflammatory mediators and target genes; TNF-α, IL-1 and 
IL-6 can stimulate the expression of one of the main regulators of angiogenesis, vascular 
endothelial growth factor (VEGF). VEGF also happens to be a target gene of NFkB [64]. Given 
the broad range of cellular processes in which NFkB is involved it is not surprising that aberrant 
NFkB signalling is associated with carcinogenesis. Tumours observed to have high levels of p65 
include; breast and stomach adenocarcinoma, non-small cell lung cancer, multiple myeloma 
and B-cell non-Hodgkin’s lymphoma. High levels of p50 has been observed in; non-small cell 
lung cancer and colon, breast, prostate, bone and brain cancer cell lines [23]. 
 
Having previously discussed the causal link between inflammation and cancer and given the 
observed activated levels of NFkB in many cancers it was proposed that NFkB may be the 





1.6.2 Targeting NFkB for cancer therapy 
 
The diverse and essential role that NFkB plays in the maintenance of several of the hallmarks 
of cancer make it an attractive anticancer target. When designing an NFkB inhibitor the role 
of this transcription factor in normal cells and in innate immunity should be taken into 
consideration. The ideal inhibitor should be more active in cancer cells than normal cells and 
the effect should be transient or even reversible to avoid extended immunosuppression. 
Seven possible points of interception within the NFkB signalling pathway have been reviewed 
by Gupta et al. (2010). These points of interception include; 1) Inhibition of protein kinases 
within the IKK complex thereby inhibiting IκBα phosphorylation. 2) Inhibition by protein 
phosphatases which act as a counterbalance inhibiting kinase action. 3) Proteasome inhibition 
and IκB ubiquitination blockers as the ubiquitination and subsequent degradation of IκBα is 
an essential step for releasing NFkB from its cytoplasmic inhibitor. 4) Blocking nuclear 
translocation of NFkB as it is essential for it to be in the nucleus to bind the DNA. 5) Blocking 
NFkB activation by inhibiting p65 acetylation which occurs in the nucleus prior to DNA binding 
and is required for activation. 6) Blocking NFkB activation by methyltransferase as methylation 
of p65 acts as a negative regulator by causing the destruction of DNA-bound, active NFkB and 
lastly 7), the most direct strategy would be to block the transcription factor from binding the 
DNA sites required for target gene transcription [75].   
 
Intercepting the NFkB signalling pathway at the point of nuclear translocation of the 
transcription factor is of particular interest to our work. Nuclear import is mediated by the 
Karyopherin proteins. Detail on the nuclear transport system is described in section 1.8 below. 
Briefly, Karyopherin beta 1 (KPNB1), a nuclear import protein that works in unison or together 
with one of the 6 Karyopherin alpha (KPNA) adaptor proteins to transport proteins containing 
a nuclear localisation sequence (NLS) into the nucleus. NFkB proteins have been reported to 
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contain a NLS that is recognised by Karyopherin proteins. A series of peptides have been 
designed to mimic the NLS of p50/NFkB thereby interfering with the nuclear translocation of 
NFkB. The peptide, SN50, was able to target the classical NFkB signalling pathway inhibiting 
the translocation of NFkB into the nucleus of endothelial and monocytic cells [76]. The N50 
motif was found to interact with Karyopherin alphas during stimulus-induced signalling 
thereby inhibiting the nuclear import of NFkB. A study by Zienkiewicz et al. (1999), reported 
the N50 peptide preferentially binds KPNA1. KPNA1 has been shown to have a more significant 
role in importing the STAT1 transcription factor [77]. Despite this, SN50 is still a commonly 
used peptide for inhibition of NFkB in laboratory-based research [78, 79]. A similar peptide, 
SN52, blocked the nuclear import of the RelB:p52 dimer thereby targeting the alternative 
NFkB pathway without affecting the classical pathway [80]. A peptide also designed to mimic 
the p50 NLS and inhibit NFkB activity, likely similar to SN50, was found to reduce inflammation 
and oxidative stress in vascular cells and macrophages as well as protect mice from the 
development of atherosclerosis [81]. Theiss et al. (2009) found that overexpressing prohibitin 
1 in intestinal epithelial cells suppressed the expression of KPNA4 thereby inhibiting NFkB 
translocation [82]. There is conflicting evidence in the literature regarding which nuclear 
import proteins are responsible for transporting NFkB into the nucleus in the classical 
signalling pathway. Fagerlund et al. (2008) and Theiss et al. (2009) report that nuclear import 
of NFkB is mediated by KPNA3 and KPNA4 while Liang et al. (2013) report that the 
KPNB1/KPNA2 transport system is needed for NFKB transport [82-84].  
 
Several studies have reported that nuclear import inhibition of NFkB has anti-inflammatory 
effects in normal cells but far fewer have shown these effects in cancer cells. Small molecule 
inhibitors are classically designed to investigate the role of a particular protein in a disease 
condition. Newer small molecule inhibitors of NFkB include; dehydroxymethyl derivatives of 
epoxyquinomicin C. These (-)-DHMEQ compounds selectively inhibit NFkB by binding to it and 
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inhibiting its DNA binding activity and has also been found to inhibit its nuclear translocation. 
Even though these compounds have shown anti-inflammatory and anticancer activity in mice 
they have so far not been developed further for clinical use [85, 86]. 
 
Designing new drugs, testing them and acquiring FDA approval can be a very lengthy process. 
This together with the fact that the mechanism of actions of many approved drugs are not 
fully understood, has led scientists to re-evaluate and repurpose already FDA-approved drugs. 
Several known drugs have been found to have unappreciated inhibitory effects on NFkB. 
Drugs such as emetine, fluorosalan, sunitinib malate, bithionol, narasin, tribromsalan, and 
lestaurtinib were found to inhibit NFkB signalling through inhibition of IκBα phosphorylation 
and cause cell death in cervical cancer cells. While the cardiac glycosides, digitoxin and 
ouabain, inhibited NFkB activity and were potent inhibitors of cancer cell growth [87]. The 
anticancer effect of these drugs could well in part be attributed to their inhibitory effect on 
NFkB. Further research is required to design effective NFkB inhibitors, particularly ones that 
preferentially affect cancer cells. 
 
1.7 The Activating Protein 1 (AP-1) signalling pathway 
 
Activating Protein 1 (AP-1) is a transcription factor comprising of JUN, FOS, Activating 
Transcription Factor (ATF) and Musculoaponeurotic Fibrosarcoma (MAF) protein families that 
function in a dimeric complex. The combination of homo- and heterodimers constitutes 
functional AP-1. AP-1 most commonly consists of c-JUN and c-FOS homo- and heterodimers 
[88, 89].  Much like NFkB it is activated by inflammatory cytokines and growth factors as well 
as the phorbol ester, PMA [90]. Activation of AP-1 occurs through stimulation of the Mitogen 
Activated Protein Kinase (MAPK) pathway leading to phosphorylation of an AP-1 subunit 
allowing its dimerization and DNA-binding [91, 92]. Phosphorylation of the c-JUN component 
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of AP-1 occurs at the serine 63 and serine 73 residues of the protein [93]. The c-JUN N-terminal 
Kinase (JNK) most commonly performs this phosphorylation [94]. Once the subunits have 
been phosphorylated and dimerised they bind their respective DNA-binding sites and initiate 
transcription of various target genes. AP-1 target genes are involved in many cellular 
processes including; proliferation, differentiation, apoptosis, angiogenesis and tumour 
invasion [89, 95, 96]. The diverse role of AP-1 is also attributed to its interactions with other 
transcription factors such as; NFkB, NFAT, Sp1 and Smad [97-101].  
 
1.7.1 Altered AP-1 expression and activity associates with multiple aspects of cancer 
development  
 
The diverse role that AP-1 plays in normal cellular functioning it is not surprising given that 
increased expression of JUN and FOS family members is associated with several cancers [88, 
96, 102]. The c-JUN and c-FOS subunits have long been characterised as oncogenes by their 
homology to the Finkel-Biskis-Jinkins viral counterparts; v-JUN and v-FOS [103]. Upregulation 
of these proteins through overexpression or by RAS signalling pathways is well established in 
promoting transformation leading to tumourigenesis [88]. Many of the oncogenic properties 
manifest through the promotion of the “Hallmarks of Cancer”.  
 
AP-1 plays an important role in cell proliferation and survival primarily through the regulation 
of target genes; cyclin D1, p53, p21 and p16. Cell cycle progression is promoted when c-JUN 
is activated by JNKs leading to the expression of cyclin D1. While JunB and JunD have been 
reported to have anti-proliferative affects their expression is often repressed in highly 
proliferative tumours [89].  Similarly, the AP-1 family members can also have contrasting pro-
apoptotic and anti-apoptotic roles which could be mediated by the differential expression of 
pro- and anti-apoptotic target genes. c-JUN also plays a repressive role on the tumour 
25 
 
suppressor, p53, which in turn promotes survival. The effects of c-JUN on survival reported to 
be cell-specific [88, 96].  
 
Inflammation and angiogenesis have previously been established as critical components of 
cancer initiation and progression. Working synergistically with the transcription factor, NFkB, 
AP-1 can enhance the inflammatory response through the expression of cytokines; IL-6, IL-1 
and TNF-α [42, 97]. Several target genes of AP-1 have also been implicated in angiogenesis. c-
FOS was found to upregulate the vascular endothelial growth factor family member, VEGF-D. 
The FRA1 subunit upregulates urokinase-type plasminogen activator (uPA) and its receptor 
(uPAR) and c-JUN and JunB were found to upregulate proliferin [88]. 
 
Invasive tumour growth requires degradation of the extracellular matrix (ECM), EMT and 
migration of cellular components all of which require genes regulated by AP-1. Matrix 
metalloproteases are responsible for the degradation of the ECM and many have AP-1 binding 
sites including; MMP-1, MMP-3 and MMP-9. Inhibition of AP-1-mediated MMP-9 expression 
has been reported to inhibit the invasive ability of liver and breast cancer cell lines [88, 104-
106]. Both c-JUN and c-FOS are able to induce EMT by causing the loss of cell polarity [107, 
108]. The combined contribution of AP-1 in enabling the hallmarks of cancer makes it of 
interest as a transcription factor to target in cancer therapy.  
 
1.7.2 Targeting AP-1 for cancer therapy 
 
The MAPK activation pathway of AP-1 provides several opportunities to target AP-1 activity. 
However, given the diverse role of MAPK signalling proteins, inhibiting MAPK proteins may 
lead to effects not specifically related to AP-1. Few studies have focused on targeting AP-1 
directly. A dominant negative mutant of c-JUN, TAM67, that lacks the transactivation domain 
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but can dimerise with other AP-1 members and bind the DNA, has been shown to inhibit AP-
1 activity. TAM67 has been reported to reduce transformation and tumourigenesis [22, 109].  
 
To identify specific inhibitors of AP-1, Ruocco et al. (2007) used a high throughput cell-based 
assay. They screened libraries of synthetic compounds, pure natural products and natural 
product extracts. These authors report that geldanamycins, heat shock protein 90 inhibitors, 
could reduce c-JUN expression and JNK activation. While bryostatins, reserpines and nigericins 
reduced AP-1 activation through the modulation of protein kinase C [110]. Natural compounds 
such as dihydroguaiaretic acid and curcumin have been reported to directly target AP-1 by 
interfering with DNA binding of the c-JUN:c-FOS dimer. This inhibition had cytotoxic effects 
on leukemia, lung cancer and colon cancer cells in vitro [111]. Depending on the point of 
interception some compounds targeting signalling pathways resulting in the activation of 
specific transcription factors may be able to target more than one transcription factor 
simultaneously. The NFkB inhibitors of the SN50 family have also shown inhibitory effects on 
the nuclear localisation and activity of AP-1 [112, 113]. Finding new strategies to directly 
target the AP-1 oncogenes, c-JUN and c-FOS, could be beneficial as an anticancer approach. 
One such strategy is to target the nuclear import of these oncogenes. Nuclear import of the 
AP-1 subunit c-JUN has been suggested to be mediated through the non-classical nuclear 
import pathway, which functions independently of KPNA adaptor proteins. KPNB1 was found 
to have a significantly greater affinity for AP-1 than Karyopherin alpha and therefore is 





1.8 The Karyopherin family of nuclear transport proteins* 
 
The Karyopherin superfamily is a major class of soluble nuclear transport proteins consisting 
of both import and export proteins. The trafficking of proteins in and out of the nucleus is 
essential for proper cellular functioning and cell survival. Proteins greater than 20-40kDa in 
size are unable to enter the nucleus through the nuclear pore complex (NPC) unaided and rely 
on facilitated transport. This facilitated transport of numerous proteins is achieved by the 
action of Karyopherin proteins. The larger Karyopherin superfamily is subdivided into the 
Karyopherin beta/Importin beta family and the Karyopherin alpha/Importin alpha family. They 
function together to achieve the nuclear transport requirements of cargo proteins. To date, 
20 genes encoding Karyopherin beta proteins in the human genome have been identified. Ten 
are nuclear import proteins, seven are involved in nuclear export, two bidirectional 





                                                           
 




Table 1.1: Classification of nuclear transporters and their association to cancer 




Karyopherin beta 1 KPNB1
NTF97, IPOB, MGC2155, 
MGC2156, MGC2157, IMB1, 
Impnb, IPO1
YES
Transportin 1 TNPO1 KPNB2, MIP, TRN, IPO2, MIP1 -
Transportin 2 TNPO2




LGMD1F, TRN-SR, MTR10A, 
TRN-SR2, IPO12
-
Importin 4 IPO4 Imp4, FLJ23338 -
Importin 5 IPO5
KPNB3, RANBP5, IMB3, 
MGC2068, Pse1
-
Importin 7 IPO7 RANBP7, Imp7 -
Importin 8 IPO8 RANBP8, IMP8 -
Importin 9 IPO9 Imp9, FLJ10402 -
Importin 11 IPO11 RanBP11 -
Karyopherin alpha 1 KPNA1 SRP1, RCH2, NPI-1, IPOA5 -
Karyopherin alpha 2 KPNA2
RCH1, SRP1alpha, IPOA1, 
QIP2
YES
Karyopherin alpha 3 KPNA3
SRP1gamma, SRP4, hSRP1, 
IPOA4
-
Karyopherin alpha 5 KPNA5 SRP6, IPOA6 -
Karyopherin alpha 6 KPNA6
IPOA7, KPNA7, MGC17918, 
FLJ11249
-
Karyopherin alpha 7 KPNA7 IPOA2 YES
B) Export
Exportin 1 XPO1 CRM1, emb YES
CSE1 Chromosome Segregation 1-Like (Yeast) CSE1L CAS, XPO2, CSE1 YES





Exportin 7 XPO7 RANBP16, KIAA0745 -
Exportin t XPOT XPO3 -
Ran binding protein 17 RANBP17 -
C) Bidirectional
Exportin 4 XPO4 FLJ13046, KIAA1721 YES
Importin 13 IPO13 IMP13, KIAA0724, RANBP13 -
D) Uncharacterised
Ran binding protein 6 RANBP6 -
Karyopherin alpha 4 KPNA4





Nuclear import of cargo proteins is most commonly described by the Classical and Non-
















The Classical import pathway involves a Karyopherin alpha adaptor protein that recognises 
and binds a cargo protein containing a classical nuclear localisation sequence (NLS). Cargoes 
transported by the classical import pathway include STAT family members and GATA-3 [97]. 
The KPNA/cargo dimer is then bound by Karyopherin beta 1 (KPNB1) to form a trimeric 
complex that can pass through the NPC. The Non-Classical import pathway on the other hand 
bypasses the need for an adapter protein and the cargoes bind KPNB1 directly. A few unique 
cargo proteins such as sterol regulatory-related protein (SREPB2) and parathyroid hormone-
related protein (PTHrP) use this Non-Classical method of nuclear import [116]. Passage 
through the NPC is mediated by the interactions between Phe-Gly repeat-containing 
Figure 1.4: The Nuclear Import and Export pathways. In the Classical nuclear import pathway NLS-cargo 
is transported into the nucleus by KPNB1 and an adaptor protein, Karyopherin alpha (A). The nuclear 
transporters and cargo dissociate in the nucleus upon RanGTP binding. Karyopherin alpha is transported 
back into the cytoplasm by the export protein, CSE1L. The Non-Classical nuclear import pathway 
transports NLS-cargo into the nucleus using KPNB1 alone. The nuclear export pathway transports NES-
cargo from the nucleus into the cytoplasm stabilised by Ran GTP.  
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nucleoporins of the NPC and KPNB1. A key event, upon arrival in the nucleus, is the binding of 
RanGTP to the KPN/cargo complex promoting the dissociation of the import complex, allowing 
the cargo to remain in the nucleus and the transport proteins to be recycled [117, 118]. The 
nuclear export protein, CSE1L, is responsible for recycling the Karyopherin alphas back into 
the cytoplasm. Nuclear export of protein cargo is primarily achieved through Exportin 1 (XPO1) 
recognising a leucine-rich nuclear export signal (NES) on the cargo and binding it to it. RanGTP 
stabilises the XPO-1 bound NES-cargo complex that can then pass through the NPC towards 
the cytoplasm. The hydrolysis of RanGTP to RanGDP, in the cytoplasm, allows the dissociation 
of the export protein and the cargo (Fig. 1.4) [119].  Although the best described role of 
Karyopherin proteins is the nuclear import and export of cargo proteins they also play an 
important role in mitosis and other cell cycle-regulated functions including regulating the 
assembly of the NPC and nuclear membrane at mitotic exit as well as DNA replication at S-
phase [120, 121].      
 
1.9 Nuclear transport in cancer 
 
The Karyopherin proteins play a fundamental role in normal cell physiology by providing the 
means of trafficking between the cytoplasm and the nucleus as well as in other cellular 
processes such as mitosis. As intracellular localisation of many proteins, as well as the nuclear 
transporters themselves has an impact on their activity status and/or function, the correct 
spatial arrangement of proteins at the correct time is critical. It is therefore no surprise that 
impaired regulation of nuclear-cytoplasmic transport has been reported to associate with 
pathogenesis. A well-researched area is the association of nuclear transport dysregulation and 
cancer, which most commonly leads to the mislocalisation of cancer-associated cargo 
proteins. For example, the nuclear accumulation of the DNA repair protein, NBS1, has been 
shown to correlate with gastric cancer progression while the cytoplasmic accumulation of 
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Wilms' Tumour protein, Wt1, was observed more frequently in malignant tissues than normal 
[122, 123].  
 
Dysregulated activity of a number of Karyopherin proteins have been implicated in cancer 
(Table 1.1, [124-132]).  This literature review will focus on KPNB1/KPNA2-mediated nuclear 
import and XPO1-mediated nuclear export. There are many junctions in the nuclear transport 
pathways at which dysregulation can occur that have been reported to be linked to cancer. 
These forms of dysregulation include; the altered expression of the nuclear transporters, 
altered localisation of nuclear transporters and the mechanistic implications of nuclear 
transporters in mitotic division and genetic instability.  
 
1.9.1 Dysregulation of nuclear transporters 
 
Elevated expression of Karyopherin proteins that associates with the global dysregulation of 
protein transport has been observed in various types of cancer. Amongst all members of the 
Karyopherin family; XPO1, KPNB1 and KPNA2 are the most frequently reported to be 
overexpressed in cancer. Kuusisto et al. (2012) found that the increased expression of these 
Karyopherin proteins in transformed cells correlates with enhanced nuclear import and export 
efficiencies in transformed cells [133]. The increased expression and thus transport of cargos 
across the nuclear membrane is proposed to be a mechanism allowing cancer cells to cope 
with their increased metabolic and proliferative demands. The increased expression of import 
proteins, in particular, might allow for increased nuclear entry of proteins that have oncogenic 
tumour promoting functions, for example ERK1/2, c-Myc and E2F1 [134-136].  
 
The link between Karyopherin overexpression and cancer has been the subject of numerous 
studies however, few studies have addressed the underlying mechanism leading to their 
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overexpression. Using molecular and bioinformatics approaches, research in our laboratory 
showed that the overexpression of both KPNB1 and KPNA2 is primarily due to dysregulated 
E2F/Rb activity in cancer cells [129]. The constitutive activation of E2F in e.g. cervical cancer 
cells was found to associate with increased expression of both KPNB1 and KPNA2. It is well-
known that HPV infection in cervical cancer results in E2F dysregulation and thus elevated 
KPNB1 and KPNA2 in this cancer. The E2F/Rb pathway is disrupted in a remarkably high 
proportion of human cancers through other mechanisms leading to the same overexpression 
phenotype [137]. Interestingly, Kuusisto et al. (2015) showed that the extent of 
overexpression of KPNB1 correlates with disease state in the MCF10 human breast tumour 
progression system, suggesting that its overexpression not only correlates with E2F 
dysregulation, but can vary according to tumour progression state [138]. Other mechanisms 
for altered Karyopherin expression have been reported. A recent study showed elevated 
KPNA2 expression resulting from decreased expression of microRNA-26b in epithelial ovarian 
carcinoma. MicroRNA-26b directly targets KPNA2 by repressing its translation and thus 
reduced microRNA-26b resulted in elevated KPNA2 expression [139].  
 
Quan et al. (2008) used bioinformatic approaches to predict transcription factors that bind 
the promoter regions of Karyopherin beta genes and identified Sp1, NRF-2, HEN-1, RREB-1 
and NFY as potential regulators of Karyopherin beta expression [140]. In line with this, van der 
Watt et al. (2011) found that NFY and Sp1 are both potential contributors to XPO1 
overexpression in cervical cancer and transformed cells [129]. A study by Kahle et al. (2005), 
found that NFY-A is imported into the nucleus by KPNB1 where it acts to transcribe its 
downstream targets [141]. This finding could explain why elevated expression of KPNB1 has 
been observed concomitant with elevated XPO1 in cervical and gastric cancer [128, 130, 142]. 
van der Watt et al. (2009) also showed that under DNA damage conditions the elevated p53 
level plays a repressive role in the transcription of the xpo1 gene [128]. It is not surprising then 
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that XPO1 overexpression is commonly observed in cancer as p53 is often expressed at low 
levels or mutated in many cancers [143]. XPO1 has also been shown to be involved in p53 
nuclear export [128] suggesting that a possible feed-back regulatory mechanism may exist. 
Under DNA damage conditions p53 expression increases and enters the nucleus thereby 
repressing XPO1 expression. The reduced XPO1 expression will in turn enhance p53 retention 
in the nucleus further repressing XPO1 expression. In p53 deficient or mutant cells the 
repression of XPO1 expression is relieved, likely leading to XPO1 overexpression. 
 
The ability of nuclear transporters to efficiently execute their functions depends on their 
ability to interact correctly with other members of the transport cycle. A truncated KPNA 
lacking part of the cargo-NLS binding domain has also shown failure to interact with and 
transport p53 into the nucleus in breast cancer cells. Despite the KPNB1 binding domain 
remaining intact in the mutant KPNA, it was localized predominantly in the cytoplasm and 
perinuclear region as opposed to the even distribution observed in wildtype KPNA [144]. This 
suggests that cargo recognition and binding by KPNA is a prerequisite for nuclear entry of 
proteins such as p53, and that pairing with KPNB1 alone is not sufficient.  
 
When nucleo-cytoplasmic transport ceases, virtually all transport factors take on new roles in 
mitosis, acting in the functional organisation of the mitotic spindle and in the reconstitution 
of the interphase nucleus at mitotic exit. Modelling studies have indicated that subtle 
dysregulation of the expression of transport factors readily affects mitotic division and can 
cause significant abnormalities in chromosome segregation, whereas nucleo-cytoplasmic 
transport is a more robust process [145, 146]. Dysregulation of nuclear transport factors can 




The role of KPNB1 as a regulator of spindle formation and function is well described. KPNB1 
generally acts by preventing the premature localisation or activity of spindle regulatory factors 
[147]. Factors, with spindle assembly functions, regulated by KPNB1 include; the spindle pole-
organizing protein NuMA [148], the microtubule-regulatory protein HURP [149], Rae1/Nup98 
[150], a regulator of the Aurora-A kinase maskin [151] and APC [152] among others. KPNB1's 
physical association and regulation of the Adenomatous polyposis coli (Apc) oncogene, itself a 
microtubule-promoting and mitotic spindle-associated factor, may be of particular relevance 
to the onset of colon cancer [152]. A novel function through which KPNB1 can globally 
regulate the mitotic apparatus has recently emerged and relates to its ability to regulate, in 
concert with the APC/C ubiquitin ligase, the stability of mitotic spindle regulatory factors 
[153].  Karyopherin alpha family members although difficult to discuss collectively, share a 
common functional feature that their down-regulation induces substantial levels of apoptosis 
[154]. They contribute to mitotic control by interacting with key spindle regulatory factors 
such as TPX2 [155].  
 
The nuclear export protein, XPO1, has well defined mitotic effects exerted at various levels of 
mitosis. These include the mitotic spindle [156]; kinetochores, stabilizing 
microtubule/kinetochore interactions essential for chromosome segregation [157]; and 
centrosomes, preventing chromosome reduplication which constitutes a major threat to 
genome stability [158, 159]. These effects are mediated through several mitotic targets that 
contain NES sequences. The interplay between XPO1 and mitotic cyclin B is interesting to note. 
XPO1 contributes to cyclin B localization and in turn cyclin B-CDK 1 complex phosphorylates 
XPO1 to finely regulate its mitotic functions [160].  It has also been reported that XPO1’s 
interaction with survivin is important to target the chromosomal passenger protein to 




Nuclear transport plays a critical role in the functioning of many cellular processes. Because 
of this, cells have developed systems to tightly control the nuclear transport processes. Within 
each junction in the regulatory pathway lies an opportunity for errors to occur, and indeed 
many of these alterations have been associated with cancer.  
 
1.9.2 Nuclear transporters as potential diagnostic markers of cancer  
 
Late diagnosis of cancer is a major contributing factor to poor patient outcome. Often, by the 
time patients present at clinics, the cancer has already progressed to later stages and the 
chances of the primary tumour having already metastasised is relatively high. This highlights 
a need for effective tools for the early detection of cancer. The ideal biomarker would be 
unique to cancer and present in easily obtainable patient samples such as serum or urine. 
Nuclear transporters have already been shown to be upregulated at the protein level in many 
cancer tissues and a few studies have investigated these proteins as potential diagnostic 
biomarkers. Wang et al. (2011) investigated potential biomarker targets that were both 
significantly up-regulated in lung cancer tissues and secreted/released from lung cancer cells. 
They achieved this by integrating two lung adenocarcinoma cell line secretome datasets with 
one adenocarcinoma microarray dataset. Using this strategy they identified KPNA2 as a 
potential diagnostic biomarker for adenocarcinoma. Elevated KPNA2 serum levels were 
confirmed in a cohort of non-small cell lung carcinoma patients (n=126) in comparison to 
healthy individuals (n=64) [162]. Similar to what was observed in lung cancer patients, KPNA2 
levels in serum were also significantly upregulated in oesophageal squamous cell carcinoma, 
epithelial ovarian cancer and colorectal cancer patients versus healthy controls validating the 
potential of KPNA2 as a diagnostic biomarker[163-165]. KPNA2 has also been identified as a 
potential diagnostic biomarker that can differentiate between grades of astrocytoma. This 
however, still requires immunohistochemical validation. The conventional criteria for 
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differentiating between WHO grade II and III astrocytomas is particularly difficult to define. 
Gousias et al. (2012) found that patients diagnosed with WHO grade II astrocytoma showed 
little/no nuclear KPNA2 immunostaining whereas half of the patients diagnosed with 
anaplastic astrocytoma (WHO grade III) showed ≥5% KPNA2 staining in the nucleus [166]. 
 
A recent study in our laboratory, using mass spectrometry analysis of proteins secreted in 
exosomes by cervical and oesophageal cancer cells found KPNB1 and XPO1, among other 
nuclear transport proteins, to be secreted at elevated levels compared to normal cells 
(unpublished data; A.Wishart, MSc Dissertation, 2017)†. It is thus possible that these proteins 
might have potential as diagnostic markers.  
 
1.9.3 Nuclear transporters and patient prognosis  
 
A study by van der Watt et al. (2009) found that KPNB1, KPNA2 and XPO1 are all upregulated 
in cervical cancer patient samples in comparison to normal tissue. KPNB1 and XPO1 but not 
KPNA2 were found to be essential for the survival of cervical cancer cells [128]. The nuclear 
importer, KPNB1, and exporter, XPO1, both show promise as cancer biomarkers and studies 
aimed at investigating their potential as prognostic markers for cervical cancer are underway. 
More recently Zhu et al. (2015) found that KPNB1 was upregulated in gastric cancer patient 
tissue and cells in comparison to their normal counterparts. Zhou et al. (2013) found XPO1 
protein levels to be significantly upregulated in gastric cancer patient tissues as well, indicating 
that both import and export machinery is upregulated in gastric cancer. The upregulation of 
KPNB1 correlated positively with Ki-67 immunostaining, infiltration depth and tumour grade 
but not TNM stage and lymph node metastasis. On the other hand, overexpression of XPO1 
                                                           
† A. Wishart. “Investigating secreted biomarkers for cancer: The potential of nucleotransport 
proteins.” MSc dissertation, University of Cape Town, 2017. 
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positively correlated with TNM stage as well as metastasis. Both increased KPNB1 and XPO1 
expression have been identified as independent prognostic factors to predict gastric cancer 
patient survival [130, 142].    
 
XPO1 has also been identified as a suitable independent prognostic marker in ovarian cancer, 
pancreatic cancer, osteosarcoma, brain cancer and acute myeloid leukaemia [167-172]. 
Studies on pancreatic cancer as well as osteosarcoma revealed XPO1 overexpression to be 
associated with increased tumour size as well as histological grade in osteosarcoma but not 
pancreatic cancer. For both pancreatic cancer and osteosarcoma there is evidence suggesting 
that increased XPO1 expression is an indicator of reduced overall and progression-free 
survival [168, 171]. Although expression levels of nuclear transporters often enhance their 
prognostic value, in some cases so does their localisation within the cell. While the localisation 
of XPO1 between the nucleus and the cytoplasm showed no significant differences among 
gastric cancer samples, the cellular localisation of XPO1 in ovarian cancer has been correlated 
with different aspects of cancer progression [130]. Enhanced cytoplasmic XPO1 has been 
associated with advanced ovarian tumour stage, poor differentiation and higher mitotic rate. 
Nuclear XPO1 levels have been associated with enhanced Cox-2 expression leading to poor 
overall patient survival [169]. Nuclear XPO1 has also been correlated with pathological stage 
in gliomas [170]. XPO1 localisation is also altered during oesophageal tumourigenesis, where 
it shifts from predominantly nuclear in normal tissue, to nuclear and cytoplasmic in cancer 
tissue. This appears to occur in the early stages of disease progression [173].  
 
The potential of nuclear transporters such as KPNB1 and XPO1 as prognostic tools is still under 
investigation and data supporting this is only available for a select few cancers. KPNA2 
however, has been well established as a prognostic marker in various cancers including; breast 
cancer, brain cancer, gastric cancer, prostate cancer, ovarian cancer, bladder cancer, liver 
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cancer, colorectal cancer, melanoma, lung cancer and oesophageal cancer [122, 165, 167, 
174-179]. Dahl et al.’s (2006) research on breast cancer was the first to identify KPNA2 as a 
prognostic marker [180]. Since then high nuclear KPNA2 expression has been linked to poor 
patient outcome. Numerous studies have shown that KPNA2 expression correlates with 
overall and progression-free survival in patients and established KPNA2 as an independent 
prognostic marker when compared to other clinical data [122, 166, 167, 176, 178, 179, 181-
183]. Interestingly, KPNA2 expression also predicted the chances of metastasis as well as 
histological grade and clinical stage of tumours. High KPNA2 expression in non-invasive 
bladder cancer increased the risk of progression to a more invasive form [182].  
 
Some malignancies have a high recurrence rate following therapeutic or surgical intervention 
and it is important to identify risk factors in these patients that might predict recurrence. 
KPNA2 expression has been identified as a marker of both early and more frequent recurrence 
in liver cancer while it is also a marker of PSA recurrence in prostate cancer [177, 184, 185]. 
In meningioma, elevated KPNA2 and XPO1 expression was observed in recurrent tumours in 
comparison to primary tumours and this correlated with increased recurrence rates [167].   
 
The evidence presented here highlights that KPNA2 serves as a valuable prognostic marker 
throughout the progression of cancer from early stage recurrence to chances of metastasis, 
as well as overall survival. While there is evidence that KPNB1 and XPO1 have shown potential 
as prognostic markers, this requires further investigation and validation. Evidence presented 
in a study by Gousias et al. (2014), shows KPNA2 expression levels correlating with XPO1 
expression levels in meningioma, suggesting that multiple nuclear transporters may too have 





1.9.4 Potential of nuclear transporters as chemotherapeutic targets       
 
The upregulation of nuclear transporters and their association with poor prognosis in cancer 
highlights their potential as therapeutic targets. Challenges may arise though when targeting 
cellular machinery that is active in both normal and cancer cells. However, studies have shown 
that cancer cells are more sensitive to nuclear transport inhibition than non-cancer [128, 138, 
186]. Specific knockdown using siRNA for nuclear import proteins, KPNB1 and KPNA2, and 
export protein, XPO1, in cancer cells frequently results in reduced proliferation and increased 
apoptosis [135, 154, 183, 185, 187]. This suggests that cancer cells may have an enhanced 
dependence on nuclear transporters for their increased proliferative and metabolic demands 
(referred to as tumour cell “addiction”).  
 
1.9.4.1 Nuclear export inhibitors as anticancers 
 
Among the Karyopherin family members the nuclear exporter, XPO1, has so far been the most 
successful chemotherapeutic target already being tested in clinical trials (Table 1.2). Several 
natural products were first described as inhibitors of XPO1 with Leptomycin B being the most 
potent. Leptomycin B showed severe cytotoxic effects in phase I clinical trials and was no 
longer pursued for use in patients. Subsequently, several Leptomycin B derivatives such as 
Anguinomycin and Kos-2464 have been synthesized in an attempt to reduce the cytotoxity 
while retaining the ability to inhibit nuclear export via XPO1, but have as yet not entered 
clinical trials. A recent review by Ishizawa et al. (2015) outlines the history of XPO1 as a 
chemotherapeutic target in more detail [188]. In 2012 the SINE (Selective inhibitors of nuclear 
export) series of drugs were identified through an in silico molecular modelling strategy and 
synthesized by Karyopharm Therapeutics (Karyopharm Therapeutics, Inc., Boston, MA, USA) 
[189]. These compounds are water-soluble and irreversibly modify a cysteine (Cys528) in the 
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NES-binding groove of XPO1 thereby inhibiting the function of the protein. KPT-185 is the most 
potent of the series and is most commonly studied in vitro. However KPT-330/Selinexor, while 
nearly as potent, has been reported to have more acceptable pharmacokinetics and has 
shown promise in phase I, II and III clinical trials in both haematological and solid tumours 
[190-192].  
 




Nature of the 
compound 
Experimental 
Status     
KPNB1 
cSN50.1 [77] 




 cSN50.1 [77] Peptide Cell Culture 
 Bimax1 [112] Peptide Cell Culture 
 Bimax2 [112] Peptide Cell Culture 
 Karyostatin 1A [194] Small molecule Cell Culture 
 Importazole [195] Small molecule Cell Culture 
XPO1 Leptomycin B [196] Antibiotic 
Phase I Clinical 
Trials 
(discontinued) 
 Ratjadone analogs [188] Antibiotic Cell Culture 
 Anguinomycin [188] Antibiotic Cell Culture 
 Goniothalamin [188] Organic molecule Cell Culture 
 Kos-2464 [188] Small molecule 
Xenograft Mouse 
Model 
 N-azolylacrylate analogs [188] Small molecule HIV Model 
 CBS9106 [188] Small molecule 
Xenograft Mouse 
Model 
 SINE series [189] Small molecule 






1.9.4.2 Potential of nuclear export inhibitors in combination therapies 
 
More recently combination treatment strategies using XPO1-inhibitors and currently available 
chemotherapeutic agents have proven to be effective in enhancing the treatment of cancer 
in model systems. Nuclear export inhibitors alone, while effective in causing cell death in vitro, 
in animal models these inhibitors while inhibiting tumour growth were less often likely to 
eliminate existing tumours. The combination therapy is thought to use the XPO1-inhibitor to 
sensitise cancer cells to chemotherapeutic agents. A review by Turner et al. (2014) extensively 
discusses a range of studies providing evidence for the efficacy of XPO1-inhbitors in 
combination with alkylating agents, anthracyclines, BRAF inhibitors, platinum drugs, protease 
inhibitors and tyrosine-kinase inhibitors against both haematological and solid tumours [197]. 
SINE compounds; KPT-185, KPT-249 and KPT-330 were able to sensitize myeloma cells to 
doxorubicin, bortezomib and carfilzomib and phase I/II clinical are currently underway [197, 
198]. A combination therapy using KPT-330 and gemcitabine has also been found to 
synergistically enhance cell death in vitro and in vivo in pancreatic cancer [199].  
 
1.9.4.3 Nuclear import inhibitors as anticancers 
 
The field of nuclear import inhibitors, while not as advanced as that of nuclear export 
inhibitors at present, is growing (Table 1.2). Most commonly KPNB1 and the KPNA isoforms 
work together to transport cargoes into the nucleus, although KPNB1 can also transport cargo 
independently. Therefore, targeting KPNB1 may have a broader spectrum of import inhibition 
while targeting a single KPNA isoform would considerably increase specificity. Pioneering work 
in the search for Karyopherin alpha/beta 1 inhibitors was started by Lin et al. in 1995. They 
among others, found that a cell-permeable peptide containing the NLS of the NFκB p50 
subunit was able to inhibit the nuclear import of transcription factors containing a NLS, such 
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as NFκB, NFAT, AP-1 and STAT1 [76, 200]. The peptide became better known as cSN50.1 and 
more recently has been found to target both SREBP/KPNB1 and KPNA/NLS-cargo mediated 
import through two separate mechanisms. The inhibition of SREBP/KPNB1-mediated import 
is thought to be through the binding of the peptide’s SSHR motif with KPNB1. The peptide is 
also able to bind all KPNA isoforms, except KPNA6, with the highest affinity for KPNA1 and in 
that way plays a role in the import inhibition of transcription factors containing a NLS [77]. 
Kosugi et al. (2008) also used peptide inhibitor design to target the KPNA/B1 import pathway 
which yielded two high affinity peptides namely; Bimax1 and Bimax2. They were found to 
specifically target the KPNA-mediated import pathway and had no effect on KPNB1-only 
mediated import although they showed no specificity for Karyopherin alpha isoforms in 
mammalian cells [112]. The chemotherapeutic ability of these import inhibitors however, 
remain unknown at present. An anti-parasitic antibiotic, Ivermectin, already on the market, 
has also been found to bind non-specifically to KPNB1/KPNA preventing binding to the cargo 
proteins [193]. Although Ivermectin has been shown to have anticancer effects this seems to 
be through a mechanism of action unrelated to nuclear import inhibition [201]. 
 
Karyostatin 1A was the first small molecule inhibitor of KPNB1-mediated nuclear import to be 
described. Its mechanism of action is thought to be through blocking the binding of RanGTP 
to KPNB1 disrupting the KPNA/B1 import pathway [194]. The potential of this compound 
including its anti-cancer effect has not been explored to date. Another small molecule 
inhibitor of nuclear import, Importazole, developed by Soderholm et al. (2011) was found to 
interfere with the interaction between RanGTP and KPNB1 and specifically disrupts KPNB1-
mediated import without affecting Transportin or XPO1-mediated transport [195]. 
Importazole successfully inhibited NFκB p65 nuclear localisation in myeloma cells and induced 
apoptosis without affecting normal plasma cells, showing promise as an anti-cancer 
compound [202]. More recently INI-43, a compound described by our research group, was 
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shown to inhibit KPNB1-mediated nuclear import in cancer cells causing cell death and 
reducing tumour size in vivo [203] (Data from this study was included in the publication). 
 
1.10 Identification of the nuclear import inhibitor: INI-43 
 
A structure-based in silico drug screen was performed in the search of identifying potential 
novel small molecules that would bind to KPNB1 and inhibit nuclear import. This was done in 
collaboration with researchers at the James Graham Brown Cancer Centre (University of 
Louisville, Kentucky, USA). The overlapping region on KPNB1 where Karyopherin alpha and 
RanGTP bind, corresponding to amino acids 331-363, is thought to be essential for KPNB1 
function and deletion of this region rendered KPNB1 unable to transport cargo into the 
nucleus [204]. Using the known crystal structure of KPNB1, a compound library consisting of 
12 662 570 small molecules was screened for their predicted ability to bind this overlapping 
region on KPNB1. Seventy-four compounds were identified from the search and numbered 
according to their predicted binding affinity to KPNB1. A number of compounds were 
screened for their ability to kill cancer cells and block the nuclear import of cargo proteins and 
of these, Compound 43, 3-(1H-1,3-benzimidazol-2-yl)-1-[3-(dimethylamino)propyl]-1H-
pyrrolol[2,3-b]quinoxalin-2-amine, which was later renamed Inhibitor of Nuclear Import-43 
(INI-43) was selected for further investigation. This compound showed the ability to inhibit 
nuclear import of KPNB1-cargoes and had half maximal response concentration (EC50~ 10 µM) 
values in cervical cancer cell lines which were in the range of current chemotherapeutics e.g. 
cisplatin and doxorubicin when used on cancer cells in culture. The small molecule inhibitor 
was found to associate with changes in KPNB1 localisation and expression levels. INI-43 has a 
quinoxaline group, a heterocyclic molecule consisting of a benzene and a pyrazine ring, as well 
as a benzimidazole side chain, a bicyclic compound with a imidazole and benzene fused 
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together (Fig. 1.5). In this study we aim to further characterise the anticancer properties of 


















The nuclear import protein, KPNB1, has been shown to have potential as an anticancer target. 
Cancer cells have many biological phenotypes that differ from non-cancer cells. There is 
growing importance that inflammation promotes many aspects of cancer progression, hence 
mechanisms for inhibiting inflammatory signalling in the tumour microenvironment might be 
favourable. Anti-inflammatory drugs may have a role in preventing malignancies but are 
generally not cytocidal [42]. An ideal drug would be able to suppress inflammation and kill 
cancer cells simultaneously. Targeting KPNB1 has the potential to inhibit the nuclear entry and 
activity of cargoes associated with cancer biology.   
Benzimidazole 
Quinoxaline 
Mono-isotopic mass: 385.2 g/mole 
Figure 1.5: Structure of the small molecule Inhibitor of Nuclear Import -43 (INI-43). A quinoxaline 
derived compound containing a benzimidazole side chain with a mono-isotopic mass of 385.2 g/mole.
45 
 
1.12 Project aims 
 
This study is aimed at investigating the role of the nuclear import protein, KPNB1, in cancer 
cell biology and the transport of transcription factors associated with inflammatory signalling 
in cancer cells.  
 
The objectives for the investigation were: 
 
i) To determine the effect of KPNB1 inhibition on cervical cancer cell biology 
including; proliferation, survival, migration and invasion.  
 
ii) To determine whether KPNB1 is required for the nuclear import, activity and 
inflammatory signalling of the transcription factors; NFkB and AP-1. 
 
iii) To investigate the anticancer role of the nuclear import inhibitor, INI-43, in an 





INVESTIGATING THE EFFECTS OF NUCLEAR IMPORT 
INHIBITION VIA KARYOPHERIN BETA 1 ON CANCER CELL 
BIOLOGY 




The nucleo-cytoplasmic transport system plays an essential role in normal cell functioning and 
defects in this system have been associated with cancer. Dysregulation of proteins in the 
transport system can be attributed to various factors. These include; altered expression or 
localisation of the transport proteins, disruption of endogenous inhibitors and the mechanistic 
implications of nuclear transporters in mitotic division and genetic instability [119, 205]. Some 
of the key hallmarks in the development of cancer include sustained proliferation and the 
activation of invasion, therefore targeting these phenotypes are considered desirable when 
designing targeted chemotherapeutic drugs [34].   
 
Our research group has focused on investigating the potential of KPNB1 as an anticancer 
target. This is based on studies showing that the expression of nuclear import proteins was 
upregulated in cervical cancer patient tissue in comparison to normal tissue [128]. The 
overexpression of KPNB1 in cervical cancer was found to be caused by altered transcriptional 
regulation by E2F. Elevated E2F activity in cervical cancer is attributed to the human 
papillomavirus E7 protein known to inhibit the retinoblastoma protein which would normally 
repress E2F activity [129]. Overexpression of the nuclear transport protein has been shown to 
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increase nuclear import efficiency in transformed cells [133]. This enhanced access of cargo 
into the nucleus is suggested to sustain the high metabolic and proliferative demands of 
cancer cells. Cancer cells have been found to require KPNB1 for their proliferation, however 
the exact mechanism of action for this requirement is not fully understood [128, 138, 203]. It 
could be attributed to either; the essential role of KPNB1 in mitosis and/or to the inability of 
certain cargoes e.g. transcription factors to gain access into the nucleus and perform their 
function in promoting proliferation [205]. Because of the central role that KPNB1 plays in the 
cell it is likely that its inhibition will affect multiple biological phenotypes of cancer cells. 
Included in the biological phenotypes of cancer cells are; increased proliferation and changes 
in cancer cell migration and invasion.  While there is evidence that KPNB1 is necessary for the 
proliferation and survival of cancer cells [128], little is known about the role of KPNB1 in the 
progression of other cancer phenotypes such as migration and invasion. 
 
Once the proliferative demands of cancer cells outweigh their nutrient supply they acquire 
invasive properties to escape the primary site of the tumour and occupy secondary locations. 
This is achieved through the expression of matrix-modifying enzymes to degrade the 
extracellular matrix thereby facilitating migration and invasion [34, 206]. Matrix 
metalloproteases -2 and -9 (MMP-2 & -9) have both been identified as key activators of cancer 
cell invasion [207, 208]. Dysregulation of the MMPs and their respective endogenous 
inhibitors; TIMP-2 and TIMP-1, might also contribute to cancer progression [104, 207]. In this 
study, we used transwell migration and invasion assays to analyse changes in motility 
following KPNB1 inhibition. The mechanism behind such changes was further investigated by 
measuring MMP and TIMP expression as well as assessing MMP activity following nuclear 




This chapter aims to further investigate the role of KPNB1 in cancer cell biology using cervical 
cancer cell lines as a model system. This includes investigating the effects of KPNB1 on 
biological endpoints including; cancer cell proliferation, survival, migration and invasion. This 
study uses two approaches to inhibit KPNB1, i) KPNB1 siRNA to directly target KPNB1 and ii) 
treatment with the small molecule Inhibitor of Nuclear Import, INI-43, previously reported to 
inhibit nuclear import associated with KPNB1 [203]. In doing so we aim to further characterise 
INI-43 as a potential anticancer drug. Our data suggests that not only does KPNB1 play a role 







 2.2.1 The role of KPNB1 in cancer cell proliferation and survival 
 
To monitor the effects of KPNB1 inhibition on cervical cancer cells, HeLa cell proliferation was 
analysed following nuclear import inhibition using KPNB1 specific siRNA as well as the small 
molecule inhibitor; INI-43.   
 
2.2.1.1 The effect of KPNB1 siRNA knockdown on cancer cell proliferation 
 
In order to determine whether KPNB1 was essential for cancer cell proliferation a pool of 
interfering RNA’s specific for KPNB1 was used to inhibit KPNB1 activity. HeLa cervical cancer 
cells were transfected with control and KPNB1 siRNA and allowed to proliferate over several 
days. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay was used to 
measure cell proliferation over 24, 48 and 72 hours. Our results show a significant reduction 
in cell proliferation within 48 hours post-transfection with KPNB1 siRNA onwards indicating 
reliance on KPNB1 for cancer cell proliferation (Fig. 2.1 A). Knockdown of KPNB1, 48 hrs post 
transfection, was checked in a parallel experiment by western blotting (Fig. 2.1 B).      
 
Having shown that KPNB1 knockdown with siRNA inhibited HeLa cervical cancer cell 





Figure 2.1: The effect of KPNB1 knockdown by KPNB1 siRNA on cancer cell proliferation. A) Hela, 
cervical cancer cells, were transfected with control and KPNB1 siRNA and cell proliferation measured 
using an MTT proliferation assay at 24, 48 and 72 hour timepoints. B) Western blot showing KPNB1 
knockdown 48 hrs post transfection. Results shown are the mean ± SEM of experiments performed in 

















2.2.1.2 EC50 determination for INI-43 in cervical cancer cells and normal fibroblasts 
 
As we have evidence suggesting that INI-43 targets KPNB1 [203], it was important to 
determine the effective concentration at which INI-43 kills 50% of viable cells for use in 
subsequent experiments aimed at determining its effects on cancer cell biology. A panel of 
cervical cancer cell lines including; HeLa, SiHa and CaSki, were used as well as non-cancer FGo 
fibroblast cells. Cells were treated with a range of nine INI-43 concentrations from 1 μM to 50 
μM. The OD595nm absorbencies obtained from the MTT cell viability assay were plotted as 
sigmoidal dose-response curves (Hill Plots) using GraphPad Prism and the EC50 calculated (Fig 
2.2). The representative EC50 values for all cell cultures including their confidence intervals 
were tabulated (Table 2.1). The cervical cancer cell lines had a very similar EC50 value for INI-
43 with HeLa at 7.1 μM, SiHa at 9.8 μM and CaSki at 7.3 μM. For all future experiments 5 or 
10 μM INI-43 was chosen to treat cervical cancer cells. The non-cancer, FGo cells, appeared to 
be slightly less sensitive to INI-43 with an EC50 value of 17.0 μM, approximately double that of 






 determination for INI-43 in cervical cancer cell lines and non-cancer cells. Cervical 
cancer cells (HeLa, SiHa and CaSki) and non-cancer fibroblast cells (FGo) were seeded into 96-well 
plates in triplicate. Cells were treated with a range of INI-43 concentrations and MTT added after 48 
hours and the absorbance read at OD
595nm
. Transformed -log[INI-43] graphs were used to determine 
the EC
50
 concentration of INI-43 in each of the cell cultures. Results shown are the mean ± SEM of 


























































2.2.1.3 KPNB1 inhibition induces cancer cell death via apoptosis 
 
KPNB1 knockdown or INI-43 treatment of cervical cancer cells resulted in significant amounts 
of cell death at the concentrations used. In order to investigate whether the mechanism of 
cell death was occurring via apoptosis, a Caspase-Glo® assay was performed looking at 
caspase 3/7 activity. The cysteine aspartic acid-specific proteases -3 and -7 (caspase-3 and -7) 
play an effector role in the activation of apoptosis in mammalian cells [209, 210]. The Caspase-
Glo® assay provides a lumogenic, tetrapeptide (DEVD) substrate for caspase 3/7. Cleavage of 
the substrate by the caspases releases aminoluciferin, a luciferase substrate, thereby 
producing a measurable light signal. The intensity of the light signal is proportional to caspase 
3/7 activity. HeLa cells were transfected with control and KPNB1 siRNA and caspase 3/7 
activity measured after 24, 48 and 72 hours. A significant increase in caspase 3/7 was observed 
across all time points measured after transfection with KPNB1 siRNA (Fig. 2.3 A).  
 
To monitor the effect of the small molecule inhibitor of nuclear import, HeLa cells were 
treated with 10 μM INI-43 and caspase 3/7 activity analysed after 3, 6 and 24 hours of 
treatment. Significant caspase 3/7 activity was observed at 6 hours and 24 hours post INI-43 
treatment (Fig. 2.3 B). A 3 hour timepoint, before significant cell death occurred, was 
therefore used in future functional experiments looking at the effects of nuclear import 
inhibition. These results show that inhibiting KPNB1  using both siRNA and INI-43 induces cell 












Figure 2.3: KPNB1 inhibition induces cell death by apoptosis. A) HeLa cells were transfected with 
control and KPNB1 siRNA and Caspase 3/7 activity measured over 72 hours using the Caspase 3/7 
GLO® assay. C= control siRNA, KD= KPNB1 knockdown. Results were normalized to a concurrent MTT 
cell viability assay. B) HeLa cells were treated with 10 μM INI-43 and Caspase 3/7 activity measured 
over 24 hours. Results were normalized to a concurrent MTT cell viability assay. Results shown are the 
mean ± SEM of experiments performed in triplicate and repeated two independent times. (*p<0.05).
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2.2.1.4 The effect of INI-43 on PMA-stimulated cancer cell proliferation 
 
The phorbol ester, PMA, is a known stimulator of the cancer phenotype by activating various 
signalling pathways associated with proliferation, migration, invasion and protection against 
apoptosis [211-213]. In an in vitro cell culture system PMA can be used to mimic such intra-
tumour signalling in order to determine whether this effect can be reversed. To investigate 
whether INI-43 could inhibit PMA-stimulated cancer cell proliferation, the cell viability of HeLa 
cells was measured over a range of INI-43 concentrations in the presence of PMA over 24 
hours. The results show that PMA treatment caused a small but significant increase in cancer 
cell proliferation but not in the presence of INI-43 at concentrations higher than 5 μM (Fig. 2.4 
A).  
 
As subsequent functional experiments assessed whether inhibition of KPNB1 inhibited PMA-
stimulated cancer phenotypes it was interesting to determine whether the EC50 value of INI-
43 might change in the presence of PMA. HeLa cells were again treated with a range of INI-43 
concentrations from 0 μM to 50 μM over 24 hrs in the presence or absence of 100 nm PMA. 
A sigmoidal dose-response curve was plotted to calculate the effective concentration at which 
50% of the cells were viable. The EC50 value for INI-43 shifted slightly from 5.4 μM to 6.0 μM 
in the presence of PMA and although the confidence intervals do not overlap a change this 















































Figure 2.4: The effect of INI-43 on PMA-stimulated cell proliferation.  A) HeLa cells were treated with 
a range of INI-43 in the presence and absence of 100 nM PMA over 24 hours. Cell proliferation was 
measured using the MTT cell viability assay. B) The EC
50
 of INI-43 in HeLa cells was measured after 48 
hours in the presence and absence of 100 nM PMA and the 95% confidence interval shown. Results 




2.2.2 The role of KPNB1 in cancer cell migration and invasion 
 
While the effect of KPNB1 inhibition on cancer cell proliferation and survival is well 
characterised (Section 2.2.1) [128, 203], little is known about its role in other cancer 
phenotypes such as migration and invasion. In this study, we investigated the requirement of 
KPNB1 expression and activity on cancer cell migration and invasion using transwell motility 
assays. The expression and activity of key matrix-modifying enzymes that have been reported 
to associate with migration and invasion; MMP-2 and MMP-9, as well as endogenous 
inhibitors; TIMP-2 and TIMP-1 were also assessed following KPNB1 inhibition.   
 
2.2.2.1 The effect of KPNB1 inhibition on cancer cell migration 
 
To determine the migratory ability of cancer cells a transwell migration assay was used. This 
assay allows cells with a migratory potential to move from the upper chamber in which they 
are placed, through the 8 μm pores towards a chemoattractant, high serum concentration, in 
the lower chamber. Migrated cells were then stained, photographed and quantified. Hela cells 
transfected with control or KPNB1 siRNA were placed in the upper chamber in the presence 
of PMA and allowed to migrate through the membrane overnight. Results are representative 
images of cell migration assays and shows fewer cells migrating following KPNB1 knockdown 
(Fig. 2.5 A). Knockdown of KPNB1 was confirmed by western blotting (Fig. 2.5 B). As KPNB1 
inhibition is known to cause cell death, a concurrent MTT viability assay at the same time point 
was performed to confirm that the results observed were due to effects on cell migration 
rather than due to cell death through KPNB1 inhibition and migrated cells corrected for live 
cells. The number of cells migrating was quantified and expressed relative to control. 
Quantification of the data shows that KPNB1 knockdown significantly inhibited the migration 






















Next, we investigated whether INI-43 had a similar effect to KPNB1 knockdown on cancer cell 
migration in a panel of cervical cancer cell lines. Representative images taken of the transwell 
membranes shows fewer Hela, SiHa and CaSki cells migrating following INI-43 treatment (Fig. 
2.6 A). A treatment time of 3 hours was selected as INI-43 had no effect on HeLa cell 
proliferation at this timepoint (Fig. 2.3 B). Although a treatment duration of INI-43 was kept 
to 3 hours, before cell death was evident, concurrent MTT cell viability assays were performed 
alongside the migration assay to correct for any possible effect that may have been due to cell 
death. Overall migrated cells were quantified which showed that INI-43 significantly reduced 
Figure 2.5: The effect of KPNB1 knockdown on the migratory potential of cancer cells. A) 
Representative images from the transwell migration chamber showing migration of HeLa cells 
following KPNB1 knockdown, arrows identifying migrating cells. Scale bar= 100μm, magnification 
x100. B) Western blot confirming KPNB1 knockdown. C) Quantification of transwell migration assay 
following KPNB1 knockdown normalised to MTT cell viability. Results shown are the mean ± SEM of 




























the migratory ability of HeLa and SiHa cells (Fig. 2.6 B). While not significant in CaSki cells, a 
trend towards reduced migratory ability following INI-43 treatment was observed.  
  
Figure 2.6: The effect of INI-43 on the migratory potential of cancer cells. A) Representative images 
showing HeLa, SiHa and CaSki cell migration through the membrane following a 3 hour 10 μM INI-43 
pre-treatment, arrows identifying migrating cells. Scale bar= 100μm, magnification x100. B) The 
relative number of HeLa, SiHa and CaSki cells that migrated through the transwell chamber following 
INI-43 treatment were quantified and normalised to MTT cell viability. Results shown are the mean ± 

























2.2.2.2 The effect of KPNB1 inhibition on cancer cell invasion 
 
Having observed that KPNB1 was required for migration of cancer cells we next questioned 
whether it was required for cancer cell invasion. A transwell assay similar to the migration 
assay described above, but with the addition of a matrigel coating on the transwell 
membrane, was used. Representative images show fewer cells were able to invade through 
the matrigel following KPNB1 inhibition using siRNA (Fig. 2.7 A & B). The number of invaded 
cells was quantified and results show a significant reduction in cell invasion following KPNB1 
inhibition (Fig. 2.7 B).   
  
Figure 2.7: Effect of KPNB1 knockdown on cervical cancer cell invasion. A) Representative images of 
the invasion transwell assay showing invasion of HeLa cells through the matrigel-coated transwell 
membrane following KPNB1 knockdown. Scale bar= 100μm, magnification x100. B) Western blot 
confirming KPNB1 knockdown. C) Quantification of the invasion assay following KPNB1 knockdown 
normalised to MTT cell viability. Results shown are the mean ± SEM of experiments performed in 






























Cervical cancer cells treated with INI-43 to inhibit nuclear import showed similar results as 
KPNB1 knockdown experiments. Representative images in Figure 2.8 (A), shows considerably 
fewer HeLa and SiHa cells invaded the matrigel-coated transwell chamber following INI-43 
treatment. Overall cell counts of invading cells were used to quantify the inhibitory effects of 
INI-43 on invasion. INI-43 was able to significantly inhibit cancer cell invasion of both HeLa and 
SiHa cells (Fig. 2.8 B). Together these results provide evidence that the inhibition of KPNB1 by 
both siRNA and INI-43 treatment inhibits multiple biological phenotypes of cervical cancer 
cells including; proliferation, migration and invasion.    
 
2.2.2.5 The effect of INI-43 on the expression of gelatinases and their endogenous inhibitors 
in cancer cells 
 
The ability of cells to invade surrounding tissues depends on the expression and activity of 
matrix metalloproteases (MMP’s). These enzymes degrade the extracellular matrix (ECM) and 
pave the way for cell migration and invasion. Tissue inhibitors of matrix metalloproteases 
(TIMPs) effectively inhibit MMP activity and it can therefore be hypothesized that the 
expression of MMP’s and TIMP’s be inversely regulated. qRT-PCR was used to assess the 
expression of MMP-2 and -9 as well as TIMP-1 and -2 following INI-43 treatment. Interestingly, 
INI-43 treatment resulted in a significant reduction in the mRNA expression of MMP-2 and 
MMP-9 (Fig. 2.9 A & B) while the expression of TIMP-1 and TIMP-2 was significantly up-
regulated (Fig. 2.9 C & D). In our experiments, PMA was unable to significantly enhance MMP 
or repress TIMP expression as suggested in the literature possibly due to the short treatment 
duration of only 3 hours in HeLa cells used in our experimental conditions. This data supports 
the inhibitory effect of nuclear import inhibition on cancer cell invasion previously seen using 


















Figure 2.8: Effect of INI-43 on cervical cancer cell invasion. A) Representative images of the invasion 
assay following 3 hr, 10 μM INI-43 pre-treatment of HeLa and SiHa cells showing the number of cells 
able to invade the matrigel-coated membrane following nuclear import inhibition. Scale bar= 100μm, 
magnification x100. B) Quantification of invasion assay following INI-43 treatment, normalised to MTT 


































Figure 2.9: Effect of INI-43 on MMP-2, MMP-9, TIMP-1 and TIMP-2 expression. qRT-PCR analysis of 
mRNA expression following 5 μM INI-43 treatment for 21 hours with the addition of 0.5 μM PMA for 
a further 3 hours in HeLa cells shown for MMP-2 (A), MMP-9 (B) and inhibitors of matrix 
metalloproteases, TIMP-1 (C) and TIMP-2 (D). Results shown are the mean ± SEM of experiments 
performed in triplicate and repeated three independent times. (*p<0.05).   
64 
 
2.2.2.6 The effect of INI-43 on MMP-9 gelatinase activity in cervical cancer cells 
 
Decreased levels of MMP mRNA expression suggests but doesn’t confirm that MMP activity is 
also affected by INI-43 treatment. A Gelatin Zymography was used to determine whether 
nuclear import inhibition through INI-43 affected the activity of MMP-9. To measure MMP 
activity, conditioned media from cervical cancer cells was collected and used in the Gelatin 
Zymography. Our results showed a slight increase in MMP activity following PMA treatment 
in HeLa and SiHa cells (Fig. 2.10 A). CaSki cells had lower MMP activity in comparison. 
Treatment with INI-43, had a substantive inhibitory effect on MMP activity in all three cervical 
cancer cell lines; HeLa, CaSki and SiHa. Quantification of the zymograms by densitometry for 
MMP-9 activity following INI-43 treatment is shown in Fig. 2.10 (B). These results support that 






Figure 2.10: Effect of INI-43 on gelatinase activity of MMP-9 in cervical cancer cells (A) Gelatin 
Zymography showing MMP-9 activity in HeLa, CaSki and SiHa conditioned media collected after 16 
hours following a 3 hour pre-treatment of 10 μM INI-43 and a 1 hour 0.5 μM PMA stimulation. Regions 
of clearing indicate areas of gelatinase activity. (B) Quantification by densitometry of MMP-9 activity 
in three cervical cancer cell lines following INI-43 treatment and PMA stimulation. Results shown were 
repeated two independent times.
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In recent years the nucleo-cytoplasmic transport system has gained interest as a targeted 
therapy for cancer. Drugs targeting the nuclear export protein, XPO1, have been successful in 
the treatment of various haematological cancers as well as solid tumours in animal models 
and in clinical trials [189, 214-219]. The Selective Inhibitor of Nuclear Export, Selinexor (KPT-
330), covalently inhibits XPO1 and after showing promising preclinical anti-tumour activity is 
currently being used in several phase I, II and III clinical trials [191, 192]. There is increasing 
interest in the field of targeting nuclear import inhibitors specifically focusing on KPNB1-
mediated transport. Supporting previous findings in our laboratory we found that KPNB1 is 
essential for cervical cancer cell proliferation. Non-cancer fibroblast cells, FGo, appear less 
sensitive to KPNB1 inhibition as a higher concentration of INI-43 was needed to achieve a level 
of cell death similar to that in cervical cancer cells. Van der Watt et al. (2009 & 2016) showed 
that normal fibroblasts, WI38, were less sensitive to KPNB1 knockdown than their 
transformed counterparts, SVWI38. Other non-cancer cells; CCD-1068SK, FGo and EPC2 
epithelial cells, were reported to be unaffected by KPNB1 inhibition using siRNA [128, 203]. 
The greater dependency of cancer cells on KPNB1 compared to normal cells provides promise 
for KPNB1 as an anticancer target.  
 
In this study, we report that inhibition of KPNB1 using both siRNA and INI-43 results in cancer 
cell death by apoptosis shown by an increase in Caspase 3/7 activity. The mechanism of cell 
death following KPNB1 inhibition using siRNA can be attributed to the activation of apoptosis 
via the intrinsic mitochondrial pathway as described by Angus et al. (2014). KPNB1 inhibition 
was found to induce prolonged M phase arrest accompanied by elevated Noxa expression and 
enhanced degradation of Mcl-1. This imbalance favours the pro-apoptotic response causing 
the translocation of Bax into the mitochondria, permeabilising the outer mitochondrial 
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membrane, releasing cytochrome c and activating various downstream effector caspases 
leading to apoptosis [186]. INI-43 treatment was similarly able to activate caspase 3/7 activity 
and induce apoptosis in cervical cancer cells following just 6 hours of treatment. A genome-
wide loss-of-function study performed by Maartens-de Kemp et al. (2013) identified a cluster 
of genes that regulate the G2-M phase transition and are essential to cell survival. Of these 
genes KPNB1 was found to be essential for tumour cell survival in head and neck and lung 
cancer cell lines [187].  
 
Self-sufficiency from growth signals is a hallmark of cancer and accounts for cancer cell’s 
unlimited proliferative potential within the tumour microenvironment. Cancer cells are 
thought to be able to produce their own growth signals which causes autocrine signalling 
stimulating proliferation [33]. The phorbol ester, PMA, can activate various signalling 
pathways that enhance proliferation [105, 106, 212]. We show that PMA increases the 
proliferation of cervical cancer cells and that INI-43 treatment inhibits PMA-stimulated 
proliferation at similar concentrations to when PMA was absent.  
 
In our study we were interested in identifying the role of KPNB1 in cancer cell migration and 
invasion. We showed that inhibiting KPNB1 reduced the migration and invasion of cancer cells 
suggesting a requirement of KPNB1 in these biological phenotypes. As cancer cells require the 
activity of matrix-modifying enzymes to invade surrounding tissue, we investigated whether 
MMP activity was affected by KPNB1 inhibition.  MMP activity was found to be significantly 
inhibited in cervical cancer cells following INI-43 treatment. Fan et al. (2016) found MMP-9 to 
be upregulated in cervical cancer tissue which correlated with a poor patient prognosis. 
Inhibiting MMP-9 activity in SiHa and HeLa cervical cancer cells reduced their migratory and 
invasive ability [220]. Similarly, MMP-2 expression was also found to be decreased following 
KPNB1 inhibition while expression of the inhibitors of matrix metalloproteases, TIMP-1 and 
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TIMP-2, were significantly increased. The role of TIMP 1 and 2 in cancer is less well defined 
and has been reported to play a differential role in different cancers [221]. TIMPs are known 
to be downregulated in a variety of cancer cell lines which is thought to contribute to the 
invasive properties of cancer cells. The overexpression of TIMP-2 in a highly metastatic 
melanoma cell line was able to inhibit metastasis [222, 223]. The matrix metalloproteases, 
MMP-2 and -9, have not only been associated with tumour invasion in breast cancer but also 
showed prognostic value where increased expression associated with poor patient survival 
[224, 225]. The inverse regulation of the MMPs and TIMPs following nuclear import inhibition 
by INI-43 as shown in our study suggests a switch in transcriptional regulation. Our results 
provide evidence that INI-43 has a suppressive effect on cancer cells in part by altering 
transcriptional patterns of genes associated with cell growth, migration and invasion. 
Together our data suggests that KPNB1 may play an important role in the migratory and 
invasive potential of cervical cancer cells. KPNB1 could be functioning as one of the key 
nuclear transporters of transcription factors associated with cancer cell migration, invasion 
and metastasis.  
 
Given the potential for off-target effects of both siRNA and INI-43, these results could be 
validated using future experimental approaches including; RNAi reagents specific for KPNB1 





KARYOPHERIN BETA 1 IS REQUIRED FOR NFkB AND AP-1 
ACTIVITY IN CERVICAL CANCER CELLS 




KPNB1 has multiple cellular roles with one of its main functions being the nuclear transport of 
transcription factors. Cell behaviour is driven by gene expression and gene expression is 
controlled by transcription factor activity. Transcription factors that have been associated 
with inflammation and cancer cell biology include the NFkB, AP-1 and STAT families of 
transcription factors. We hypothesised that the changes in cancer cell biology we observed 
when inhibiting KPNB1 may in part be a result of interfering with the nuclear import and hence 
activity of these key transcription factors required by cancer cells. We therefore investigated 
the effects of inhibiting nuclear import via KPNB1 on the nuclear entry and activity of NFkB 
and AP-1, as both have been implicated in acquiring the hallmarks of cancer. 
 
NFkB is comprised of two subunits; p65 and p50, which both contain a nuclear localisation 
sequence (NLS), suggesting that they require a nuclear transport protein for their nuclear 
import [84]. There is contradicting evidence in the literature regarding the exact nuclear 
transporter; KPNA3/4, KPNB1, XPO7 or IPO8, for which NFkB is a cargo protein [83, 84]. We 
were thus interested in investigating whether KPNB1 is necessary for NFkB nuclear 
translocation and ultimately its transcriptional activity in cervical cancer cells. To monitor 
NFkB cellular localisation; Immunofluorescence, nuclear/cytoplasmic separation and 
electromobility shift assays were used. NFkB is responsive to PMA, which under normal 
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conditions induces nuclear localisation and therefore activation. Activity of the transcription 
factor was measured using transcriptional reporter assays and by assessing inflammatory 
target gene expression. As for NFkB, the transcription factor AP-1 has been reported to have 
a NLS present on the c-JUN subunit, although nuclear import of c-JUN is not limited to KPNB1 
alone [226]. Nuclear transport proteins; Transportin 2 and Importin’s 5, 7 and 9 are also 
reported to transport c-JUN [97]. AP-1 most commonly consists of c-JUN and c-FOS homo- and 
heterodimers and is activated through inflammatory cytokine signalling but also through PMA 
stimulation [88, 90]. Like for NFkB, several AP-1 target genes are implicated in the 
development and progression of cancer. We were therefore interested in determining 
whether KPNB1 may influence activity and target gene expression of the AP-1 transcription 
factor.  
 
In this chapter, we investigated the effects of inhibiting KPNB1 and nuclear import using siRNA 
and the small molecule inhibitor, INI-43, on NFkB and AP-1 transcriptional function and 
inflammatory target gene expression. Furthermore, the dependence of cervical cancer cells 







3.2.1. KPNB1 is necessary for NFkB cellular translocation 
 
3.2.1.1. Monitoring the effects of KPNB1 inhibition on NFkB subcellular localisation by 
immunofluorescent analysis 
 
To determine whether KPNB1 was required for NFkB translocation into the nucleus, the NFkB 
p65 subunit was monitored using immunofluorescence. HeLa cervical cancer cells were 
transfected with siRNA inhibiting KPNB1 after which they were stimulated with PMA to 
activate NFkB nuclear translocation. In control siRNA transfected cells stimulated with PMA 
p65 immunofluorescence appeared predominantly nuclear, while with KPNB1 inhibition, p65 
fluorescence was predominantly cytoplasmic (Fig. 3.1 A). All images were quantified 
separating cells into two categories; 1) showing predominantly nuclear staining or 2) showing 
predominantly cytoplasmic staining and represented as a bar graph (Fig. 3.1 B). Approximately 
250 cells per condition were scored and results show a substantive (81 %) retention of p65 
staining in the cytoplasm of KPNB1-inhibited cells. Concurrently western blot analysis was 
performed and shows knockdown of KPNB1 in HeLa cells (Fig. 3.1 C). These results show that 
KPNB1 is necessary for NFkB nuclear localisation.   
 
As further support and to monitor the effects of inhibiting nuclear transport via KPNB1 using 
a small molecule inhibitor, HeLa and SiHa cells were treated with INI-43. Results show that 
NFkB p65 is predominantly cytoplasmic in untreated cells while PMA stimulated the nuclear 
entry of NFkB. A pre-treatment with INI-43 was able to block nuclear entry of p65 in PMA 
treated HeLa cells (Fig. 3.2 A). For quantification purposes cells were also divided into the 
nuclear or cytoplasmic categories as before and represented as a bar graph (Fig. 3.2 B). A 
72 
 
cytoplasmic retention of 85 % of the p65 resulted following INI-43 treatment. Similar 
observations were made using SiHa cells treated with INI-43 where treatment with the INI-43 
resulted in a perinuclear staining of p65 (Fig. 3.3 A). SiHa cells are smaller in size than HeLa 
cells and have a less distinct separation of nuclear and cytoplasmic regions when viewed under 
the microscope, thus presenting a more perinuclear p65 staining rather than cytoplasmic. 
Quantification of the nuclear or cytoplasmic categories are represented as a bar graph and 
show that INI-43 treatment caused 94 % of the p65 to be excluded from the nucleus in 
comparison to control untreated cells (Fig. 3.3 B). These results support that nuclear import 






Figure 3.1: Effect of KPNB1 knockdown on NFkB p65 cellular localisation. A) Representative 
immunofluorescent images of HeLa cells transfected with control or KPNB1 siRNA and stimulated with 
0.5 μM PMA for 1 hour, showing cellular localisation of Cy3-labelled NFkB p65 (red). DAPI (blue) was 
used as a nuclear stain. Scale bar= 10μm, magnification x1000. B) Immunofluorescent localisation of 
NFkB p65 was quantified, covering 250 cells over 25 images per treatment and categorized as showing 
“predominantly cytoplasmic” or “predominantly nuclear” staining. The graph was plotted using the 
percentage nuclear and cytoplasmic p65 fluorescence. C) Western blot confirming KPNB1 knockdown. 
















































Figure 3.2: The effect of INI-43 on NFkB p65 cellular localisation in HeLa cells. A) HeLa cervical cancer 
cells were plated onto glass coverslips and pre-treated with 10 μM INI-43 for 2 hours and further 
stimulated with 0.5 μM PMA for an additional hour still in the presence of INI-43. NFkB p65 was Cy3-
labelled (red) while nuclei were stained with DAPI (blue). B) Immunofluorescent localisation of NFkB 
p65 was quantified, covering 250 cells over 25 images per treatment and categorized as showing 
“predominantly cytoplasmic” or “predominantly nuclear” staining. The graph was plotted using the 
percentage nuclear and cytoplasmic p65 fluorescence. Scale bar= 10μm, magnification x1000. 





























Figure 3.3: The effect of INI-43 on NFkB p65 cellular localisation in SiHa cells. A) SiHa cervical cancer 
cells were plated onto glass coverslips and pre-treated with 10 μM INI-43 for 2 hours and further 
stimulated with 0.5 μM PMA for an additional hour still in the presence of INI-43. NFkB p65 was Cy3-
labelled (red) while nuclei were stained with DAPI (blue). B) Immunofluorescent localisation of NFkB 
p65 was quantified, covering 250 cells over 25 images per treatment and categorized as showing 
“predominantly cytoplasmic” or “predominantly nuclear” staining. The graph was plotted using the 
percentage nuclear and cytoplasmic p65 fluorescence. Scale bar= 10μm, magnification x1000. 
Experiments were performed at least three independent times.




















3.2.1.2 Investigating the effects of KPNB1 inhibition on NFkB subcellular localisation using 
western blotting 
 
Western blot analysis was used as an independent measure of NFkB subcellular localisation 
by fractionating cellular protein into cytoplasmic and nuclear fractions following nuclear 
import inhibition. HeLa cells transfected with KPNB1 siRNA showed reduced p65 and p50 
protein levels in the nuclear fraction and increased protein levels in the cytoplasmic fraction, 
in comparison to the control (Fig. 3.4 A).  
 
HeLa cells stimulated with PMA show an increase in nuclear p65 and p50 protein levels in 
comparison to unstimulated cells (Fig. 3.4 B). While, INI-43 pre-treatment resulted in reduced 
p65 and p50 protein levels in the nuclear fraction and increased protein levels in the 
cytoplasmic fraction. Similarly, PMA stimulation caused increased nuclear levels of p50 in SiHa 
cells while INI-43 treatment reduced both the nuclear and cytoplasmic protein levels of p50 
(Fig. 3.4 C). These results support the requirement of KPNB1-mediated nuclear transport of 
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Figure 3.4: The effect of KPNB1 inhibition on nuclear entry of NFkB p65 and p50 in cervical cancer 
cells. A) Western blot analysis of NFĸB p65 and p50 expression in the cytoplasmic and nuclear protein 
fraction of HeLa cells transfected with control and KPNB1 siRNA before a 1 hour 0.5 μM stimulation 
with PMA. B) Western blot analysis of HeLa cells following a 2 hour pre-treatment with INI-43 followed 
by a 1 hour 0.5 μM PMA stimulation showing NFkB p65 and p50 expression in the cytoplasmic and 
nuclear protein fractions. C) Western blot analysis of SiHa cells treated as per HeLa cells above showing 
NFkB p50 cellular localisation. β-tubulin or GAPDH were used as a cytoplasmic loading control while 




3.2.1.3 Effect of KPNB1 inhibition on NFkB in the nuclear cell fraction using electromobility 
shift assays 
 
Electromobility shift assays were used to investigate NFkB binding to a NFkB consensus 
sequence in control and KPNB1-inhibited cells. Nuclear protein lysates from control and 
KPNB1-inhibited cells were incubated with an NFkB consensus sequence (5’-
AGTTGAGGGGACTTTCCCAGGC-3’). A strong DNA-binding complex was detected in nuclear 
protein lysates from control siRNA transfected cells in the presence of PMA stimulation (Fig. 
3.5 A). Complex formation was substantially reduced when KPNB1 was inhibited using siRNA. 
Western blotting was used to confirm protein nuclear/cytoplasmic fractionation and KPNB1 
knockdown (Fig. 3.5 B).  
 
INI-43 treatment similarly reduced DNA-protein complex formation in comparison to the 
PMA-stimulated control (Fig. 3.5 C). Supershift analysis was used to confirm p65 and p50 in 
the DNA-protein complex. For this, protein lysates were incubated with either the p65 or p50 
antibody. Incubation with the p65 antibody in the binding reaction resulted in a supershifted 
complex indicating the presence of NFkB p65 (Fig. 3.5 D). A reduction in the binding when the 
supershift was performed using the NFkB p50 antibody suggests competitive binding of the 
protein with the biotin-labelled oligonucleotide. Together, these results confirm that KPNB1 






Figure 3.5: Formation of a nuclear NFkB/DNA binding complex following KPNB1 inhibition. A) 
Electromobility shift assay (EMSA) showing binding of nuclear protein to a biotin-labelled NFĸB 
oligonucleotide following KPNB1 siRNA transfection in PMA-stimulated HeLa cells. B) Western blot 
analysis of fractionated protein samples confirmed KPNB1 knockdown and fractionation. C) EMSA of 
nuclear extracts obtained from cells pre-treated with 10 μM INI-43 for 2 hours followed by a 1 hour 
0.5 μM PMA stimulation. D) Supershift analysis with the NFĸB p65 antibody showing a shift in the DNA-
protein complex while the p50 antibody reduced protein binding both confirming the presence of 
NFkB in the DNA-protein complex. Experiments were repeated two independent times.  
Free 
Probe   +          +     PMA 
  0        10     INI-43 (μM)  
Free 
Probe +            +     PMA 
+            -      Cntl siRNA 
 -            +     KPNB1 siRNA 
Cyto Nuc 




Probe +        +        +      PMA 
+        +        +      Cntl siRNA 
-         -         +      p50 Ab 







3.2.2 The effect of KPNB1 inhibition on NFkB transcriptional activity 
 
Our earlier results established that NFkB requires KPNB1 for its entry into the nucleus. By 
implication, then inhibiting KPNB1 should result in a change in NFkB transcriptional activity 
and transcriptional regulation of its target genes. The transcriptional activity of NFkB was 
monitored using a luciferase reporter construct containing an NFkB consensus binding site. 
KPNB1 inhibition using siRNA significantly reduced NFkB transcriptional activity using the NFkB 
promoter construct (Fig. 3.6 A). The effects of INI-43 and two commercially available nuclear 
import inhibitors of KPNB1, Importazole [195] and Ivermectin [193], on NFkB transcriptional 
activity was also measured following PMA stimulation. Nuclear import inhibitors were used at 
EC50 and half EC50 concentrations. PMA stimulation significantly increased NFkB transcriptional 
activity while pre-treatment with all three of the nuclear import inhibitors significantly 
reduced NFkB transcriptional activity (Fig. 3.6 B). Treatment of cells with a specific NFkB 
inhibitor, JSH-23, also showed a significant reduction in NFkB activity comparable to that of 
INI-43 (Fig. 3.6 C). A concentration of 20 µM JSH-23 was required to obtain a similar inhibition 
of NFkB transcriptional activity as 10 µM INI-43. This suggests that INI-43 is effective at 
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Figure 3.6: The effect of inhibiting nuclear import on the transcriptional activity of NFkB. A) NFĸB 
transcriptional activity using an NFkB binding site-luciferase reporter transiently transfected into HeLa 
cells following KPNB1 knockdown and stimulation with PMA. B) NFkB transcriptional activity was 
measured following overnight pre-treatment with KPNB1 inhibitors; INI-43, Importazole and 
Ivermectin at 0.5x and 1x IC
50
 followed by a 3 hour 0.5 μM PMA treatment (24 hour total treatment).  
C) NFĸB transcriptional activity in HeLa cells following a 21 hour pre-treatment with INI-43 or JSH-23 
and a 3 hour 0.5 μM PMA stimulation (24 hr total treatment time). Results shown are the mean ± SEM 
of experiments performed in quadruplicate and repeated three independent times. (
#
p<0.05, 




3.2.3 The effect of KPNB1 inhibition on NFkB inflammatory target gene expression  
 
Ultimately if NFkB transcriptional activity is affected this implications for NFkB target gene 
expression. NFkB plays a critical role in inflammatory signalling and therefore the target genes 
chosen for further investigation are inflammatory cytokines reported to be involved in cell 
biology changes associated with cancer. The expression of inflammatory cytokines; IL-1β, IL-6 
and TNF-α were monitored in response to KPNB1 inhibition. HeLa cells transfected with KPNB1 
siRNA showed reduced expression of the KPNB1 gene as well as significant reduction in mRNA 
expression of all three inflammatory cytokines (Fig. 3.7 A). The small molecule inhibitor, INI-
43, had a similar inhibitory effect and significantly inhibited PMA-stimulated IL-1β, IL-6 and 
TNF-α gene expression which was comparable to the effect of the NFkB inhibitor, JSH-23 (Fig. 
3.7 B, C & D). A significantly enhanced reduction of IL-1β and TNF-α mRNA expression in INI-
43 treated cells in comparison to the effect of JSH-23 was observed. This suggests that INI-43 
affects NFkB and other possible transcription factors that could regulate the expression of 
these cytokines (Fig. 3.7 B & D).  
 
3.2.4 The effect of KPNB1 inhibition on AP-1 transcriptional activity 
 
Having established that the inhibition of KPNB1 negatively affected NFkB activity we were 
interested in determining effects on another transcription factor, AP-1. The transcriptional 
activity of AP-1 was quantified using a luciferase reporter construct containing four AP-1 
binding sites in a luciferase reporter construct. The effect of nuclear import inhibition using 
INI-43 as well as two other nuclear import inhibitors; Importazole and Ivermectin was 
assessed. PMA was used to stimulate AP-1 transcriptional activity (Fig. 3.8 A). Nuclear import 
inhibition by all three small molecules at their EC50 and half EC50 concentrations for 3 hours 















Figure 3.7: The effect of KPNB1 inhibition on NFkB inflammatory target gene expression. A) qRT-PCR 
analysis of mRNA expression showed the effect of KPNB1 knockdown (C= Control, KD= Knockdown) 
on KPNB1 mRNA expression, confirming knockdown, as well as expression of inflammatory target 
genes; IL-1β, IL-6 and TNF-α. B) IL-1β mRNA expression shown following stimulation for 1 hour with 
0.5 μM PMA as well as pre-treatment for 2 hours with 10 μM INI-43 or 23 hours 20 μM JSH-23 followed 
by 1 hour PMA stimulation. The same conditions were used to look at mRNA expression IL-6 (C) and 
TNF-α (D). Target gene expression was normalized to expression of the housekeeping gene, GusB. 




obtained in SiHa cells (Fig. 3.8 B). In SiHa cells we also showed that the inhibitory effect of INI-
43 was comparable to that of a JNK inhibitor (SP600125), an upstream inhibitor of AP-1 (Fig. 
3.8 B). For AP-1 to be active it needs to be located in the nucleus and its subunits 
phosphorylated by an upstream signalling kinase. For example, the c-JUN component can be 
phosphorylated by JNK and in turn become activated. We investigated whether inhibiting 
nuclear import via KPNB1 could affect the activation/ phosphorylation of c-JUN in a similar 
manner to that of a JNK inhibitor. Our results show that PMA was able to stimulate c-JUN 
phosphorylation i.e. AP-1 activation, and that treatment with INI-43 and SP600125 
significantly reduced c-JUN phosphorylation (Fig. 3.9). These results support that INI-43 



























Figure 3.8: The effect of nuclear import inhibition on AP-1 transcriptional activity. A) AP-1 
transcriptional activity in HeLa cells was measured using a luciferase reporter construct with multiple 
AP-1 binding sites following overnight pre-treatment with KPNB1 inhibitors; INI-43, Importazole and 
Ivermectin at 0.5x and 1x IC
50
 followed by a 3 hour 0.5 μM PMA treatment (24 hour total treatment). 
B) AP-1 transcriptional activity was also measured in SiHa cells following an overnight pre-treatment 
with 10 μM INI-43 or a 1 hour pre-treatment with SP600125 followed by a 3 hour 0.5 μM PMA 
stimulation. Results shown are the mean ± SEM of experiments performed in quadruplicate and 
repeated three independent times. (
#
p<0.05, significantly different from untreated control) (*p<0.05, 















3.2.5 The effect of KPNB1 inhibition on AP-1 inflammatory target gene expression 
 
Having shown that inhibiting KPNB1-mediated functions with INI-43 blocks AP-1 
transcriptional activity, we next investigated its effect on AP-1 target genes. The expression of 
AP-1 target genes; IL-6 and GM-CSF, associated with inflammation, were evaluated using qRT-
PCR. Stimulation with PMA significantly increased mRNA expression of both genes while pre-
treatment with INI-43 was able to reduce this expression (Fig. 3.10 A & B). As a positive control 
for AP-1 inhibition the JNK inhibitor, SP600125, an upstream inhibitor of the AP-1 signalling 
pathway was included. Activation of AP-1 requires that c-JUN be phosphorylated in the 
nucleus by phosphorylated JNK, although nuclear import of JNK is NLS-independent and 
therefore not reliant on KPNB1 [227, 228]. The enhanced inhibition by INI-43 on IL-6 
expression in comparison to the effect of SP600125 (Fig. 3.10 A) again suggests that the effect 
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Figure 3.9: The effect of INI-43 on c-JUN phosphorylation in HeLa cells. Western blot analysis was 
used to determine the level of c-JUN phosphorylation following stimulation with 0.5 μM PMA and/or 
pre-treated with INI-43 or SP600125. GAPDH expression was used as a loading control. Western blot 
















3.2.6 The effect of KPNB1 inhibition on IL-6 target gene activity and expression 
 
The interleukin 6 (IL-6) inflammatory cytokine is a target gene of both NFkB and AP-1 
transcription factors. Previous experiments showed that both the NFkB inhibitor, JSH-23, and 
the AP-1 inhibitor, SP600125, could significantly inhibit IL-6 mRNA expression. INI-43 
treatment however, had a greater inhibitory effect on IL-6 mRNA expression. To further 
explore this, we next investigated the effect of KPNB1 inhibition on the IL-6 promoter.  
 
3.2.6.1 The effect of KPNB1 inhibition on IL-6 promoter activity 
 
The full-length IL-6 promoter has multiple transcription factor binding sites including NFkB 
and AP-1 binding sites both of which are important for inflammatory signalling (Fig. 3.11 A). 
We obtained the IL-6-PXP2 plasmid as a gift from Prof Luiz Zerbini, (ICGEB, University of Cape 
Figure 3.10: The effect of INI-43 on AP-1 target gene expression. qRT-PCR was used to measre the 
mRNA expression of AP-1 target genes; IL-6 (A) and GM-CSF (B). HeLa cells were pre-treated with 10 
μM INI-43 for 2 hours or 20 μM SP600125 for 1 hour followed by 0.5 μM PMA stimulation for an 
additional hour. Results shown are the mean ± SEM of experiments performed in triplicate repeated 









Town) for investigation on whether KPNB1 inhibition could reduce IL-6 promoter activity given 
the effect we observed on NFkB and AP-1 transcriptional activity using artificial reporter 
constructs. Plasmid mapping was performed to confirm the IL-6 promoter construct. Digestion 
of the full-length plasmid with the restriction enzymes BamH1 and XHO1 released the IL-6 
promoter insert of 1180 bps (Fig. 3.11 B). The insert was isolated and subjected to digestion 
by the NLAIII and NEB4 restriction enzymes which revealed four fragments; 526 bps, 310 bps, 
233 bps and 82 bps, perfectly matching the size of the fragments expected from the restriction 
map (Fig. 3.11 C). This served to confirm the identity of the IL-6-PXP2 promoter plasmid. The 
IL-6-PXP2 plasmid was transfected into HeLa cells and IL-6 promoter activity measured in 
control and KPNB1 inhibited cells. Both siRNA knockdown (Fig. 3.11 D) and INI-43 (Fig. 3.11 E) 
treatment had a significant inhibitory effect on IL-6 promoter activity. This data shows that 
inhibiting KPNB1 has an inhibitory effect on the activity of the IL-6 promoter which 
corresponds to the inability of the transcription factors, NFkB and AP-1, to enter the nucleus.      
 
3.2.6.2 Investigating the effect of KPNB1 inhibition on IL-6 mRNA expression in cancer and 
non-cancer cells 
 
The expression of the inflammatory cytokine IL-6 was investigated further in cervical cancer 
cell lines, HeLa, SiHa and CaSki, and a non-cancer fibroblast cell culture, FGo. INI-43 treatment 
significantly reduced PMA-stimulated IL-6 expression in HeLa, SiHa and CaSki cervical cancer 
cells (Fig. 3.12 A, B & C). However, INI-43 treatment had no effect on PMA-stimulated IL-6 
expression in the non-cancer cells (Fig. 3.12 D). These results support the proposal that cancer 
cells are more sensitive to the effects of nuclear import inhibition via KPNB1 than non-cancer 
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Figure 3.11: The effect of inhibiting KPNB1 on IL-6 promoter activity. A) A diagram showing the 
transcription factor binding sites on the full-length IL-6 promoter. B) The pXP2-IL-6 luciferase plasmid 
was digested using BamH1 and XHO1 to release the IL-6 promoter insert. Image shows agarose gel 
electrophoresis separating the linearized pXP2 vector (6171bps) and the IL-6 promoter insert 
(1180bps). C) Digestion of the IL-6 promoter insert by NLAIII and NEB4 showing four digestion products 
of sizes; 526 bps, 310 bps, 233 bps and 82 bps. D) IL-6 promoter activity is shown for HeLa cells 
transfected with control or KPNB1 siRNA using an IL-6 promoter luciferase reporter plasmid. E) IL-6 
promoter activity shown for HeLa cells treated with 10 μM INI-43 for 21 hours followed by a 3 hour 
0.5 μM PMA stimulation. Results shown are the mean ± SEM of experiments performed in 
quadruplicate and repeated three independent times. (
#
p<0.05, significantly different from untreated 



























Figure 3.12: The effect of INI-43 on IL-6 mRNA expression in cervical cancer cells and normal 
fibroblasts. qRT-PCR was used to measure IL-6 mRNA expression in cervical cancer cells; HeLa (A), SiHa 
(B), and CaSki (C) and normal fibroblasts; FGo (D) after pre-treatment for 2 hours with 10 μM INI-43 
followed by 1 hour 0.5 μM PMA stimulation.  Results shown are the mean ± SEM of experiments 
performed in triplicate and repeated three independent times. (
#
p<0.05, significantly different from 
untreated control) (*p<0.05, significantly different from PMA-stimulated control)
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3.2.6.3 The effect of INI-43 treatment on IL-6 protein expression in cervical cancer cells 
 
We next monitored whether changes observed at the IL-6 mRNA levels translated to changes 
in the cytokine protein levels in cervical cancer cells. A Cytometric Bead Array was used to 
measure the concentration of secreted IL-6 present in the media of cervical cancer cell lines 
following INI-43 treatment. A standard curve was generated using known concentrations of 
IL-6 in order to quantify the IL-6 concentration in unknown samples (Fig. 3.13 A). Experiments 
were performed in triplicate with 300 events being recorded per sample. Treatment with INI-
43 was able to significantly reduce PMA-stimulated IL-6 protein levels in HeLa and SiHa but 
not in CaSki cells (Fig. 3.13 B). The generally reduced secreted levels of IL-6 by CaSki cells, in 
comparison to that of HeLa and SiHa, could account for the inability to see an effect following 
INI-43 treatment.     
 
3.2.7 Cervical cancer cell motility depends on inflammatory transcription factor activity 
 
There is evidence in the literature that NFkB and AP-1 signalling contributes to cancer cell 
migration and invasion through the expression of inflammatory cytokines such as IL-6 and 
TNF-α [41]. We have shown above that NFkB and AP-1 signalling can be modulated through 
inhibiting the function of KPNB1. As a result of this we wanted to investigate whether the 
changes in cervical cancer cell motility seen when KPNB1 was inhibited are potentially 
attributed to the inhibition of NFkB and AP-1 signalling. In order to do this we performed a 
transwell migration assay where HeLa cells were treated with INI-43 alongside cells where 
NFkB was inhibited (JSH-23) as well as AP-1 signalling inhibited (SP600125). Inhibiting NFkB 
signalling showed a trend towards reducing HeLa cancer cell migration the results were not 
significantly different from the control (Fig. 3.14 A). Inhibiting KPNB1 using INI-43 and 




































Figure 3.13: The effect of INI-43 on IL-6 protein expression in cervical cancer cells. A) For the 
Cytometric Bead Array samples of known IL-6 concentration were run on the BD Accuri C6 to create a 
standard curve from which samples of unknown IL-6 concentration could be calculated. B) Conditioned 
media was collected from cervical cancer cells overnight following a pre-treatment for 2 hours with 10 
μM INI-43 and a 1 hour 0.5 μM PMA stimulation, the Cytometric Bead Array was used to determine 
the IL-6 concentration (μg/ml) in these samples. Results shown are the mean ± SEM of experiments 
performed in triplicate, recording 300 events per sample, and repeated twice (
#
p<0.05, significantly 
different from untreated control) (*p<0.05, significantly different from PMA-stimulated control)
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cancer cells (Fig. 3.14 A). Quantification of the migration data is shown in Figure 3.14 (B). The 
data suggests that suppressed NFkB and AP-1 signalling following KPNB1 inhibition together 





















Figure 3.14: The role of transcription factors, NFkB and AP-1, in cervical cancer cell motility. A) 
Representative images of a transwell migration assay showing the amount of HeLa cells that were able 
to migrate through the membrane in the presence of 0.5 μM PMA (control) and following a 3 hour 
pre-treatment with 10 μM INI-43 and 20 μM JSH-23 and a 2 hour pre-treatment with 20 μM SP600125. 
Scale bar= 100μm, magnification x100. B) Quantification of the migration assay showing HeLa cell 
migration following INI-43, JSH-23 and SP600125 treatment, normalized to MTT cell viability. Results 






Our earlier data suggested that KPNB1 may play an important role in the survival as well as 
migratory and invasive potential of cervical cancer cells. A potential mechanism of action for 
the cell biology changes seen when KPNB1 is inhibited could relate to its function as a nuclear 
import protein. KPNB1 may be one of the key nuclear transporters of transcription factors 
associated with cancer cell growth, migration, invasion and metastasis.  
 
NFkB and AP-1 are among the main transcription factors implicated in the development and 
maintenance of the hallmarks of cancer through the initiation of target gene expression [42, 
88, 229]. As these transcription factors both require access to the nucleus in order to be 
functional we hypothesized that inhibiting nuclear import via KPNB1 may lead to their 
inactivity and ultimately various downstream effects on cancer cell biology. We identified 
KPNB1 to be required for the subcellular translocation and activity of the NFkB transcription 
factor. A study by Liang et al. (2013) found KPNB1 to be responsible for the cellular 
translocation of NFkB p65 and inhibiting its function resulted in the retention of NFkB p65 in 
the cytoplasm leading to reduced NFkB transcriptional activity [84]. Our data is in support of 
these findings. NFkB is an important mediator of inflammation while other transcription 
factors such as AP-1 have also been known to initiate expression of inflammatory cytokines 
[22, 62]. In this study we questioned whether inhibiting NFkB and AP-1 activity via inhibiting 
KPNB1 associated with the inhibition of inflammatory gene expression. KPNB1 was inhibited 
using two approaches; RNA interference and drug-mediated inhibition. The canonical NFkB 
pathway as well as c-JUN activation pathway was stimulated in cell culture using PMA which 
enhanced IL-1β, IL-6, TNF-α and GM-CSF expression. We show that stimulated cytokine 
expression could be blocked following inhibition of KPNB1 or through transcription factor 
specific inhibitors further confirming the reliance of NFkB and AP-1 activity on the nuclear 
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importer. NFkB and AP-1 both have a binding site on the IL-6 promoter and therefore both 
play a role in the initiation of IL-6 expression. The ability of both the NFkB inhibitor and the 
JNK inhibitor to block IL-6 mRNA expression confirms this. Stimulated IL-6 mRNA expression 
was inhibited by INI-43 treatment in all three cervical cancer cell lines but had no effect on 
the non-cancer cells used in our study. This suggests that the cancer cells are more sensitive 
to the inhibition of KPNB1, as was previously suggested in the proliferation studies. The 
inhibition of IL-6 expression in cancer cells was also seen at a protein level in HeLa and SiHa 
cells. In line with our findings, a study by Jin et al. (2012) showed that the alkaloid, 
Crytopleurine, was able to inhibit TNF-α, PMA or LPS stimulation of NFkB in breast cancer cells. 
Theses authors show that NFkB nuclear localisation and activity were both inhibited by 
Crytopleurine and caused reduced IL-6 and IL-1β target gene expression among others. 
Furthermore, they found inhibition of NFkB to inhibit MMP-9 expression and in turn reduce 
invasion of cancer cells using a transwell assay [230]. The pro-inflammatory cytokines; IL-1β, 
IL-6, TNF-α and GM-CSF have been implicated in cell biology changes required for tumour 
progression [46, 231-233]. These changes include increased migratory ability and invasive 
potential which are required for the epithelial-to-mesenchymal transition (EMT) that 
precedes metastasis [206]. On activation of the transcription factor, NFkB, target genes such 
as TNF-α and IL-6 can subsequently form a positive feedback loop further activating NFkB as 
well as other transcription factors such as AP-1 [74]. Together activation of these transcription 
factors has been associated with down-regulated E-cadherin expression and upregulation of 
matrix metalloprotease production ultimately promoting EMT [47, 73, 88]. Both transcription 
factors have been found to play a primary role in regulating MMP expression [40, 88, 104].  
 
To identify whether either NFkB or AP-1 are required for the migration of cervical cancer cells, 
each transcription factor was individually inhibited alongside INI-43 and the effect on 
migration analysed. Although inhibition of the AP-1 signalling pathway was able to 
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significantly reduce migration, neither inhibition of AP-1 or NFkB on their own were able to 
reduce migratory potential of cancer cells to the extent of the nuclear import inhibitor. This 
suggests that the effects seen following KPNB1 inhibition may be mediated through more than 
one transcription factor signalling pathway. 
 
Transcription factors of the FOS/JUN, CREB/ATF and NFkB families are known to act 
synergistically to significantly increase the expression of the same target gene. It has therefore 
been proposed that inhibiting more than one transcription factor acting synergistically may 
be a more appropriate approach when thinking about anticancer strategies [234]. Darnell 
(2002) proposed that inhibiting nuclear import proteins may be a way of specifically targeting 
multiple overactive transcription factors [23]. Our data provides evidence that supports 
Darnell’s proposal, showing that inhibiting KPNB1 affects AP-1 and NFkB transcriptional 
activities required for cancer cell biology.  
 
The first evidence of KPNB1 possibly being involved in inflammation was in a model of 
collagen-induced arthritis. Sun et al. (2016) showed that the anti-inflammatory effects were a 
result of nuclear import inhibition of IL-1β-induced STAT3 which in turn reduced the 
expression of IL-6 and MMP-1 leading to reduced invasion of fibroblast-like synoviocytes 
[235]. To our knowledge our study is a first to identify KPNB1 as a potential therapeutic target 
for inflammatory signalling in cancer associated with enhanced proliferation, motility and 
invasiveness. Much research has been done on targeting individual transcription factors as a 
chemotherapeutic approach. This approach is often associated with broad-range side effects 
given the diverse role of each transcription factor in normal cellular functioning. Cancer cells 
however, have been reported to become “addicted” and highly dependent on the activity of 
certain transcription factors or oncogenes, hence inhibiting their function is thought to affect 
cancer cells to a greater extent than non-cancer cells [236]. Ideally a targeted approach would 
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be required to limit such off-target effects. Targeting KPNB1 as a means of transcription factor 
inhibition may be a favourable approach in cancers where KPNB1 is overexpressed e.g. in 
cervical cancer tissue in comparison to normal tissue. We have previously shown that normal 
cells are less dependent on KPNB1 for proliferation and survival [128, 203]. These results 
provide evidence for the nuclear import protein, KPNB1, in supporting the biological 
phenotype of cancer cells and that inhibiting its expression and activity has multiple inhibitory 
effects on cancer cells. Given that KPNB1 cargo proteins range beyond NFkB and AP-1, it would 
be worth considering the effect of KPNB1 inhibition on the activity of tumour suppressor 
protein cargoes, from a personalised medicine point of view. To further characterise the role 
of the small molecule inhibitor of nuclear import, INI-43, as a potential chemotherapeutic, 
further investigation on its effects on tumour growth and development using in vivo models 





THE EFFECT OF INI-43 ON IN VIVO TUMOUR GROWTH AND 
MORPHOLOGY  




Extensive in vitro studies using cervical cancer cell lines in tissue culture has provided evidence 
for the role of KPNB1 as an anticancer target. Cancer cell proliferation, migration and invasion 
was inhibited following KPNB1-mediated nuclear import inhibition using both siRNA and small 
molecule approaches. This suggests that these effects are mediated through the inhibition of 
nuclear entry of transcription factors implicated with cancer cell biology such as; NFkB and 
AP-1. While yielding promising data, research using cell culture models have limitations as 
they do not take the tumour microenvironment and host interactions into account. Little is 
known regarding the in vivo effects of KPNB1 inhibition on tumour development. Our 
laboratory has made attempts to generate stable and inducible KPNB1 knockdown cells for 
investigation in in vivo models, with little success. The lack of generating KPNB1 knockdown 
cancer cells was likely due to leaky systems and the lethality of the knockdown in cancer cells. 
We previously showed that the inhibitory effects of INI-43 on nuclear import in vitro is likely 
through targeting KPNB1 as the effects of INI-43 on KPNB1 target proteins and cancer cell 
biology closely mimics those where KPNB1 was inhibited specifically through siRNA 
knockdown.  
 
In this study, we aimed to investigate the effects of INI-43 treatment on tumour growth using 
an in vivo mouse xenograft model for cervical cancer. Along with the analysis of tumour 
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growth following INI-43 treatment it is of interest to investigate the effect of INI-43 on KPNB1 
expression and localisation in vivo using immunohistochemical staining. Previously, INI-43 has 
been shown to alter the cellular localisation of KPNB1 in vitro by causing KPNB1 to be retained 
in the cytoplasm and on the perinuclear membrane as opposed to being located 
predominantly in the nucleus of untreated cells [203]. 
 
When solid tumours begin to grow and progress to a more invasive phenotype several 
characteristic changes occur. Initially cancer cells closely represent their tissue of origin but as 
they develop and grow they begin to lose their characteristic cellular architecture and 
organisation. Grading of cancer tumours is commonly used by pathologists to describe cellular 
appearance based on their differentiation state. A well-differentiated tumour closely 
represents the tissue of origin and contains recognisable structure and organisation. While 
poorly-differentiated tumours lose their characteristic phenotype and structure. 
Differentiation state correlates with proliferative and invasiveness of tumours [237]. As 
tumours grow their nutritional demands increase which stimulates the formation of stroma, 
a supportive network within the tumour. Stroma is produced in close relationship with host 
fibroblasts and consists of the extracellular matrix (ECM); composed of fibrous proteins such 
as collagen, proteoglycans and hyaluronic acid, and the stromal cells. These cells include the 
fibroblasts but also adipocytes and immune cells. The stromal matrix is also filled with various 
cytokines, chemokines, growth factors and ECM-modifying enzymes [238, 239]. These 
components of the stroma work together with the cancer cells to promote growth, 
angiogenesis and invasion and is therefore an essential part of a growing tumour [240-242]. 
A drug that disrupts the development of the stroma within tumours could have significant 




In this chapter, an ectopic xenograft mouse model for cervical cancer will be used to 
investigate the effect of INI-43 on tumour growth and the generation of histological data of 
KPNB1 levels, Ki-67 levels and morphological changes in control and INI-43-treated tumour 
sections. Our data suggests that the inhibition of tumour growth following INI-43 treatment 
associates with changes in tumour tissue morphology and structure as well as expression of 





4.2.1 The effect of INI-43 on tumour growth in an ectopic xenograft mouse model 
 
Karyopherin beta 1 has shown promise as an anticancer target in in vitro studies and to further 
investigate its potential in an in vivo system, an ectopic xenograft mouse model was used. 
Cytotoxicity studies were performed prior to this study and showed that mice tolerated a 
range of INI-43 treatment concentrations including 50 mg/kg, the concentration used in this 
study [203]. CaSki, cervical cancer cells, were subcutaneously injected into the hind flank of 
athymic nude mice and tumours allowed to develop. Treatment through intraperitoneal 
injection of the vehicle (DMSO) or 50 mg/kg INI-43 commenced once tumours were palpable. 
Injections were performed three times per week for the duration of 4 weeks. The tumour size 
was measured using calipers over the course of treatment and tumour volume calculated. 
Analysis of tumour volume showed that INI-43 treatment resulted in a significant reduction in 
tumour size compared to the controls (Fig. 4.1). This result provides additional support for INI-
43 as a small molecule with anticancer activity.      
 
  
Figure 4.1: Tumour growth in an ectopic xenograft mouse model following INI-43 treatment. Tumour 
volume in control (DMSO) and INI-43 treated (50 mg/kg) nude mice bearing ectopic CaSki, cervical 




4.2.2 The effect of INI-43 treatment on KPNB1 expression and localisation in vivo 
 
At the end of the in vivo xenograft mouse study the tumours were removed for histological 
analysis. As INI-43 has been proposed to target KPNB1, it was of interest to investigate the 
expression and localisation of KPNB1 in the tumour samples following INI-43 treatment. 
Immunoperoxidase staining using an antibody specific for KPNB1 was used to analyse KPNB1 
expression and localisation within the tumours. All immunohistological sections were ‘blind’ 
assessed and scored with assistance from an anatomical pathologist based in the Division of 
Anatomical Pathology at the University of Cape Town.  
 
4.2.2.1 Expression of KPNB1 in INI-43-treated tumours 
 
For immunohistochemical analysis of KPNB1 expression, human liver tissue was used as a 
positive control. Specificity of the antibody was confirmed with the negative control showing 
no immunoperoxidase (brown) staining and with only the haematoxylin (blue) counterstain 
visible while the positive control showed widespread immunoperoxidase staining (Fig. 4.2 A). 
KPNB1 has been known to be overexpressed in cervical cancer tissue in comparison to normal 
cervical tissue [128]. Here we support that data and show low KPNB1 expression seen in 
normal human endocervical tissue (Fig. 4.2 B). In comparison, untreated cervical cancer 
tumour samples from the xenograft mouse study showed substantially high levels of KPNB1 
expression (Fig. 4.2 C). Sections from INI-43-treated samples, in contrast, showed a 
considerably reduced KPNB1 staining (Fig. 4.2 C).      
 
4.2.2.2 Cellular localisation of KPNB1 within INI-43-treated tumours 
 
Previously, using in vitro analysis we observed that KPNB1 showed predominantly nuclear 
localisation in untreated cervical cancer cells but following INI-43 treatment KPNB1 
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localisation was more cytoplasmic and in the perinuclear space [203]. Immunohistological 
sections were thus examined to determine KPNB1 expression in the nuclear and cytoplasmic 
compartments in sections from control and INI-43-treated tumours. The percentage of tissue 
showing either weak, moderate or strong KPNB1 staining was determined and the average 
percentage tabulated in Table 4.1. The results show that INI-43-treated tumour cells had 
reduced cytoplasmic KPNB1 expression levels (100% of cells showed weaker staining) 
compared to control tumours showing 60% strong cytoplasmic staining and 40% weak 
staining. Nuclear expression levels of KPNB1 remained largely unchanged. Also noted was that 
normal endocervical tissue showed exclusively nuclear KPNB1 expression while the cervical 
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Figure 4.2 A & B: Immunohistochemical analysis of KPNB1 expression in INI-43-treated tumours. A) 
Negative and positive controls in human liver tissue samples for KPNB1 immunoperoxidase staining 
(brown), counterstained with Haemotoxylin (blue). B) KPNB1 staining in normal human endocervix 
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Figure 4.2 C: Immunohistochemical analysis of KPNB1 expression in INI-43-treated tumours. 
Representative images of KPNB1 staining in untreated control (DMSO) and INI-43-treated (50 mg/kg) 
CaSki xenograft tumours. Results shown represent tumour samples from 3 mice per treatment. Scale 















To further investigate the localisation of KPNB1 in the tumours, the percentage of cells that 
showed nuclear versus cytoplasmic expression of KPNB1 was assessed. KPNB1 showed a 
greater cytoplasmic localisation and less nuclear staining in INI-43-treated tumour cells (Fig. 
4.3 A & B). Fewer cells in the INI-43-treated tumours showed nuclear KPNB1 staining with 
more cells showing cytoplasmic KPNB1 localisation of which the cytoplasmic KPNB1 
expression levels were considerably reduced. Together with the previous results, nuclear 
KPNB1 expression levels remain unchanged however fewer cells within the tumour showed 
nuclear KPNB1 staining. Reciprocally more cells showed cytoplasmic KPNB1 localisation 
although the cytoplasmic KPNB1 expression levels were considerably reduced. 
 
  
























Figure 4.3: KPNB1 cellular distribution within INI-43-treated tumours. A) Bar graph showing the 
average percentage of cells with cytoplasmic or nuclear KPNB1 staining across 3 tumours per 
treatment shown as the mean ± SEM. B) Representative images showing immunoperoxidase staining 
for KPNB1 with arrows indicating nuclear (N) and cytoplasmic (C) staining for control and INI-43-
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4.2.3 The effect of INI-43 on cellular proliferation of in vivo tumours 
 
Nuclear import inhibition using INI-43 could significantly reduce tumour growth in vivo as well 
as have cytotoxic effects in vitro. These results lead us to investigate the effect of INI-43 on 
proliferation of cells within the xenograft tumours. Immunoperoxidase staining for the marker 
of proliferation, Ki-67, was used to detect proliferating cells within the tumours. As controls 
for Ki-67 staining, tissue of the human appendix that contains actively proliferating cells was 
used as a positive control and a negative control which showed no immunoperoxidase staining 
and only the haematoxylin counterstain (Fig. 4.4 A).  Results showed considerably fewer cells 
stained positive for Ki-67 in the INI-43-treated tumours in comparison to the control (Fig. 4.4 
B). The reduced proliferation of INI-43-treated tumours is in support of our previous results 
which show reduced tumour size in mice following INI-43 treatment. In addition, it was noted 
that Ki-67 staining appeared negative in regions of well-differentiated tissue and positive in 






Figure 4.4: Assessment of proliferation following INI-43 treatment in vivo. A) Images representative 
of the negative and positive controls for Ki-67 immunoperoxidase staining in human appendix tissue 
samples, counterstained with Haemotoxylin. B) Representative images of Ki-67 staining in control 
untreated and INI-43-treated tumours. C) A representative image of differential Ki-67 staining showing 
positive staining in poorly-differentiated tissue and the basal cell layer and negative staining in areas 
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4.2.4 Monitoring histological changes in tumours treated with INI-43 
 
4.2.4.1 The effect of INI-43 on differentiation status 
 
The correlation between positive Ki-67 staining and poor tissue differentiation in the previous 
result is to be expected as poorly-differentiated tissue is characteristically invasive and 
actively proliferating while the inverse is true for well-differentiated tissue. The reduced 
presence of proliferating cells after treatment with INI-43, as determined through Ki-67 
immunostaining, lead us to further investigate the differentiation status of tissue within the 
tumours. Tissue differentiation is generally used as a visual means to grade cancer tumours. 
Well-differentiated tissue closely represents the tissue of origin, with the cells appearing large 
and eosinophilic with well-defined nucleoli. The cells are also layered in a uniform 
architectural pattern and generally grow at a slower rate. In contrast, poorly-differentiated 
tissue lose most of their epithelial characteristics and architecture. The cells contain poorly-
defined nucleoli and have enlarged or even multiple nuclei. Poorly-differentiated tissue tends 
to grow and spread more quickly. H&E staining of the tumour sections allowed us to 
distinguish between well- and poorly-differentiated tissue. INI-43-treated tumours showed a 
trend towards containing more well-differentiated tissue and less poorly-differentiated tissue 
than the control untreated tumours (Fig. 4.5 A). The percentage of tissue that was well- versus 
poorly-differentiated in all the control and treated tumours was quantified and shown in Fig. 






Figure 4.5: Tumour morphology following INI-43 treatment.  A) H&E stained histological sections 
showing poorly-differentiated (green arrow) and well-differentiated (blue arrow) tissue in control 
(DMSO) and INI-43-treated tumours. (N) Region of necrosis. Scale bar= 50 μm, magnification x200. B)  
Bar graph showing the average percentage of tissue that was poorly or well-differentiated across the 





















50 μm 50 μm 
50 μm 50 μm 
111 
 
4.2.4.2 The effect of INI-43 on other histological features relevant to cancer 
 
The role of necrosis, cystic change and inflammatory stroma may also be relevant to the 
progression of cancer and the overall outcome of patients. Staining with H&E allowed the 
detection of these histological features within the xenograft tumour samples. Our main 
observations are summarised in Table 4.2 and include; 1) that extensive necrosis formed part 
of all the tumours regardless of treatment, 2) the presence of cystic change was substantially 
less in INI-43-treated tumours in comparison to control untreated tumours and 3) the 
presence of stroma containing inflammatory cells was virtually absent in INI-43-treated 
tumours but easily identifiable untreated tumours. Representative images of the presence of 
these histological features (necrosis, cystic change and inflammation) are presented in Fig. 4.6 
(A). Also noted was that while infiltrating, inflammatory stroma can be seen surrounding 
cancer tissue in the control tumours, it is minimally detected in INI-43-treated tumours (Fig. 
4.6 B). The effect of nuclear import inhibition on cystic change and inflammation within the 
tumour may contribute to its anticancer effect.  
  




Figure 4.6: Representative images of histological findings. A) Representative H&E stained tumour 
sections with arrows indicating necrosis, cystic change (Scale bar= 50 μm, magnification x200) and 
inflammation containing neutrophils (green) and lymphocytes (blue) (Scale bar= 25 μm, magnification 
x400). B)  H&E stained sections showing the presence (shown by arrow) or absence of inflammatory 
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4.2.5 The effect of INI-43 on the expression of ECM components  
 
4.2.5.1 Effect of INI-43 on Type I and Type IV collagen expression 
 
The histological data presented above showed that INI-43-treated tumours contained minimal 
stroma surrounding cancer cells. Although stroma is predominantly a product of host 
fibroblasts, cancer cells can also produce ECM components thereby contributing to the 
generation of their own niche [238]. Collagen is a predominant component of stroma and the 
ECM. The observation of diminished stroma in the INI-43-treated tumour environment 
prompted us to investigate the effects of INI-43 on collagen expression in cancer cells. Type I 
collagen forms the predominant component of the interstitial matrix while Type IV collagen is 
the main component of basement membranes, and both have been implicated in cancer cell 
proliferation and motility [238, 239]. We therefore investigated the effects of INI-43 on Type 
I and Type IV collagen expression in CaSki, cervical cancer cells. Results show that CaSki cells 
treated with INI-43 showed no significant change in Type I alpha I collagen (COL1A1) 
expression in the presence or absence of PMA stimulation (Fig. 4.7 A & B). INI-43 treatment 
however, significantly reduced the expression of Type IV alpha I collagen (COL4A1) expression 
in both unstimulated (Fig. 4.7 C) and PMA stimulated cells (Fig. 4.7 D). This data suggests that 
INI-43 treatment may have an effect on the levels of ECM components.  
 
4.2.5.2 Effect of INI-43 on the ECM degrading enzyme, MMP-9 
 
The expression of Type IV collagen degrading enzymes such as MMP-9 have also been found 
to be upregulated in cancer and contribute to poor cellular differentiation and increased 
invasion of cancer cells [244]. We were therefore interested in monitoring the effect of INI-43 
on PMA-stimulated MMP-9 expression in CaSki cells. Our results showed an increase in MMP-
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9 expression with PMA stimulation which was significantly inhibited by pre-treatment with 
INI-43 (Fig. 4.7 E). 
 
  
Figure 4.7: The effect of INI-43 on the expression of ECM components in vitro. A) qRT-PCR was used 
to measure mRNA expression of collagen type I (COL1A1) following a 24 hr treatment with 5 µM INI-
43 alone or B) including a 3 hr stimulation with 0.5 µM PMA. C) mRNA expression of collagen type IV 
(COL4A1) following a 24 hr treatment with 5 µM INI-43 alone or D) including a 3 hr stimulation with 
0.5 µM PMA. E) mRNA expression of MMP-9 following a 24 hr treatment with 5 µM INI-43 including a 
3 hr stimulation with 0.5 µM PMA. Results shown are the mean ± SEM of experiments performed in 
triplicate and repeated three independent times. (
*
p< 0.05).  
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Together these results suggest that the inhibition of nuclear import associated with KPNB1, 
using the small molecule inhibitor: INI-43, results in modification of the expression of ECM 
components and ECM modulating factors. 
 
4.2.6 Effect of INI-43 on cancer cell morphology 
 
Having observed a reduction in poorly-differentiated, invasive and proliferative tissue in in 
vivo tumours treated with INI-43, we postulated that INI-43 treatment may cause changes in 
cancer cell morphology. Cancer cells undergo a shift in morphology from being more epithelial 
in nature to becoming more mesenchymal which facilitates motility and promotes their 
invasiveness.  
 
4.2.6.1 The effect of INI-43 on β-catenin  
 
The protein, β-catenin, which forms part of adherens junctions plays an important role in 
morphogenic change of epithelial cells. In cancer, it causes the cells to lose their tight cell-to-
cell adhesion and assume a more mesenchymal phenotype by releasing from the cell 
membrane and translocating to the nucleus. In the nucleus β-catenin exerts its effects through 
regulating genes that promote motility and inhibit adhesion [245]. We investigated the effect 
of INI-43 on β-catenin and found that INI-43 treatment of CaSki cells caused a significant 
reduction in the nuclear presence of β-catenin (Fig. 4.8 A). A scan of immunofluorescent 
intensity across the cell diameter shows localisation of β-catenin (Cy-3) overlaps with the DAPI 
stain (nucleus) in control cells and a reduction in β-catenin fluorescent intensity in the nucleus 
of INI-43-treated cells (Fig. 4.8 B). Quantification of β-catenin nuclear intensity data shows a 
significant reduction following INI-43 treatment (Fig. 4.8 C). The overall expression of β-
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catenin remained unchanged as observed by quantification of the whole cell fluorescent 
intensity (Fig. 4.8 D).   
 
  
Figure 4.8: Expression and localisation of the mesenchymal marker, β-catenin, following INI-43 
treatment in vitro. A) Representative immunofluorescent images showing β-catenin (Cy3-red) 
expression and localisation in CaSki cells following 24 hr treatment with 5 μM INI-43. DAPI (blue) was 
used to stain nuclei.  Scale bar= 10μm, magnification x1000. B) Correlation between Cy3 (β-catenin) 
and DAPI (nucleus) fluorescent intensity in control and INI-43-treated CaSki cells performed using 
ImageJ. C) Quantification of β-catenin localisation across 50 cells per treatment showing the relative 
nuclear fluorescent intensity. D) Quantification of the mean whole cell fluorescent intensity per 
treatment. Results shown are the mean ± SEM of experiments performed two independent times. (
*
p< 








































































































































4.2.6.2 Effect of INI-43 on cytoskeletal rearrangement 
 
A reduction in nuclear β-catenin has been reported to correlate with morphological changes 
such as a loss in mesenchymal-like characteristics and a gain in epithelial characteristics. Thus, 
to further investigate the effects of INI-43 on the morphology of cancer cells, CaSki cells were 
stained with Phalloidin which binds polymeric filamentous actin (F-actin) and allows 
visualisation of the cytoskeletal arrangement. Fluorescent images showed that cells treated 
with INI-43 appeared to be smaller in size, more closely packed and had considerably fewer 
cytoplasmic protrusions (Fig. 4.9 A). To quantify this data, 50 cells per condition were 
monitored. The number of cytoplasmic protrusions per cell were counted and results show 
that INI-43 treatment significantly reduced the number of cytoplasmic protrusions (Fig. 4.9 B). 
In addition, a small but significant reduction in cell size was observed (Fig. 4.9 C). A reduction 
in cell size or the number of cytoplasmic protrusions is consistent with the development of 
more epithelial characteristics suggesting that INI-43 treatment contributes to a change in 


































Figure 4.9: Analysis of F-actin rearrangement following INI-43 treatment in vitro. A) Representative 
immunofluorescent images of CaSki cells stained with Phalloidin (red) for F-actin and DAPI (blue) for 
the nuclei following treatment with 5 μM INI-43 for 24 hrs. Arrows indicate cytoplasmic protrusions. 
Scale bar= 10μm, magnification x1000. B) Bar graph representing the number of cytoplasmic 
protrusions per cell following INI-43 treatment. C) The area of 50 cells per treatment was measured 
using ImageJ and represented using a bar graph. Results shown are the mean ± SEM of experiments 
performed two independent times. (
*





In this study, we investigated the pre-clinical potential of INI-43 as an anticancer drug, 
following initial in vitro studies. For this, we used an in vivo mouse model. CaSki, cervical 
cancer, cells formed ectopic xenograft tumours in nude mice. Prior toxicology studies 
determined that the mice used in our study tolerated a dose of 50 mg/kg INI-43 with no side 
effects observed. This dose was thus used to investigate the effects of INI-43 on in vivo tumour 
development. Treatment with 50 mg/kg INI-43 three times per week significantly reduced 
tumour size in vivo. This finding is significant and to our knowledge is a first to test and show 
the anticancer ability of a potential nuclear import inhibitor in vivo. There is however 
substantial data in the literature for the use of nuclear export inhibitors as anticancer drugs in 
mouse models. The Selective Inhibitors of Nuclear Export or SINE compounds, KPT-330 and 
KPT-251 that target the nuclear exporter XPO1, have been shown to significantly reduce 
tumour growth of a renal cell carcinoma xenograft mouse model [217, 246]. KPT-330 was also 
able to reduce tumour growth in a pancreatic orthotopic and subcutaneous mouse model 
[214]. Similar to the reported effects seen in these studies our study showed that tumour 
growth could be inhibited, exhibiting a cytostatic effect. Selinexor, KPT-330, is currently being 
used in a wide selection of clinical trials against solid tumours and haematological 
malignancies [192]. In addition, inhibition of XPO1 has been found to sensitise cells to 
conventional chemotherapeutic drugs and inhibitors of nuclear export have shown potential 
in combination therapies in vitro [197]. Similarly, inhibition of KPNB1 using INI-43 sensitised 
cervical cancer cells in culture to Cisplatin treatment (unpublished data; A. Chi, PhD Thesis, 
2016‡). This suggests that INI-43 also has the clinical potential to be explored further in 
combination therapies.     
                                                           
‡A. Chi, “Investigating a novel small molecule inhibitor of nuclear import as an anti-cancer approach.” 




As INI-43 is suggested to physically target and inhibit KPNB1 function, we investigated 
whether this had any effect on the expression or localisation of KPNB1 within INI-43-treated 
tumours. We found that with INI-43 treatment, more cells showed cytoplasmic KPNB1 staining 
compared to nuclear staining in comparison to the untreated control tumours. The KPNB1 
staining pattern also appeared reduced in the cytoplasm. These results are consistent with in 
vitro data from our laboratory that showed that INI-43 not only caused the cytoplasmic 
retention of KPNB1 but also caused a reduction in cytoplasmic and nuclear levels as seen in 
experiments using immunofluorescence and cyclohexamide treatment to inhibit protein 
synthesis [203]. The reduction in KPNB1 levels is attributed to an increase in its degradation 
in response to INI-43 treatment (unpublished data; S. Carden, MSc Dissertation, 2017§).  
 
KPNB1 was found to be highly expressed in the cytoplasmic and nuclear compartments of 
diffuse large B-cell lymphoma, hepatocellular carcinoma and gastric cancer tissue. In all cases 
this correlated with increased Ki-67 expression, a marker of proliferation, and shorter overall 
patient survival [142, 247, 248]. In hepatocellular carcinoma and gastric cancer, both solid 
tumours, KPNB1 overexpression correlated with poorly-differentiated tumours as well as Ki-
67 staining [142, 248]. Our data is in support of this as control tumours showed higher KPNB1 
expression, a greater percentage of poorly-differentiated tissue and increased Ki-67 staining. 
In contrast the INI-43-treated tumours showed reduced KPNB1 expression, a greater 
percentage of well-differentiated tissue and reduced Ki-67 staining. The reduced proliferation 
and presence of better differentiated tissue in tumours where KPNB1 expression was reduced 
suggests that KPNB1 plays a role in cervical cancer tumour development. Extensive research 
has been done describing KPNA2, one of KPNB1’s adaptor proteins, as a prognostic marker in 
                                                           
§ S.Carden, “Modulating the expression and activity of the nuclear import protein, Karyopherin B1, in 
cancer cells.” MSc Dissertation, University of Cape Town, 2017 
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cancer. The close relationship between these two proteins suggests that the clinical relevance 
of KPNA2 expression and localisation in tumours may be applicable to KPNB1 as well. 
Increased nuclear expression of KPNA2 has also been found to correlate with poor tissue 
differentiation and increased Ki-67 expression in hepatocellular and oesophageal squamous 
cell carcinoma [178, 249]. Erben et al. (2015) found that the cytoplasmic or nuclear expression 
pattern of KPNA2 affected patient outcome in head and neck squamous cell cancer. Patients 
with tumours expressing high levels of nuclear and cytoplasmic KPNA2 had a better prognosis 
than patients expressing only high levels of nuclear KPNA2 and no cytoplasmic expression 
[250]. This data suggests that not only expression but also cellular localisation of the nuclear 
import protein may be relevant to cancer progression. The association between KPNB1 
expression and localisation with patient clinical outcome is of interest to our research group 
and forms part of on-going research in our laboratory.  
 
On identifying other histological differences between control and INI-43-treated tumours that 
associate with the anticancer effect of INI-43, it was found that INI-43-treated tumours were 
absent of or contained far less inflammatory stroma. A possible reason for this could be the 
prevention of leukocyte migration into the tumour which has been suggested to have anti-
inflammatory effects and prevents tumour progression [207]. The development of stroma and 
infiltration of immune cells into the tumour is largely dependent on the communication 
between cancer cells and the host microenvironment through chemokines and cytokines [44, 
239, 241, 251]. Although the components of the ECM are mainly produced by the stromal 
cells, cancer cells too can produce their own ECM components and this is thought to 
contribute to the production of their own niche [252-254]. Among these ECM components are 
Type I collagen, a major component of interstitial matrix, and Type IV collagen, a major 
component of basement membranes. Studies in pancreatic cancer found that the cancer cells 
produced far greater quantities of Type IV collagen in comparison to Type I and that Type IV 
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collagen associated much more closely with cancer cells in tumours [255, 256]. Our study 
showed that INI-43 treatment of cervical cancer cells reduced the expression of Type IV 
collagen. Type IV collagen has been found to be important for adhesion, migration, survival, 
proliferation and differentiation of cancer cells. Inhibition of Type IV collagen using siRNA was 
able to significantly reduce cell growth and migration while increasing apoptosis in pancreatic 
cancer cells [253]. Type IV collagen was also able to induce EMT in breast cancer cells [257]. 
The expression of Type IV collagen is regulated by a tight balance between MMP-2 and -9 and 
their inhibitors, TIMP-1 and TIMP-2 [258]. Following INI-43 treatment it was found that MMP-
9 expression was significantly reduced. As cancer cells adopt a more mesenchymal phenotype 
which favours migration and invasion they show increased MMP expression, changes in the 
cytoskeleton to facilitate this as well as β-catenin nuclear localisation among other features 
[257]. Our data shows that INI-43 treatment was able to reduce β-catenin nuclear localisation 
as well as cause cytoskeletal changes such as; causing a reduction in the number of 
cytoplasmic protrusions and cell size. These features are characteristic of a more epithelial, 
tightly-packed phenotype. In gastric cancer tumours, increased nuclear KPNA2 expression 
associated with increased nuclear accumulation of β-catenin while reduced KPNA2 expression 
correlated with cytoplasmic β-catenin expression [122]. This suggests that increased 
expression of the nuclear transporter associates with EMT even though β-catenin nuclear 
import is independent of the Karyopherin family [259]. KPNA2 knockdown was able to reverse 
EMT [139]. This evidence suggests that the reduced nuclear localisation of β-catenin following 
INI-43 treatment, is not necessarily directly associated with KPNB1 inhibition and that an 
alternative mechanism may exist. 
 
In conclusion, this study has determined that INI-43 is able to inhibit tumour growth in vivo. 
Reduced KPNB1 expression and altered localisation may contribute to cancer progression and 
could explain the reduced Ki-67 expression and presence of more well-differentiated tissue in 
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INI-43-treated tumours. Inhibition of KPNB1 in cancer cells may also disrupt the expression of 
genes required for communication with the tumour microenvironment and establishment of 
the ECM. Together these results begin to elucidate the role of INI-43 in vivo and provide 
further evidence of its anticancer properties. Further investigation into how KPNB1 inhibition 






            
 
Targeted therapy is a novel and innovative chemotherapeutic approach which identifies a 
molecular lesion or dysregulated pathway that cancer cells are dependent on. Key 
components of the nuclear transport system including the nuclear import proteins; KPNB1 
and KPNA2, and nuclear export protein, XPO1, have been identified in our laboratory and 
others as potential therapeutic targets and prognostic markers [122, 128, 130, 138, 142, 169, 
175, 260]. This study set out to investigate the role of KPNB1 in cancer cell biology changes 
and inflammatory signalling associated with tumourigenesis. The nuclear import protein, 
KPNB1, was inhibited using targeted siRNA and a small molecule inhibitor, INI-43, and changes 
in cancer cell proliferation, survival, migration and invasion monitored in vitro. To elucidate 
the mechanism behind these cell biology changes the effect of KPNB1 inhibition of 
transcription factors associated with cancer cell biology such as NFkB and AP-1 and 
inflammatory target gene expression were investigated. The pre-clinical anticancer potential 
of INI-43 treatment was also further investigated using an ectopic xenograft mouse model. 
Our study aimed to further characterise the anticancer potential of KPNB1 inhibition. 
 
Previous studies in our laboratory using cervical tissue, found KPNB1 to be overexpressed in 
cervical cancer tissue compared to normal cervical tissue suggesting it may have value as a 
chemotherapeutic target [128]. In this study and others, KPNB1 was found to be essential for 
cancer cell proliferation and survival while normal cell proliferation and survival was relatively 
unaffected by the inhibition of KPNB1 [202, 203, 247, 248]. These findings indicated that 
cancer cells have a greater dependency on KPNB1 than normal cells for their proliferation. 
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Little however, is known about the role of KPNB1 in other cancer cell biological phenotypes 
such as migration and invasion. In this study, we show that inhibition of KPNB1 using either 
siRNA or the small molecule, INI-43, significantly reduced the migration and invasion of 
cervical cancer cells. Treatment with INI-43 was also found to negatively regulate matrix 
metalloproteases (MMPs), which facilitate cell motility, and was positively associated with 
elevated levels of endogenous inhibitors of MMPs. Our results showed that INI-43 treatment 
reduced PMA-stimulated MMP-2 and -9 expression and increased TIMP-1 and -2 expression. 
Both MMP’s and TIMPs are tightly regulated by inflammatory transcription factor signalling 
and their dysregulation has been associated with the progression of cancer [40, 88, 104]. 
Considering this we proposed that KPNB1 may be the key transporter of transcription factors 
associated with cancer cell growth, migration and invasion. 
 
Two such transcription factors closely involved in the development and maintenance of the 
hallmarks of cancer are, NFkB and AP-1 [74, 88]. Nuclear import of these transcription factors 
is essential for their activity. We thus questioned a potential role of KPNB1 in the nuclear 
import of these transcription factors. This was achieved by inhibiting KPNB1 and monitoring 
effects on NFkB and AP-1. Using western blotting and immunofluorescent microscopy, we 
showed that KPNB1 is essential for the nuclear import of NFkB. Transcriptional activity assays, 
using luciferase reporter assays for NFkB and AP-1, showed that the activities of both 
transcription factors were negatively impacted when KPNB1 was inhibited using KPNB1 siRNA 
and INI-43. The inhibitory effect on transcriptional activity was comparable to that of 
commercially available nuclear import inhibitors; Importazole and Ivermectin. Interestingly, a 
lower concentration of INI-43 (5 µM) has the same inhibitory effect as Importazole and 





 Next we investigated whether the effect of KPNB1 inhibition on NFkB and AP-1 transcriptional 
activity translated to the level of target gene expression. The expression of key inflammatory 
genes which are known targets of NFkB and/or AP-1; IL-1β, IL-6, TNF-α and GM-CSF was 
monitored in cervical cancer cells in response to KPNB1 inhibition. These inflammatory 
cytokines have been implicated in promoting proliferation and facilitating cancer cell 
migration and invasion [46, 231-233]. Inhibition of KPNB1 significantly inhibited PMA-
stimulated expression of these cytokines in cancer cells. The substantially greater reduction 
in IL-1β and TNF-α expression following INI-43 treatment compared to the effect of the NFkB 
inhibitor, JSH-23, and in IL-6 expression compared to the JNK inhibitor, SP600125, suggests 
that KPNB1 inhibition may have an effect on multiple transcription factors. The activity and 
expression of the IL-6 target gene was investigated further as this gene is under the control of 
both the NFkB and AP-1 transcription factors. Interleukin 6 promoter activity was significantly 
reduced following KPNB1 inhibition using both siRNA and INI-43. INI-43 treatment also 
significantly reduced the IL-6 protein secretion from HeLa and SiHa cells. Our data also showed 
that while INI-43 caused a significant reduction in IL-6 mRNA expression in cervical cancer cell 
lines; HeLa, SiHa and CaSki, little/no effect was detected on normal fibroblast IL-6 expression 
at the same concentration. These results support our earlier findings that cancer cells are 
more sensitive to the effects of KPNB1 inhibition. Cancer cells are known to become 
“addicted” to certain transcription factors or oncogenes and could be the reason why cancer 
cells are more reliant on KPNB1 than normal cells [236].  
 
To further elucidate whether either NFkB or AP-1 are required for the migration of cervical 
cancer cells, each transcription factor was individually inhibited using JSH-23 and SP600125 
alongside INI-43 and the effect on migration analysed. Inhibition of the AP-1 signalling 
pathway using SP600125 significantly reduced migration and inhibition of NFkB using JSH-23 
showed a downward trend towards inhibiting migration that was however, not significant. 
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Neither inhibition of AP-1 or NFkB on their own reduced the migratory potential of cancer 
cells to the extent of that observed with INI-43. This further suggests that the effects seen 
following KPNB1 inhibition are mediated through more than one transcription factor signalling 
pathway. It is not uncommon for transcription factors to act synergistically to achieve 
enhanced transcriptional regulation of the same target gene. Transcription factors of the 
JUN/FOS, CREB/ATF and NFkB families most commonly act together to enhance expression of 
a single target gene [234].  Darnell (2002) proposed that targeting nuclear import proteins 
may be an effective way of inhibiting multiple overactive signalling pathways [23]. Our findings 
are in support of this proposal, showing that KPNB1 inhibition affects the transcriptional 
activity of both NFkB and AP-1.  
 
Extensive in vitro studies using cervical cancer cell lines in tissue culture to provide evidence 
for the role of KPNB1 as an anticancer target has been performed however, little is known 
about the in vivo effects of KPNB1 inhibition on tumour development. A significant finding 
from our study showed that INI-43 treatment inhibited tumour growth in an ectopic xenograft 
mouse model. We had previously reported that the cellular and signalling effects of KPNB1 
inhibition using either siRNA or INI-43 yielded very comparable results, supporting that INI-
43-induced anticancer activity is mediated through KPNB1. We therefore investigated 
whether INI-43 treatment of tumours influenced the expression or localisation of KPNB1. Our 
study found that INI-43 treatment resulted in more tumour cells showing cytoplasmic KPNB1 
staining compared to nuclear staining in comparison to the DMSO-treated control tumours. 
The KPNB1 staining pattern also appeared reduced in the cytoplasm. These results were in 
support of our in vitro data in our laboratory that showed that INI-43 not only caused the 
cytoplasmic retention of KPNB1 but also caused a reduction in cytoplasmic and nuclear levels 
as seen in experiments using immunofluorescence and cyclohexamide treatment to inhibit 
protein synthesis [203]. The reduction in KPNB1 levels was attributed to an increase in its 
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degradation in response to INI-43 treatment (unpublished data; S. Carden, MSc Dissertation, 
2017**).  The cellular localisation and expression levels of KPNB1 and its adaptor protein 
KPNA2 have been correlated to proliferation and differentiation status of the tumour as well 
as patient outcome [142, 178, 179, 248, 249]. Increased KPNB1 expression positively 
correlated with tumour grade and size and associated with poor survival in patients with 
hepatocellular and gastric carcinoma [142, 248]. Patients with tumours expressing high levels 
of nuclear and cytoplasmic KPNA2 had a better prognosis than patients expressing only high 
levels of nuclear KPNA2 and no cytoplasmic expression [250]. In support of these findings our 
data shows that INI-43-treated tumours, expressing lower levels of cytoplasmic KPNB1, had 
reduced levels of proliferation (Ki-67 staining) and appeared more well-differentiated. In 
comparison, the control tumours, expressing higher levels of KPNB1, had increased levels of 
proliferation and appeared poorly-differentiated. These results implicate KPNB1 as being 
required for cervical cancer tumour progression.  
 
On further investigation of other histological differences between control and INI-43-treated 
tumours, that associate with the anticancer effect of INI-43, it was found that INI-43-treated 
tumours were absent of or contained far less inflammatory stroma. Our previous findings 
show that KPNB1 inhibition reduced NFkB and AP-1 activity consequently leading to the 
reduced expression of inflammatory cytokines. These inflammatory cytokines play an 
important role in the recruitment and development of the inflammatory stromal components 
making up the ECM [197, 239, 241, 251]. This could provide an explanation for the absence of 
inflammatory stroma in the INI-43-treated tumours. Although most components of the ECM 
are produced by fibroblasts or other host cells, cancer cells behave aberrantly and can 
contribute to the production of their own niche [252, 253]. This led us to investigate the role 
                                                           
** S.Carden, “Modulating the expression and activity of the nuclear import protein, Karyopherin B1, in 
cancer cells.” MSc Dissertation, University of Cape Town, 2017 
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of KPNB1 inhibition in cancer cells on the expression of certain ECM components. We found 
INI-43 treatment to inhibit the expression of type IV collagen in cancer cells, an ECM 
component important for cancer cell adhesion, proliferation and motility [253]. Another 
factor important for cancer cell motility, MMP-9, was also inhibited by INI-43 treatment. 
Together these results suggest that INI-43 treatment influences the formation of the tumour 
stroma, contributing to its anticancer activity.  
 
An increase in MMP expression is also characteristic of cells of a mesenchymal phenotype 
[257]. The enhanced activation of NFkB in cancer cells has been shown to promote the 
progression of cancer cells to a more mesenchymal-like phenotype by inhibiting E-cadherin 
expression, a characteristic epithelial marker [47]. In more mesenchymal cells, the loss of E-
cadherin from adherens junctions activates cytosolic β-catenin and stimulates its nuclear 
translocation [245]. A mesenchymal phenotype facilitates migration and invasion of cancer 
cells. We therefore investigated the effect of INI-43 treatment on changes in the cytoskeleton 
and β-catenin nuclear localisation both characteristic features of the transition between 
epithelial and mesenchymal phenotypes. Our data shows that INI-43 treatment could reduce 
β-catenin nuclear localisation as well as cause cytoskeletal changes including; a reduction in 
the number of cytoplasmic protrusions and a reduction in cell size. Together these findings 
suggest that INI-43 treatment is causing a loss of mesenchymal-like features of the cancer cells 
assayed in our study, likely to affect their invasive capabilities.     
 
The key findings of this study are summarised diagrammatically in Figure 5.1. During normal 
cell growth conditions, KPNB1-mediated nuclear import cargo proteins such as transcription 
factors containing a NLS are transported into the nucleus together with or without the 
Karyopherin alpha adaptor protein. Once in the nucleus the transcription factor is available to 
bind the DNA and induce target gene expression (Fig. 5.1 A). In various cancers KPNB1 has 
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been shown to be overexpressed [128]. This overexpression has been associated with 
enhanced nuclear import rates of KPNB1 cargoes including transcription factors such as NFkB 
and AP-1 [133, 247]. Once in the nucleus the increased activity of these transcription factors 
associates with the increased proliferation, survival, increased motility and inflammation seen 
in cancer (Fig. 5.1 B). Upon treatment with the nuclear import inhibitor, INI-43, or through 
inhibition of KPNB1 using siRNA, NFkB and AP-1 are inhibited from entering the nucleus. The 
consequences of inhibiting NFkB and AP-1 nuclear localisation and activity have anticancer 
effects. These include; a reduction in cancer cell proliferation and increase in apoptosis. A 
reduction in migration and invasion of cancer cells characterised by a transcriptional switch, 
blocking MMP-2 and -9 expression and increasing TIMP-1 and -2 expression. Reduced 
expression of inflammatory cytokines; IL-6, IL-1β, TNF-α and GM-CSF, and a significant 
reduction in tumour growth in a cervical cancer mouse model (Fig. 5.1 C). These 
transcriptional changes have implications for cancer cell biology, hence the observed changes 
in cancer cell proliferation, migration, invasion and tumour formation when KPNB1 is 
inhibited.  
 
This study provides significant evidence supporting the use of targeted therapies toward 
KPNB1 as an anticancer approach. Further development of KPNB1-mediated nuclear import 








Figure 5.1: Summary of findings following KPNB1-mediated nuclear import inhibition in cancer.  
A) KPNB1-mediated nuclear import in normal cells showing the transport of a transcription factor 
across the nuclear envelope into the nucleus using the Karyopherin alpha adapter protein (α) and 
KPNB1. B) A depiction of KPNB1-mediated nuclear import in cancer. The overexpression of KPNB1 in 
cancer cells allows for enhanced nuclear import rates of transcription factors responsible for 
increasing proliferation, survival, motility and inflammation in cancer.  C) Inhibition of KPNB1-
mediated nuclear import using siRNA or INI-43, blocked nuclear import of transcription factors; NFkB 
and AP-1 in cancer cells. As a result reduced proliferation, increased apoptosis, reduced migration and 
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MATERIALS AND METHODS 




6.1.1 Cell lines 
 
Human cervical carcinoma cell lines, HeLa, SiHa and CaSki were obtained from the American 
Type Culture Collection (ATCC) (Rockville, MD, USA). Normal human skin fibroblast cell 




Small-interfering RNA (siRNA) was used to inhibit gene expression. The KPNB1 siRNA (sc-
35736) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). A non-silencing 
control siRNA (MISSION® Positive Control siRNA) was purchased from Sigma-Aldrich (St Louis, 
MO, USA). Both products were purchased as a lyophilized powder and resuspended in RNase-




6.1.3.1 Inhibitor of Nuclear Import-43 (INI-43) 
Inhibitor of Nuclear Import-43 (Chemical name: 3-(1H-benzimidazol-2-yl)-1-(3-
dimethylaminopropyl)pyrrolo[5,4-b]quinoxalin-2-amine)) was purchased from MolPort 
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Chemicals (MolPort-000-492-602, Riga, Latvia) as a powder. The compound was dissolved in 
DMSO to a stock solution of 10 mM and stored at -20°C.  
 
6.1.3.2 Phorbol-12-myristate-13-acetate (PMA) 
The phorbol ester, PMA, was purchased from Sigma-Aldrich (St Louis, MO, USA) as a powder 
and dissolved in DMSO to a stock concentration of 1 mM and stored at -80°C. 
 
6.1.3.3 JSH-23 
The NFkB inhibitor, JSH-23, was purchased from Sigma-Aldrich (St Louis, MO, USA) as a 
powder and dissolved in DMSO to a stock concentration of 25 mM and stored at -80°C. 
 
6.1.3.4 SP600125 
The selective inhibitor of c-Jun N-terminal kinase (JNK), SP600125, was purchased from Sigma-
Aldrich (St Louis, MO, USA) as a powder and dissolved in DMSO to a stock concentration of 25 
mM and stored at -80°C. 
   
6.1.3.5 Ivermectin 
Nuclear import inhibitor, Ivermectin, was purchased from Sigma-Aldrich (St Louis, MO, USA) 
as a powder and dissolved in DMSO to a stock concentration of 50 mM and stored at -20°C.  
 
6.1.3.6 Importazole 
Nuclear import inhibitor, Importazole, was purchased from Sigma-Aldrich (St Louis, MO, USA) 







The NFkB p65 reporter construct in a pGL4 vector contains five copies of the p65 binding site 
that drives transcription of the luciferase reporter gene luc2P was purchased from Promega 
(Madison, WI, USA).  The AP-1 reporter plasmid containing four AP-1-Luc binding sites was 
received from Professor M. Birrer (Harvard Medical School, MA, USA). This plasmid contained 
four wildtype AP-1 binding sites (TGAC/GTCA) upstream of the minimal promoter sequence 
from the albumin gene and the firefly luciferase reporter gene [261]. The full-length IL-6 
promoter construct inserted into the BamH1-HindIII sites of the pXP2-luciferase vector was 
kindly received from Prof L. Zerbini (ICGEB, Cape Town, South Africa) [262]. A plasmid 
encoding the Renilla luciferase reporter gene, pRL-TK (Promega, Madison, WI, USA), was used 




The following antibodies were used for Western Blotting, Immunofluorescent and 
Immunohistochemistry experiments and were purchased from Santa Cruz Biotechnology 
(Dallas, Texas, USA): anti-NFkB p65 (sc-7151X), anti-NFkB p50 (sc-7178X), anti-KPNB1 (sc-
11367), anti-p-c-JUN (sc-16312-R), anti-c-JUN (sc-44), anti-β-tubulin (sc-9104), anti-GAPDH 
(sc-47724) and anti-TBP (sc-204). Another antibody used for Immunohistochemistry was the 
anti-Ki-67 (M7240, Dako, Glostrup, Denmark). Secondary antibodies used were Goat anti-
Rabbit IgG (H + L)-HRP Conjugate (#1706515, Bio-Rad), Goat anti-Mouse IgG (H + L)-HRP 
Conjugate (#1706516, Bio-Rad), Cy-3-conjugated Goat ant-rabbit (#111-165-144, Jackson 
ImmunoResearch) and Dako REAL EnVision-HRP Goat ant-rabbit (K4011)) or Goat anti-mouse 






Animal ethics approval was obtained from the Faculty of Health Sciences Animal Ethics 
Committee, University of Cape Town, South Africa (reference number 012/009). The live 
animal experiments were performed together with Ms. Alicia Chi, a PhD student in our 
laboratory. Female athymic nude mice (Strain: UCT 21) 4-6 weeks old were obtained from the 
SPF Research Animal Facility (Health Science Faculty, University of Cape Town, South Africa) 
and all procedures were carried out in strict accordance with the guidelines of the Facility’s 
Animal Ethics Committee. The mice were housed in the BSL2 Research Animal Facility with 6 
mice per cage in autoclaved polysulfone cages, provided with red plastic housing for 
enrichment and were given access to food and water ad libitum. The room was maintained at 








All cells used were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco, Life 
Technologies, Carlsbad, CA, USA) supplemented with 100 U/ml penicillin, 100 μg/ml 
streptomycin and 10% Fetal Calf Serum (FCS) (Gibco, Life Technologies, Carlsbad, CA, USA). All 





6.2.1.2 Sub-culturing cells 
 
Cells were grown adherently in 10 cm tissue culture dishes to about 80-90% confluency before 
being washed with 1x PBS and removed from the plate by trypsinisation using 3 ml trypsin-
EDTA solution at 37°C. Once cells had detached, the trypsin-EDTA-cell suspension was 
neutralised with the addition of 3 ml fresh culture medium. The cell suspension was 
centrifuged at 500 x G for approximately 5 minutes to pellet cells. The supernatant was 
removed and the cell pellet resuspended in the required volume of culture medium. Cells 
were generally sub-cultured at a ratio of 1:6.      
 
6.2.1.3 Cryopreservation and Reconstitution  
 
For long term storage of tissue culture cells, cells were grown to 80-90% confluency and 
collected by trypsinisation as described above. The cell pellet was resuspended on chilled 
freezing medium at a concentration of about 1 x 106 cells per ml. Cells were transferred to 
cryovials and frozen at -80°C before being transferred to liquid nitrogen. To reconstitute cells, 
a single cryovial containing 1 ml of cell suspension was thawed rapidly at 37°C in a waterbath 
and added to 9 ml fresh culture medium in a 10 cm tissue culture dish.  
 
6.2.1.4 Mycoplasma test 
 
Cells were regularly tested for mycoplasma contamination to ensure they were mycoplasma-
free. Cells were grown in penicillin and streptomycin-free culture medium for 4-5 days before 
being plated onto glass coverslips. The cells were then fixed and stained with Hoescht 
fluorescent DNA-binding stain before mounting and visualisation on a Zeiss Axiovert 200M 





6.2.2.1 siRNA (KPNB1) 
 
Short-interfering RNA (siRNA) was used to inhibit KPNB1 gene expression (sc-35736, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). Control siRNA (sc-37007, Santa Cruz Biotechnology) 
consisting of a scrambled RNA sequence was used as a non-silencing control. siRNAs were 
resuspended in RNAse-free water and used at a stock concentration of 10 μM. Cells were 
plated at a density of 30 000, 120 000 or 250 000 cells in a 24-well plate, 35 mm dish or 60 
mm dish respectively and allowed to settle overnight. The transfection mixture was prepared 
in serum-free DMEM using TransFectin Lipid Reagent (Bio-Rad, Hercules, CA, USA) according 
to the manufacturer’s instructions and incubated with the cells for 7 hours. Thereafter the 
medium was replaced with fresh culture medium for an additional 17-41 hours. The effect of 




The luciferase reporter plasmids were transfected into cervical cancer cells to measure NFkB 
and AP-1 transcriptional activity as well as IL-6 promoter activity. Cells were seeded at a 
concentration of 30 000 cells/well in a 24-well plate in 500 μl fresh culture media and allowed 
to adhere overnight. The transfection mix per well was prepared in 50 μl antibiotic-free and 
serum-free culture medium. The luciferase reporter plasmid (100 ng), Renilla luciferase 
reporter gene (10 ng) and GeneCellinTM Transfection Reagent (0.4 μl) (Celtic Molecular 
Diagnostics, South Africa) was diluted in the antibiotic-free and serum-free culture medium, 
vortexed briefly and allowed to stand at room temperature for 15 mins before being added 
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drop-wise to the cells. Culture medium was replaced after 7 hours and cells allowed a further 
17-41 hours to incubate before being assayed.  
 
6.2.3 EC50 determination 
 
Cells were plated in 96-well plates at a density of 5000 cells/well in 90 μl culture medium and 
allowed to adhere overnight. All experiments were seeded in triplicate and included cell-free 
media controls. For EC50 determination cells were treated with 10 μl of varying concentrations 
of drug for 48 hrs. Following treatment 10 μl MTT reagent (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide, Sigma-Aldrich, USA) was added for 4 hours. Formazan crystals 
were solubilised using 100 μl Solubilisation solution for 24 hours. Absorbencies were 
measuring at OD595nm using a Biotek microplate spectrophotometer (Winooski, VT, USA). The 
absorbance of drug treated cells was normalised to the absorbance of drug-containing culture 
medium and the EC50 value (Effective half-maximal concentration of the drug) calculated using 
GraphPad Prism V5.0.   
 
6.2.4 Cell viability assay 
 
Cells were plated in 96-well plates at a density of 2000 cells/well in 90 μl culture medium and 
allowed to adhere overnight. All experiments were seeded in triplicate and included cell-free 
media controls. For cell viability assays, cells were cultured for various time points up to 3 days 
following transfection with KPNB1/control siRNA. Following treatment, 10 μl MTT (Sigma-
Aldrich, USA) was added for 4 hours and crystals solubilised for 24 hours with 100 μl 
Solubilisation solution. Absorbencies were measured at OD595nm using a BioTek microplate 
spectrophotometer (Winooski, VT, USA). Cell viability was normalised to cell-free controls and 




6.2.5 Caspase 3/7 Glo cell death assay  
 
Cells were plated in 96-well plates at a density of 4000 cells/well and treated with INI-43 for 
various periods of time. Caspase-3/7 activity was monitored at each time point using the 
Caspase-Glo 3/7 assay (Promega, Madison, WI, USA), according to the manufacturer's 
instructions. Luminescence was measured using the Veritas microplate luminometer 
(Promega) and normalized to OD595nm readings of MTT experiments performed in parallel. 
 
6.2.6 Transwell migration and invasion assays 
 
Cells were seeded into 35 mm dishes and treated accordingly before being trypsinised, 
resuspended in 0.1% FCS-containing DMEM and seeded at 30 000 cells/well into 12-well 
Transwell migration chambers (Greiner Bio-One, Austria) or 24-well matrigel-covered 
Transwell invasion chambers (BD Biosciences, USA) with an 8 µm pore size. The chambers 
were placed into a lower chamber containing 20% FCS-containing DMEM and the cells allowed 
to migrate/invade through the membrane or matrigel matrix over 24 hrs. The cells that were 
unable to move through the membrane were removed while the remaining cells were fixed 
in methanol, stained with crystal violet, counted and imaged under the Zeiss Primovert phase 
contrast microscope (Carl Zeiss, Jena, Germany). Results were normalised to an MTT cell 
viability assay and western blotting confirmed KPNB1 knockdown. 
 
6.2.7 Gelatin Zymography 
 
Cells were seeded into 35 mm plates and treated with 10 μM INI-43 for 3 hours. The treatment 
was removed and serum-free media placed onto the cells to condition for 16 hrs. Conditioned 
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media was collected and centrifuged at 500 x G to remove any cellular debri. After which it 
was combined with sample buffer, equal volumes loaded into a gelatin gel and run at 125 V 
until the tracking dye reached the bottom. The gel was removed and placed in a renaturing 
solution before being placed in the developing buffer and allowed to incubate at 37°C 
overnight to facilitate gelatinase activity. The staining solution was used to dye the gel while 
the destaining solution exposed areas of gelatinase activity.  
 
6.2.8 Analysis of mRNA expression 
 
6.2.8.1 RNA isolation 
 
Cells were plated at a density of 250 000 cells/ 60 mm plate and cells were transfected with 
siRNA (48 hrs) or treated with the relevant compounds. Cells were washed with 1x PBS 
following treatment and RNA harvested using Qiazol (Qiagen, Hilden, Germany), according to 
the manufacturer’s instructions. Chloroform was added to the samples at 0.2 ml/1 ml Qiazol, 
mixed and incubated at room temperature for 3 mins. Samples were centrifuged at 12000 x 
G for 15 mins (4°C) to allow for the separation of phases. The upper aqueous phase was 
transferred to a new tube and the RNA precipitated in 500 μl isopropanol /1 ml Qiazol by 
vortexing and incubating at room temperature for 10 mins. Samples were centrifuged for 
another 10mins at 12000 x G. The supernatant was discarded and the pellet washed in 1000 
μl 75% ethanol/1 ml Qiazol for 5 mins at 7500 x G. Ethanol was discarded and the pellet 
containing the extracted RNA allowed to air-dry before being suspended in 0.01% DEPC-
treated H2O. RNA was quantitated using the NanoDrop 2000 (Thermo Fisher Scientific, 





6.2.8.2 cDNA conversion 
 
Synthesis of cDNA used 2 μg RNA made up to a volume of 8 μl. One μl random hexamers were 
added and the samples incubated at 70°C for 10 mins before returning to ice for 5 mins. 
Samples were combined with 11 μl of the PCR Mastermix to bring the total reaction volume 
to 20 μl. The PCR conditions were as follows; 10 mins at 25°C, 30 mins at 42°C and 2 mins at 
80°C. 
 
6.2.8.3 Quantitative real-time PCR (qRT-PCR) 
 
Quantitative real-time PCR was performed using the StepOne Real-time PCR system (Applied 
Biosystems, USA). 2-4 μl cDNA was amplified using the KAPA SYBR Fast mastermix (Kapa 
Biosystems, Cape Town, South Africa) in combination with one of the primer pairs under the 
conditions stated in the table below (Table 1). Samples were standardised to the house-












IL-1β Forward 5’ CCACCTCCAGGGACAGGATA 3’ 
176 bps 58°C 50 
IL-1β Reverse 5’ TGGGATCTACACTCTCCAGC 3’ 
IL-6 Forward 5’ GGATTCAATGAGGAGACTTGCC 3’ 
213 bps 58°C 40 
IL-6 Reverse 5’ CAGGCTGGCATTTGTGGTTG 3’ 
TNF-α Forward 5’ GTAGCCCATGTTGTAGCAAACC 3’ 
256 bps 58°C 40 
TNF-α Reverse 5’ TGATGGCAGAGAGGAGGTTG 3’ 
GM-CSF Forward 5’ GACACTGCTGCTGAGATGAATG 3’ 
173 bps 55°C 40 
GM-CSF Reverse 5’ CAGTGCTGCTTGTAGTGGCT 3’ 
KPNB1 Forward 5’ CCAGTGCCGAGTGGAATG 3’ 
191 bps 55°C 40 
KPNB1 Reverse 5’ AAATCCCTGACCCTCCTTC 3’ 
MMP-2 Forward 5’ TGGCGATGGATACCCCTTT 3’ 
117 bps 55°C 40 
MMP-2 Reverse 5’ TTCTCCCAAGGTCCATAGCTCAT 3’ 
MMP-9 Forward 5’ CCGGACCAAGGATACAGTTT 3’ 
108 bps 60°C 40 
MMP-9 Reverse 5’ GCGGTACATAGGGTACATGAG 3’ 
TIMP-1 Forward 5’ AGAGACACCAGAGAACCCA 3’ 
148 bps 55°C 40 
TIMP-1 Reverse 5’ TGATGACGAGGTCGGAATTG 3’ 
TIMP-2 Forward 5’ CATGATCCCGTGCTACATCTC 3’ 
105 bps 55°C 40 
TIMP-2 Reverse 5’ TTGATGCAGGCGAAGAACT 3’ 
COL1A1 Forward 5’ TCTGCGACAACGGCAAGGTG 3’ 
146 bps 60°C 40 
COL1A1 Reverse 5’ GACGCCGGTGGTTTCTTGGT 3’ 
COL4A1 Forward 5’ CAGGATGCAATGGCACAACG 3’ 
115 bps 55°C 40 
COL4A1 Reverse 5’ TCACCTGGATCACCCTTCA 3’ 













Cells were cultured on glass coverslips in 6-well plates. Following treatment the cells were 
fixed in ice-cold 4% paraformaldehyde in PBS for 15 mins at room temperature followed by 
two washes with cold PBS. Permeabilisation of cells was achieved using 0.25% Triton X-100 in 
PBS for 10 mins. Cells were washed in PBS, 3x5 mins. Cells were then blocked using 1% BSA in 
PBST with 0.3 M glycine for quenching, for 30 mins. NFkB p65 primary antibody was used at a 
dilution of 1:200 in 1% BSA in PBST for 1 hr at RT. Primary antibody was washed off with PBS, 
3x5 mins. Secondary antibody, GαR-Cy3, was diluted at a concentration of 1:300 in 1% BSA in 
PBST and placed on the cells for 1 hr at RT in the dark. Secondary antibody was washed off 
with PBS, 3x5 mins. DAPI (200 ug/ml) (Sigma-Aldrich, USA) was diluted to 1:400 in PBS and 
placed on the cells for 5 mins before being washing off with PBS. Coverslips were mounted 
using Mowial. Fluorescent images were captured at 100x in oil immersion using a Zeiss 
Axiovert 200M fluorescent microscope with AxioVision 4.8 Zeiss software and an AxioCam 
HRm (Carl Zeiss, Jena, Germany).      
 
6.2.10 Actin staining  
 
Cells were cultured on glass cover slips in 6-well plates. Following treatment for 24 hours with 
5 µM INI-43 the cells were fixed in ice-cold 4% paraformaldehyde in PBS for 15 mins at room 
temperature. The cells were washed twice with cold PBS and permeabilised in 0.1% Triton X-
100 in PBS for 5 mins followed by another two PBS washes. Cells were blocked in 1% BSA in 
PBS with 0.1M glycine for quenching for 30 mins. Cells were then incubated in 50 ng/ml 
Phalloidin-Tetramethylrodamine B isothiocyanate (Sigma-Aldrich, USA) in 1% BSA in PBS for 
30 mins followed by two PBS washes. The nuclei were stained using DAPI (200 ug/ml) (Sigma-
Aldrich, USA) diluted to 1:400 in PBS and placed on the cells for 5 mins before being washed 
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off with PBS. Coverslips were mounted using Mowial. Fluorescent images were captured at 
100x in oil immersion using a Zeiss Axiovert 200M fluorescent microscope with AxioVision 4.8 
Zeiss software and an AxioCam HRm (Carl Zeiss, Jena, Germany). ImageJ software was used to 
measure changes in cell size while the number of processes per cell were counted by eye and 
averaged for each condition.        
 
6.2.11 Protein harvest and quantification 
 
6.2.11.1 Whole cell lysates from cultured cells 
 
Following relevant treatment of cells in 35 mm or 60 mm tissue culture dishes protein was 
harvested on ice in RIPA buffer containing a fresh mixture of complete protease inhibitors 
(Roche, Basel, Switzerland) and 0.1 M Sodium Orthovanadate to inhibit phosphatase activity. 
A cell scraper was used to remove the cell lysate from the tissue culture dish. Samples were 
sonicated for 10 seconds before undergoing centrifugation at 10000 x G for 10 mins to remove 
any cellular debri. The supernatant was stored at -80°C until further use.  
 
6.2.11.2 Nuclear and cytoplasmic fractionation  
 
Separate cytoplasmic and nuclear proteins were extracted to analyse protein expression in 
individual cellular compartments. Cells were plated at a density of 250 000 cells/ 60 mm plate 
and treated accordingly before being removed by trypinisation as detailed previously and the 
cells pelleted by centrifugation. Protein was extracted and fractionated using either the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific, Waltham, MA, 
USA) according to the manufacturer’s instructions or our in-house fractionation protocol as 
detailed here. The cell pellets were resuspended in Harvest Buffer on ice for 5 minutes, 
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followed by centrifugation at 1000 x G for 10 minutes which separated the cytoplasmic 
fraction (supernatant) and the nuclear fraction (pellet). The cytoplasmic fraction was 
centrifuged again at 14 000 x G for 15 minutes, and the supernatant stored at -80°C. The 
nuclear pellet was washed in Buffer A, and centrifuged at 1000 x G for 5 minutes. The pellet 
was then resuspended in Buffer C and vortexed for 15 minutes at 4°C to extract the nuclear 
protein, followed by centrifugation at 14 000 x G for 10 minutes. The supernatant containing 
the nuclear protein was collected and stored at -80°C. 
 
6.2.11.3 BCA assay 
 
All protein samples were quantified in 96-well plates using the BCA Protein Assay Kit (Pierce, 
Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's instructions. 
The absorbencies at OD595nm were determined using a Biotek microplate spectrophotometer 
(Winooski, VT, USA), alongside the BSA protein standards. A standard curve was plotted using 
BSA standards and the sample protein concentration calculated. Equal amounts of protein 
were made up using H2O and 4x Loading dye to obtain equal volumes.  
 
6.2.12 Western Blot analysis 
 
6.2.12.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
protein transfer  
 
Equal amounts of protein (10-30 μg) were loaded into a 10-15% SDS polyacrylamide gel and 
run in 1x running buffer at 180 V for up to 70 mins. A broad range protein ladder was loaded 
(5 µl) to determine size of protein bands (Fig. A1.1). Proteins were transferred to a Hybond-
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ECL nitrocellulose membrane (AEC-Amersham, Johannesburg, South Africa) in 1x transfer 
buffer for 1 hour at 100 V. 
 
6.2.12.2 Immunoblotting and chemiluminescent detection 
 
Membranes are then blocked in 5% non-fat dried milk in TBS-T for 1 hour before the primary 
antibody was applied at its relevant dilution (Table 2) to the membrane overnight at 4°C. After 
three 10 min washes in TBS-T the secondary antibody was applied for 1 hour at room 
temperature. Membranes were again washed three times for 10 mins each before protein 
were detected using Lumiglo (KPL, Inc., Gaithersburg, MD, USA) or ClarityTM Western ECL 
Substrate (Biorad, Hercules, CA, USA) depending on the strength of the signal. The 
chemiluminescent signal was detected by exposing the membrane to X-ray film (AGFA, 
Mortsel, Belgium), followed by immersing the film in developer (AGFA G128), water, then 
fixative (AGFA G333C) and water. 
 








1:1000 in 5% 
BSA 
GαR 1:5000 in 5% milk Biorad Clarity 
Anti-cJUN 
1:1000 in 5% 
BSA 
GαR 1:5000 in 5% milk Lumiglo 
Anti-NFkB p65 
1:5000 in 5% 
milk 
GαR 1:5000 in 5% milk Biorad Clarity 
Anti-NFkB p50 1:5000 in TBS-T GαR 1:5000 in 5% milk Biorad Clarity 
Anti-KPNB1 1:1000 in TBS-T GαR 1:5000 in TBS-T Lumiglo 
Anti-TBP 1:500 in TBS-T GαR 1:5000 in TBS-T Lumiglo 
Anti-Β-tubulin 1:1000 in TBS-T GαR 1:5000 in 5% milk Lumiglo 




6.2.12.3 Stripping and re-probing immunoblots 
 
Membranes were stripped of bound antibodies by submerging the membrane in 10 ml 
Stripping buffer for 14 mins turning the membrane around halfway. The buffer was 
neutralised using 1 ml 1 M Tris-EDTA pH 7.5, the membrane was then washed using TBS-T and 
blocked and probed with a new primary antibody as detailed above.   
 
6.2.13 Electromobility shift assay 
 
6.2.13.1 Biotin-labelling of DNA probe 
 
The wild-type NFkB oligonucleotide used as a probe for direct binding studies was as follows; 
5’-AGTTGAGGGGACTTTCCCAGGC-3’ and 3’-TCAACTCCCCTGAAAGGGTCCG-5’. 1 μM forward 
and reverse probe was labelled using the Biotin 3’ End Labelling Kit (Pierce, Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Equal parts of 
labelled probe were annealed under the following conditions; 3 mins- 95°C, 10 mins- 65°C, 60 
mins- 37°C and 1 min- 25°C. 
 
6.2.13.2 Supershift and controls 
 
For the supershift, 2 μl NFĸB X p65/p50 antibody was added to the binding reaction. For the 
controls 1 μl 50 μM unlabelled double-stranded wild-type oligonucleotide or unlabelled 
double-stranded mutant oligonucleotide, 5'-AGTTGAGGCGACTTTCCCAGGC-3' and 3’-
GCCTGGGAAAGTCGCCTCAACT-5’, was added to the binding reaction. The incubation at room 




6.2.13.3 Gel electrophoresis and membrane transfer 
 
The binding reaction contained; 5 μg nuclear protein, 5x Incubation buffer, poly DI/DC and 5 
μl biotin-labelled double-stranded NFĸB oligonucleotide. The reaction was incubated at room 
temperature for 10 mins without the labelled oligonucleotide and a further 30 mins on ice 
with the oligonucleotide. DNA loading dye was added to the samples, loaded into a 
polyacrylamide gel and run at 200 V for 60 mins in 0.5x TBE on ice. DNA-protein complexes 
were transferred to a N+ Hybond membrane (AEC-Amersham, Johannesburg, South Africa) at 
100 V in 0.5x TBE for 30 mins on ice. The membrane was cross-linked using the SpectrolinkerTM 
XL-1000 (Thomas Scientific, Swedesboro, NJ, USA). 
 
6.2.13.4 Chemiluminescent detection 
 
Protein-DNA complexes were detected on the membrane using the Chemiluminescent 
Nucleic Acid Detection Kit (Pierce, Thermo Fisher Scientific, Waltham, MA, USA) as per the 
manufacturer’s instructions. 
 
6.2.14 Large-scale Plasmid preparation 
 
To produce adequate quantities of luciferase plasmids for experimental procedures the 
Qiagen MaxiPrep Kit (Hilden, Germany) was used for large-scale production. Plasmids were 
first transformed by adding 50 ng plasmid DNA to 30 μl JM109 competent cells (Promega, 
USA). The mixture was incubated on ice for 20 mins, at 42°C for 2 mins and then on ice again 
for 2 mins before being transferred to 450 μl Luria Broth and incubated at 37°C for 1 hr while 
shaking at 150 rpm. The transformation mix (100 μl) was plated onto Ampicillin-selective Luria 
Broth agar plates and incubated overnight at 37°C. A white colony was selected from the agar 
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plate and inoculated into 5 ml Luria Broth containing 60 μg/ml Ampicillin and incubated for 8 
hrs at 37°C while shaking at 200 rpm. 0.5 ml culture was transferred to 100 ml Luria Broth 
containing 100 ug/ml Ampicillin and incubated for a further 16 hrs at 37°C while shaking. 
Bacterial cultures were then harvested by centrifugation at 6000 x G and resuspended in 
Buffer P1 containing 100 ug/ml RNAse. Resuspended pellets were lysed in Buffer P2 for 5 mins 
at room temperature after which the solution was neutralised using Buffer P3 for 20 mins on 
ice. The supernatant was isolated firstly by centrifugation at 20000 x G for 30 mins followed 
by a second centrifugation step of 15 mins to ensure removal of all suspended material 
(including genomic DNA, proteins and cell debri). A Qiagen-tip 500 was washed using Buffer 
QBT, according to the manufacturer’s instructions, and the supernatant applied to the tip. 
Following various washes with Buffer QC the DNA was eluted off the tip using Buffer QF and 
precipitated using 0.7 volumes isopropanol and centrifuged at 15000 x G for 30 mins. The 
pellet was washed a final time with 70% ethanol and allowed to air dry before being 
resuspended in TE buffer, pH 8.0. The DNA concentration was measured using the NanoDrop 
2000 (Thermo Fisher Scientific, Waltham, MA, USA). To confirm isolation of the correct 
plasmids, plasmids were cut by digestion with restriction enzymes and electrophoresed on an 
agarose gel. A DNA ladder was loaded alongside the samples in the agarose gel to allow 
measurement of DNA fragment size in base pairs (Fig. A1.2). 
 
6.2.15 Luciferase assays 
 
Cells were seeded and transfected with the luciferase reporter plasmid in a 24-well plate as 
detailed earlier. Following relevant treatments to inhibit KPNB1 or transcription factor activity 
cells were lysed in 100 μl 1x Passive lysis buffer (Promega, USA). Luciferase firefly activity was 
assayed using the Dual Luciferase kit (Promega, USA) on the Glomax 96 microplate 
luminometer (Promega, USA). Promoter activity was normalised to Renilla luciferase activity.  
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6.2.16 Cytometric Bead Array (CBA) 
 
Cells were plated at a density of 150 000 cells/ well in a 6-well plate. Cells were treated with 
INI-43 and stimulated with PMA before treatment was removed and 1 ml fresh medium was 
placed on the cells to condition for 16 hrs. Conditioned media was collected, centrifuged at 
600 x G for 10 mins at 4°C to remove any cellular debris and stored at -80°C until use. A BDTM 
Cytometric Bead Array (CBA) (BD Biosciences, USA) was used to measure inflammatory 
cytokine levels in conditioned media specifically using the Human Inflammatory Cytokine Kit. 
Samples and standards were prepared according to the manufacturer’s instructions and 
assayed on the BD Accuri C6 Flow Cytometer (BD Biosciences, USA). Cytokine levels were 
quantified using a standard curve and the results analysed using FlowJo software (Ashland, 
Oregan, USA).    
 
6.2.17 In vivo tumourigenesis assay 
 
Cervical cancer cells, CaSki, were used in the tumourigenesis assay. Cells (5 x 106) suspended 
in PBS were subcutaneously injected into the hind flank of each nude mouse. Drug treatment 
commenced once tumours were palpable and the mice randomly divided into two groups of 
six mice each. The vehicle control group was administered DMSO while the treatment group 
received INI-43 both at a concentration of 50 mg/kg every 2-3 days for 4 weeks. Throughout 
the study mice were weighed daily as a measure of health and tumours measured using a 
calliper twice a week. Tumour size was calculated using the following formula: tumour volume 
(mm3) = (length x width x width)/2. At the end of the study mice were euthanised after which 
the tumours were extracted, weighed, photographed and formalin-fixed for further 






6.2.18.1 Sample processing 
 
Formalin-fixed tumours were processed in the Leica TP1020 Processor (Wetzlar, Germany). 
Specimens were paraffin-wax embedded. A Leica microtome was used to cut 1-2 μm sections 
which were floated onto APS-coated slides (Marienfield, Germany).  Slides were heat-fixed at 
60°C for 30 mins.  
 
6.2.18.2 Haemotoxylin and Eosin staining 
 
Slides were dewaxed in xylol and rehydrated through a decreasing ethanol gradient. Samples 
were placed into Haematoxylin for 9 mins, rinsed in water, washed in Scott’s water and placed 
in Eosin for 3 mins. Slides were dehydrated in an increasing ethanol gradient, placed in xylol 
and mounted in resin (Entellan, Merck, Darmstadt, Germany). 
 
6.2.18.3 Immunoperoxidase staining 
 
Slides were dewaxed in xylol and rehydrated through a decreasing ethanol gradient. Samples 
were blocked for endogenous peroxidase activity using 3% Hydrogen peroxide in water for 15 
mins. Antigen retrieval was achieved using 0.01 M citrate buffer pH 6.0 for 2 mins (KPNB1) or 
1 mM EDTA, pH 8.0 for 1 min 30 secs (KI-67) in a pressure cooker. Slides were washed with 
PBS-T in between steps. KPNB1 primary antibody, 1:100 in PBS, was placed onto the samples 
for 2 hrs at room temperature while KI-67 primary antibody, 1:100 in PBS, was placed on the 
samples for 1 hr at room temperature. Envision polyclonal rabbit secondary antibody (KPNB1) 
or Envision monoclonal mouse secondary antibody (KI-67) was placed onto the samples for 
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30 mins. The chromogen DAB (Dako, Glostrup, Denmark) was used for 8 mins to develop the 
peroxidase colour while 10 mins in 1% copper sulphate enhanced the colour. Haematoxylin 
was used as a counter stain and slides were dehydrated across an increasing ethanol gradient 
before being placed in xylol and mounted using in resin (Entellan, Merck, Darmstadt, 
Germany). All samples were assessed and scored by a professional pathologist, Prof Dhiren 
Govender, UCT Division of Anatomical Pathology.  
 
6.2.19 Statistical analysis 
 
Experiments were performed in triplicate or quadruplicate and expressed as the mean ± 
standard error of the mean (SEM), unless otherwise stated. Experiments were repeated at 
least two independent times. For data analysis a two-tailed Student’s t-test was used where 
a p-value of <0.05 was considered statistically significant. Statistical analysis was performed 




6.3.1 Tissue culture solutions 
 
Complete Media    
500 ml DMEM 
50 ml FCS (10%) 





10x PBS    
40 g NaCl 
1 g KCl 
3.82 g Na2HPO4.2H2O 
2.1 g KH2PO4 
Up to 500 ml dH2O 
 
Cryopreservation Media   
20% FCS 
10% DMSO 
70% Complete media 
 
Solubilisation Solution    
25 g SDS 
76.6 ul conc. HCL 
Up to 250 ml with dH2O 
 
MTT      
0.1 g MTT 





6.3.2 Gelatin Zymography solutions 
 
4x Sample buffer    
2.5 ml 1 M Tris pH 6.8 
3 ml 20% SDS 
0.5 ml 0.1% Bromophenol Blue 
4 ml Glycerol 
 
Separating Gel    
2.26 ml dH2O 
1.25 ml 1% gelatin 
4.16 ml 30% Acrylamide/Bis-acrylamide 
4.7 ml 1 M Tris-HCL buffer, pH 8.8 
62.5 ul 20% SDS 
37.5 ul 10% AMPS 
7.5 ul TEMED 
 
Stacking Gel     
2.625 ml dH2O 
500 ul 30% Acrylamide/Bis-acrylamide 
625 ul 1 M Tris-HCL buffer, pH 6.8 
25 ul 20% SDS 
18.76 ul 10% AMPS 





10x Running Buffer    
30.29 g Tris 
144 g Glycine 
pH 8.3 
Up to 1 L with dH2O 
 
1x Running Buffer    
5 ml 20% SDS 
100 ml 10x Running Buffer 
895 ml dH2O 
 
10x Renaturing Solution   
25% Triton-X100 in dH2O 
 
10x Developing Buffer    
500 ml 1 M Tris-HCL, pH 7.8 
83.98 g NaCl 
5.5 g CaCl2 
2 g Brij-35 
 
Staining Solution    
5 g Coomassie Blue R-250 
50 ml Methanol 
100 ml Acetic Acid 




Destaining Solution   
50 ml Acetic Acid 
100 ml Methanol 
850 ml dH2O 
 
6.3.3 RNA solutions 
 
DEPC dH2O     
100 ul DEPC 
1 L dH2O 
 
RNA integrity gel    
0.75 g Agarose 
5 ml 10x MOPS 
42 ml dH2O 
2.7 ml Formaldehyde (37%) 
2.5 ul Ethidium bromide 
 
10x MOPS    
41.86 g MOPS 
16.6 ml 3 M Sodium Acetate 






RNA loading dye   
720 ul Formamide 
160 ul 10x MOPS 
260 ul Formaldehyde (37%) 
40 ul dH2O 
100 ul 80% Glycerol 
200 ul 0.25% Bromophenol blue 
 
PCR Mastermix     
4 ul 5x Reaction buffer 
1.6 ul MgCl2 
2 ul 10 nM dNTPs 
1 ul RNAsin 
1 ul Reverse transcriptase 
1.4 ul DEPC dH2O 
 
6.3.4 Immunocytochemistry solutions 
 
16% Paraformaldehyde   
16 g Paraformaldehyde 
Up to 80 ml dH2O 
 
PBS-T      
1 L 1x PBS 




Fixative    
2.5 ml 16% Paraformaldehyde 
1 ml 10x PBS 
6.5 ml dH2O 
 
Permeabilisation solution   
0.125 ml Triton X-100 
49.875 ml PBS 
Blocking Solution    
0.5 g BSA 
1.126 g Glycine (0.3 M) 
Up to 50 ml PBS-T 
 
Mowial    
9.6 g Moviol 4-88 
24 ml Glycerol 
24 ml dH2O 
48 ml 0.2 M Tris, pH 8.5 




6.3.5 Protein solutions 
 
RIPA Buffer     
3 ml 5 M NaCl 
1 ml Triton X-100 
1 g Sodium deoxycholate 
1 ml 10% SDS 
1 ml 1 M Tris pH 7.4 
94 ml dH2O 
 
Harvest Buffer 
10 mM HEPES pH 7.9 
50 mM NaCl 
0.5 M Sucrose 
0.1 mM EDTA 
0.5% Triton X-100 
Add fresh PI and Na2VO5 
 
Buffer A 
10 mM HEPES pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 






10 mM HEPES pH 7.9 
500 mM NaCl 
0.1 mM EDTA 
0.1 mM EGTA 
0.1% NP40 
Add fresh PI and Na2VO5 
 
10x TBS    
60.5 g Tris 
87.5 g NaCl 
Up to 1 L dH2O 
pH 7.5 
 
TBS-T     
100 ml 10xTBS 
900 ml dH2O 
500 ul Tween-20 
 
10x Transfer Buffer    
72 g Glycine 
19 g Tris 





1x Transfer Buffer    
100 ml 10x Transfer Buffer 
200 ml Isopropanol 
700 ml dH2O 
 
10x Running Buffer    
20 g Glycine 
31.6 g Tris  
50 ml 10% SDS 
Up to 500 ml dH2O 
 
4x Loading dye    
2.5 ml 1 M Tris pH 6.8 
3 ml 20% SDS 
0.5 ml 0.1% Bromophenol Blue 
4 ml Glycerol 
50 ul β-mercaptoethanol/0.5 ml 
 
10% Resolving Gel    
2.85 ml dH2O 
3.75 ml 1 M Tris pH 8.8 
3.3 ml 30% Acrylamide/Bis-acrylamide 
50 ul 10% SDS 
175 ul 10% AMPS  




15% Resolving Gel    
1.55 ml dH2O 
3.75 ml 1 M Tris pH 8.8 
5 ml 30% Acrylamide/Bis-acrylamide 
50 ul 10% SDS 
175 ul 10% AMPS  
17.5 ul TEMED 
 
4% Stacking Gel   
3.65 ml dH2O 
0.625 ml 1 M Tris pH 6.8 
0.65 ml 30% Acrylamide/Bis-acrylamide 
50 ul 10% SDS 
60 ul 10% AMPS  
6 ul TEMED 
 
Stripping Buffer 
37.54 g Glycine 






6.3.6 Electromobility shift assay solutions 
 
5x Incubation Buffer   
100 mM HEPES, pH 7.9 
250 mM KCl 
2.5 mM DTT (Add fresh) 
1 mM EDTA 
5 mM MgCl2 
20% Ficoll 400 
 
Gel      
5.4 ml 30% Acrylamide/Bis-acrylamide 
2 ml 10x TBE 
13.8 ml dH2O 
200 ul 10% AMPS 
10 ul TEMED 
 
6.3.7 Bacterial solutions 
 
Luria Broth     
5 g Tryptone 
2.5 g Yeast Extract 
2.5 g NaCl 





Luria Agar     
2.5 g Tryptone 
1.25 g Yeast Extract 
2.5 g NaCl 
3.75 g Agar 
 
Resuspension Buffer (P1)   
6.06 g Tris 
3.72 g Na2EDTA.2H2O  
800 ml dH2O 
pH 8.0 
100 mg/l RNAse A 
 
Lysis Buffer (P2)    
8.0 g NaOH 
50 ml 20%SDS 
950 ml dH2O 
 
Neutralisation Buffer (P3)   
294.5 g Potassium acetate 
500 ml dH2O 





Equilibration Buffer (QBT)   
43.83 g NaCl 
10.46 g MOPS 
800 ml dH2O 
pH 7.0 
150 ml Isopropanol 
15 ml 10% Triton X-100 
 
Wash Buffer (QC)    
58.44 g NaCl 
10.46 g MOPS 
800 ml dH2O 
pH 7.0 
150 ml Isopropanol 
 
Elution Buffer (QF)   
73.05 g NaCl 
6.06 g Tris  
800 ml dH2O 
pH 8.5 





6.3.8 DNA solutions 
 
TE Buffer 
1 ml 1 M Tris pH 8.0 
0.2 ml 0.5 M EDTA pH 8.0 
98.8 ml dH2O  
pH 8.0 
 
10x TBE    
108 g Tris 
55 g Boric Acid 
7.4 g EDTA 
Up to 1 L dH2O 
 
1% DNA gel     
0.5 g Agarose 
50 ml 1x TBE 





6.3.9 Immunohistochemistry solutions 
Mayer’s Haemotoxylin 
50 g Aluminum potassium sulphate 
1 L dH2O 
1 g Haematoxylin 
0.2 g Sodium iodate 
20 ml Glacial acetic acid 
 
Eosin Y Stock solution 
2 g Eosin Y 
40 ml dH2O 
160 ml 95% ethanol 
 
Eosin Y Working solution 
200 ml Eosin Y stock solution 
600 ml 80% ethanol 
4 ml glacial acetic acid 
 
10x Citrate Buffer    
0.1 M Citrate  






10x EDTA Buffer    
10 mM EDTA 










Figure A1.1: Color Prestained Protein Standard, Broad Range (11-245 kDa). Protein ladder used to 
determine size of protein bands on SDS-PAGE gels of 10-15%. 
Figure A1.2: O’GeneRuler DNA Ladder Mix (100-10000 bps).  DNA ladder used to measure size of DNA 
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ABSTRACT
Karyopherin β1 is a nuclear import protein involved in the transport of proteins 
containing a nuclear localisation sequence. Elevated Karyopherin β1 expression 
has been reported in cancer and transformed cells and is essential for cancer cell 
proliferation and survival. Transcription factors such as NFĸB and AP-1 contain a 
nuclear localisation sequence and initiate the expression of multiple factors associated 
with inflammation and cancer cell biology. Our study investigated the effect of 
inhibiting nuclear import via Karyopherin β1 on cancer cell motility and inflammatory 
signaling using siRNA and the novel small molecule, Inhibitor of Nuclear Import-43, 
INI-43. Inhibition of Karyopherin β1 led to reduced migration and invasion of cervical 
cancer cells. Karyopherin β1 is essential for the translocation of NFĸB into the 
nucleus as nuclear import inhibition caused its cytoplasmic retention and decreased 
transcriptional activity. A similar decrease was seen in AP-1 transcriptional activity 
upon Karyopherin β1 inhibition. Consequently reduced interleukin-6, interleukin-1 
beta, tumour necrosis factor alpha and granulocyte macrophage colony stimulating 
factor expression, target genes of NFkB and AP-1, was observed. Migration studies 
inhibiting individual transcription factors suggested that INI-43 may affect a 
combination of signaling events. Our study provides further evidence that inhibiting 
KPNB1 has anti-cancer effects and shows promise as a chemotherapeutic target.
INTRODUCTION
The Karyopherin beta superfamily forms the major 
class of soluble transport proteins that transport proteins 
larger than 20-40kDa through the nuclear pore complex 
(NPC). Karyopherin β1 (KPNB1) is the predominant 
nuclear import protein and transports cargo into the 
nucleus independently (non-classical pathway) or through 
the association with a karyopherin adaptor protein 
(classical pathway) [1]. In the classical import pathway 
cargo is identified by a Karyopherin alpha protein through 
a nuclear localisation sequence (NLS) and binds forming 
a dimer. Together this dimer then binds KPNB1 and is 
allowed access through the NPC as a trimeric complex 
[2–4]. In the non-classical pathway KPNB1 is able to 
directly recognise a specific NLS on the cargo, binding 
to it. The nuclear transport system plays a critical role in 
normal cell functioning and therefore it isn’t unusual that 
its dysregulation has been associated with carcinogenesis. 
KPNB1 expression has been found to be upregulated in 
various cancers including cervical cancer and correlates 
with a poor patient prognosis in gastric cancer [5, 6].
One of the classical hallmarks of cancer is the 
ability of cancer cells to invade tissue surrounding the 
site of the primary tumour and metastasize to a secondary 
location [7]. This occurrence is responsible for the 
majority of cancer-related deaths. When Hanahan and 
Weinberg (2011) revisited the classical hallmarks they 
noted that an inflammatory microenvironment plays an 
important role in sustaining many of the other hallmarks 
of cancer including the ability of cancer cells to invade 
[8]. The presence of chemokines and cytokines in the 
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tumour microenvironment, whether produced by cancer 
cells or infiltrating immune cells, directly contribute to 
the activation of transcription factors such as NFkB and 
AP-1 [9–11]. TNF-α is a cytokine commonly known 
to activate both NFkB and AP-1 [12]. The activation 
of such transcription factors initiates the expression of 
various target genes contributing to cancer progression by 
enhancing proliferation (IL-1, TNF-α, GM-CSF, Cyclin 
D1), evading apoptosis (BCL2, TRAF2, BCL3) and 
promoting cell invasion (IL-1, IL-6, TNF, MMPs) [13–20].
The NFĸB family consists of 5 members of which 
p65 and p50 are activated in the canonical activation 
pathway in an inflammatory response. Activation and 
translocation of the transcription factor into the nucleus 
can be induced in most cell types but some cells such as 
macrophages and tumour cells can have constitutively 
active NFĸB. Activation can be stimulated by several 
events including the presence of cytokines or artificially 
in response to the phorbol ester, phorbol-12-myristate-13-
acetate (PMA) [21, 22]. It has been identified that NFκB’s 
p65 and p50 subunits have a classical NLS, suggesting 
that they require KPNB1 for their nuclear import [23]. No 
mutations in the NFĸB gene or its inhibitors have been 
associated with cancer but rather the increased presence 
of activated NFĸB has been associated with an increase in 
inflammation promoting carcinogenesis [10, 24–27].
Activator protein 1 (AP-1) is a transcription factor 
consisting of dimers of mainly JUN and FOS family 
members. Much like NFkB it is activated by inflammatory 
cytokines and growth factors as well as the phorbol ester, 
PMA. AP-1 regulates genes involved in many cellular 
processes including; proliferation, differentiation, 
apoptosis, angiogenesis and tumour invasion. Increased 
expression of JUN and FOS family members is associated 
with several cancers [28–30]. Nuclear import of AP-1 
is suggested to be mediated through the non-classical 
nuclear import pathway as KPNB1 was found to have a 
significantly greater affinity for AP-1 than Karyopherin 
alpha and therefore is reported to be transported into the 
nucleus by KPNB1 alone [31].
As NFkB and AP-1 play such a pivotal role 
in inflammatory signaling and promoting the cancer 
phenotype, inhibiting their function could have 
chemotherapeutic benefits [32–36]. The small molecule 
inhibitor of KPNB1, INI-43, has been described by van 
der Watt et al. (2016) to interfere with nuclear import 
of transcription factors such as NFAT. Nuclear import 
inhibition through KPNB1 has also previously been 
shown in our laboratory and by others to have anti-
cancer potential by inhibiting cancer cell proliferation 
and inducing cell death by apoptosis in vitro as well 
as inhibiting tumour growth in vivo [5, 37–39]. As 
both NFĸB and AP-1 require KPNB1 for their nuclear 
translocation we hypothesized that inhibiting KPNB1 
could inhibit the activity of these transcription factors. 
Thereby blocking the expression of inflammatory target 
genes which contribute to the invasive potential of cancer 
cells. In this study we investigated the effects of inhibiting 
KPNB1 using siRNA and a novel small molecule, INI-43, 
on cancer cell migration and invasion as well as NFkB and 
AP-1 transcriptional function.
RESULTS
KPNB1 is required for the migration and 
invasion of cervical cancer cells
In our previous studies we have reported that 
KPNB1 is required for the survival and proliferation of 
cervical cancer cells and that inhibition of its expression 
and activity resulted in cell death via apoptosis [5, 37]. 
Little is known about the role of KPNB1 in other cancer 
phenotypes such as migration and invasion. In this study, 
we investigated the requirement of KPNB1 expression 
and activity for cancer cell migration and invasion. Using 
transwell migration assays, we showed that knocking 
down KPNB1 using siRNA reduced the ability of HeLa 
cervical cancer cells to migrate through the transwell 
membrane in the presence of PMA stimulation (Figure 
1A). Quantification of the migration of control and 
KPNB1 siRNA treated cells shows a significant reduction 
in migration when KPNB1 expression is inhibited (Figure 
1B). The small molecule inhibitor of nuclear import, INI-
43, was also able to reduce the migratory ability of HeLa 
and SiHa cervical cancer cells (Figure 1C). Quantification 
of migratory ability following INI-43 treatment shows 
significant reductions in migration in both cervical cancer 
cell lines (Figure 1D). The invasive ability of cervical 
cancer cells was assessed using a transwell invasion 
plate with matrigel-coated chambers. The inhibition 
of KPNB1 by both siRNA (Figure 2A & 2B) and INI-
43 (Figure 2C & 2D) significantly interfered with both 
HeLa and SiHa cancer cell invasion. As these assays 
assessed the role of nuclear import inhibition of cancer 
cell motility, the effect of cell death was eliminated by 
optimizing treatment duration and normalizing the results 
to concurrent live cells as measured using the MTT cell 
proliferation assay. The ability of cancer cells to invade 
the extracellular matrix is dependent on the activity of 
matrix metalloproteases (MMPs). We therefore assessed 
gelatinase activity of MMP-9 using a gelatin Zymography 
and looked at MMP-2, TIMP-1 and TIMP-2 expression 
using qRT-PCR following nuclear import inhibition. 
Conditioned media was collected from HeLa and SiHa 
cells following INI-43 treatment and PMA stimulation 
and the results showed a substantial reduction in MMP-9 
activity following nuclear import inhibition (Figure 3A). 
The expression of MMP-2 was found to be downregulated 
following INI-43 treatment in HeLa cells (Figure 3B) 
while the inhibitors of matrix metalloproteases, TIMP-1 
and TIMP-2, were significantly upregulated (Figure 3C & 
3D). Together these results provide further evidence for 
the role of KPNB1 in cancer cell biological processes such 
as migration and invasion.
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Figure 1: Effect of KPNB1 inhibition on cervical cancer cell migration. (A) Representative images from the transwell migration 
chamber showing migration of HeLa cells following KPNB1 knockdown, arrows identifying migrating cells. Scale bar represents 100 μm. 
(B) Quantification of transwell migration assay following KPNB1 knockdown normalized to MTT cell viability. (C) Representative images
showing HeLa and SiHa cell migration through the membrane following a 3 hour 10 μM INI-43 pre-treatment, arrows identifying migrating
cells (D) The number of HeLa and SiHa cells that migrated through the transwell chamber following INI-43 treatment were quantified and
normalized to MTT cell viability. Results shown are the mean ± SD of experiments performed in triplicate. (*p<0.05).
Figure 2: Effect of KPNB1 inhibition on cervical cancer cell invasion. (A) Representative images of the invasion transwell 
assay showing invasion of HeLa cells through the matrigel-coated transwell membrane following KPNB1 knockdown. Scale bar represents 
100 μm. (B) Quantification of the invasion assay following KPNB1 knockdown normalized to MTT cell viability. Western blot confirmed 
KPNB1 knockdown. (C) Representative images of the invasion assay following 3 hr 10 μM INI-43 pre-treatment of HeLa and SiHa cells 
showing the number of cells able to invade the matrigel-coated membrane following nuclear import inhibition. (D) Quantification of 
invasion assay following INI-43 treatment, normalized to MTT cell viability. Results shown are the mean ± SD of experiments performed 
in triplicate. (*p<0.05).
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Inhibition of KPNB1 interferes with NFkB 
subcellular localisation
Cancer cell proliferation, migration and invasion 
has a strong association with the correct function of 
transcription factors that associate with cancer such as 
NFkB. For NFkB to be active as a transcription factor it is 
essential that it is transported into the nucleus where it can 
bind the DNA and initiate transcription of its target genes. 
Here, we investigated the requirement of the nuclear 
import protein, KPNB1, for subcellular localisation of 
the NFkB p65/p50 dimer in cervical cancer cells using 
multiple techniques including; immunofluorescent 
analysis, nuclear/cytoplasmic protein separation and 
electromobility shift assays (EMSA). Translocation 
of NFkB into the nucleus was stimulated using PMA. 
Immunofluorescent analysis shows that PMA treatment 
results in the translocation of NFkB into the nucleus 
but inhibiting KPNB1 through siRNA transfection or 
INI-43 pre-treatment blocks nuclear translocation of 
Figure 3: KPNB1 inhibition affects MMP-9 activity and MMP-2, TIMP-1 and TIMP-2 expression. (A) Gelatin Zymography 
showing MMP-9 activity in HeLa and SiHa conditioned media collected after 16 hours following a 3 hour pre-treatment of 10 μM INI-43 
and a 1 hour 0.5 μM PMA stimulation. qRT-PCR analysis of mRNA expression following 5 μM INI-43 treatment for 21 hours with the 
addition of 0.5 μM PMA for a further 3 hours in HeLa cells shown for MMP-2 (B) and inhibitors of matrix metalloproteases, TIMP-1 (C) 
and TIMP-2 (D). Results shown are the mean ± SD of experiments performed in triplicate. (*p<0.05).
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NFkB and causes its cytoplasmic retention (Figure 4A). 
Quantification of fluorescent images shows an overall 
reduction in nuclear NFkB in KPNB1 inhibited cells 
following PMA stimulation (Figure 4B). Western blotting 
was used to validate KPNB1 knockdown (Figure 4C). 
These findings were independently validated using 
nuclear/cytoplasmic fractionation of protein samples 
followed by western blot analysis for the p65 and p50 
subunits of NFkB. In the presence of KPNB1 siRNA 
or treatment with INI-43, a decrease in nuclear and 
concomitant increase in cytoplasmic NFkB p65 and 
p50 was observed (Figure 4D). To further elucidate the 
effect of inhibiting KPNB1 on NFkB, EMSAs were 
performed to investigate the ability of nuclear NFkB to 
bind a NFkB consensus sequence. A substantial decrease 
in the presence of the nuclear NFkB/DNA complex 
was observed following nuclear import inhibition using 
KPNB1 siRNA or INI-43 treatment (Figure 5A & 5B). 
Western blotting was used to confirm protein nuclear/
cytoplasmic fractionation and KPNB1 knockdown (Figure 
5A). Supershift analysis with antibodies specific to the 
NFkB p65 and p50 subunits identified NFkB p65 as a 
protein present in the complex. A reduction in the binding 
when the supershift was performed using the NFkB p50 
antibody suggests competitive binding of the protein with 
the biotin-labelled oligonucleotide (Figure 5C). Together, 
Figure 4: NFkB localisation following KPNB1 inhibition. (A) Representative immunofluorescent images showing NFĸB p65 
expression and localisation as well as nuclear staining (DAPI) in HeLa cells. The results show the changes in cellular localisation of NFkB 
following a 1 hour treatment with 0.5 μM PMA, as well as inhibiting KPNB1 through siRNA knockdown or 3 hour pre-treatment with 10 
μM INI-43 in addition to PMA stimulation (x100 Objective). Scale bar represents 10 μm. (B) Screening of 250 cells over 25 fluorescent 
images per treatment were scored into “predominantly nuclear” or “predominantly cytoplasmic” p65 fluorescence according to nuclear/
cytoplasmic fluorescent intensity analysis. The graph was plotted using the percentage nuclear and cytoplasmic p65 fluorescence. (C) 
Knockdown of KPNB1 was confirmed by western blot. (D) Western blot analysis of NFĸB p65 and p50 expression in the cytoplasmic and 
nuclear protein fraction of HeLa cells transfected with KPNB1 siRNA or pre-treated with 10 μM INI-43 for 3 hours before a 1 hour 0.5 
μM stimulation with PMA. β-tubulin was used as a cytoplasmic loading control while TBP (TATA-binding protein) was used as a nuclear 
loading control. Densitometric analysis was normalized to loading controls.
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these results confirm that KPNB1 is necessary for NFkB 
nuclear localisation.
NFkB transcriptional activity and inflammatory 
target gene expression are inhibited in KPNB1-
inhibited cells
Since it was established that NFkB requires KPNB1 
for its transport into the nucleus, we postulated that 
inhibiting KPNB1 should result in a change in NFkB 
transcriptional activity and NFkB target gene expression. 
The transcriptional activity of NFkB was quantified using 
a luciferase reporter assay of both an artificial NFkB 
consensus binding site containing promoter as well as a 
known NFkB target gene, the IL-6 promoter-luciferase 
construct. Our data shows that inhibiting KPNB1 using 
siRNA resulted in significantly reduced transcriptional 
activity of the NFkB promoter-luciferase construct (Figure 
6A). Treatment of HeLa cells with INI-43 also resulted 
in a significant reduction of PMA-stimulated NFkB 
transcriptional activity in a dose-dependent manner to a 
level which was comparable to the effect of the NFkB 
inhibitor, JSH-23 (Figure 6B). The IL-6 promoter was 
similarly inhibited by both KPNB1 siRNA (Figure 6C) 
and INI-43 treatment (Figure 6D). As inhibiting KPNB1 
resulted in an inhibition of NFkB activity we next 
investigated whether inhibiting nuclear import affects the 
expression of NFkB target genes specifically involved 
in inflammatory signaling associated with cell biology 
changes in cancer. Inflammatory cytokines; IL-6, IL-1β 
and TNF-α are target genes of NFkB and the expression 
was monitored in response to KPNB1 inhibition. HeLa 
cells transfected with KPNB1 siRNA showed not only 
reduced mRNA expression of the KPNB1 gene but a 
significant reduction in the mRNA expression of all three 
inflammatory cytokines (Figure 7A). The small molecule 
inhibitor, INI-43, had a similar inhibitory effect and 
significantly inhibited PMA-stimulated IL-6 (Figure 7B), 
Figure 5: Formation of a nuclear NFkB/DNA binding complex following KPNB1 inhibition. (A) Electromobility shift 
assay (EMSA) showing binding of nuclear protein to a biotin-labelled NFĸB oligonucleotide following KPNB1 siRNA transfection in 
PMA-stimulated HeLa cells. Western blot analysis of fractionated protein samples confirmed KPNB1 knockdown and fractionation. (B) 
EMSA of nuclear extracts obtained from cells pre-treated with 10 μM INI-43 for 2 hours followed by a 1 hour 0.5 μM PMA stimulation. 
(C) Supershift analysis with the NFĸB p65 antibody showing a shift in the DNA-protein complex while the p50 antibody reduced protein
binding both confirming the presence of NFkB in the DNA-protein complex.
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Figure 7: KPNB1 inhibition affects inflammatory NFkB target gene expression. (A) qRT-PCR analysis of mRNA expression 
showed the effect of KPNB1 knockdown (C= Control, KD= Knockdown) on KPNB1 mRNA expression, confirming knockdown, as well as 
expression of inflammatory target genes; IL-6, IL-1β and TNF-α. (B) IL-6 mRNA expression shown following stimulation for 1 hour with 
0.5 μM PMA as well as pre-treatment for 2 hours with 10 μM INI-43 or 23 hours 20 μM JSH-23 followed by 1 hour PMA stimulation. The 
same conditions were used to look at IL-1β mRNA expression (C) and TNF-α (D). Target gene expression was normalized to expression of 
the housekeeping gene, GAPDH. Results shown are the mean ± SD of experiments performed in triplicate. (*p<0.05)
Figure 6: KPNB1 inhibition affects NFkB transcriptional activity. (A) NFĸB transcriptional activity using an NFkB binding 
site-luciferase reporter transiently transfected into HeLa cells following KPNB1 knockdown and stimulation with PMA. (B) NFĸB 
transcriptional activity in HeLa cells following a 3 hour 0.5 μM PMA stimulation but subsequently inhibited following a 21 hour pre-
treatment with INI-43 and JSH-23 treatment (24 hr total treatment time). (C) IL-6 promoter activity shown following KPNB1 knockdown 
and stimulation with PMA. (D) The effect of 0.5 μM PMA stimulation for 3 hours on IL-6 promoter activity is shown in HeLa cells followed 
by pre-treatment with 10 μM INI-43 for 21 hours. Results shown are the mean ± SD of experiments performed in quadruplicate. (*p<0.05)
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IL-1β (Figure 7C) and TNF-α (Figure 7D) gene expression 
which was comparable to the effect of the NFkB inhibitor, 
JSH-23. The enhanced reduction of TNF-α mRNA 
expression in INI-43 treated cells in comparison to the 
effect of JSH-23 suggests that KPNB1 inhibition by INI-
43 on NFkB alone may not be fully responsible for the 
effect of INI-43 on inflammatory target gene expression 
(Figure 7D). Other transcription factors such as AP-1 are 
also known to regulate cytokine expression, namely IL-6, 
and may too depend on KPNB1 for its activity. Together 
these results provide evidence that the inhibition of nuclear 
import via KPNB1 associates with decreased expression 
of pro-inflammatory cytokine expression.
KPNB1 inhibition affects activity and target 
gene expression of the AP-1 transcription factor
Transcription factors, other than NFkB, also contain 
a nuclear localisation sequence (NLS) and may depend 
on KPNB1 for nuclear entry. The transcription factor 
AP-1 has been reported to have a NLS present on the 
c-JUN component, although nuclear import of c-JUN
is not limited to KPNB1 only [40]. We investigated
whether KPNB1 may also influence activity and target
gene expression of the AP-1 transcription factor. The
transcriptional activity of AP-1 was quantified using a
luciferase reporter construct containing multiple artificial
AP-1 binding sites. Our data shows that the small
molecule inhibitor of nuclear import, INI-43, was able to
significantly reduce PMA-stimulated AP-1 transcriptional
activity (Figure 8A). The expression of inflammatory-
associated target genes of AP-1; IL-6 (Figure 8B) and
GM-CSF (Figure 8C) were analysed using qRT-PCR.
Stimulation with PMA significantly increased mRNA 
expression of both genes while pre-treatment with INI-43
was able to reduce this expression which was comparable
to the effect of the JNK inhibitor, SP600125, which is
an upstream inhibitor of the AP-1 signaling pathway.
Activation of AP-1 requires that c-JUN be phosphorylated
in the nucleus by phosphorylated JNK, although nuclear
import of JNK is NLS-independent and therefore not
reliant on KPNB1 [41, 42]. Western blotting was used
Figure 8: AP-1 activity and target gene expression in affected by KPNB1 inhibition. (A) A luciferase reporter assay showed 
AP-1 transcriptional activity in HeLa cells following a 3 hour 0.5 μM PMA treatment as well as a 21 hour pre-treatment with 10 μM INI-
43. (B) qRT-PCR analysis of AP-1 target genes IL-6 and (C) GM-CSF shows mRNA expression following stimulation for 1 hour with
0.5 μM PMA and a 2 hour pre-treatment with 10 μM INI-43 or 1 hour pre-treatment with 20 μM SP600125. (D) Western blotting showed
phosphorylation levels of c-JUN in HeLa cells following a 1 hour treatment with PMA and a 2 hour pre-treatment with INI-43 or 1 hour
pre-treatment with SP600125. Densitometric analysis shows phosphorylated levels of c-JUN normalized to total c-JUN. Results shown are
the mean ± SD of experiments performed in triplicate. (*p<0.05)
Oncotarget32841www.impactjournals.com/oncotarget
to assess the phosphorylation of c-JUN and showed that 
PMA stimulation increased c-JUN phosphorylation while 
INI-43 treatment at 0.5x and 1x IC50 as well as SP600125 
reduced phosphorylation (Figure 8D). These results show 
that the AP-1 transcription factor is dependent on KPNB1 
for its activity and target gene expression.
Cervical cancer cell motility depends on 
inflammatory transcription factor activity
There is evidence in the literature that NFkB and 
AP-1 signaling contributes to cancer cell migration and 
invasion through the expression of inflammatory cytokines 
such as IL-6 and TNF-α [43]. We have shown above that 
NFkB and AP-1 signaling can be modulated through 
inhibiting the function of KPNB1. As a result of this we 
wanted to investigate whether the changes is cervical 
cancer cell motility seen when KPNB1 was inhibited are 
potentially attributed to the inhibition of NFkB and AP-1 
signaling. In order to do this we performed a transwell 
migration assay where HeLa cells were treated with INI-
43 alongside cells where NFkB was inhibited (JSH-23) 
as well as AP-1 signaling inhibited (SP600125). Although 
inhibiting NFkB signaling showed a trend towards 
reducing HeLa cancer cell migration the results were not 
significantly different from the control while inhibiting 
KPNB1 using INI-43 and inhibiting AP-1 signaling using 
SP600125 significantly reduced the migratory ability of 
cervical cancer cells (Figure 9A). Quantification of the 
migration data is shown in Figure 9B. The data suggests 
Figure 9: Cervical cancer cell migration depends on AP-1 signaling activity. (A) Representative images of a transwell migration 
assay showing the amount of HeLa cells that were able to migrate through the membrane in the presence of 0.5 μM PMA (control) and 
following a 3 hour pre-treatment with 10 μM INI-43 and 20 μM JSH-23 and a 2 hour pre-treatment with 20 μM SP600125. Scale bar 
represents 100 μm. (B) Quantification of the migration assay showing HeLa cell migration following INI-43, JSH-23 and SP600125 
treatment, normalized to MTT cell viability. Results shown are the mean ± SD of experiments performed in triplicate. (*p<0.05)
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that suppressed NFkB and AP-1 signaling following 
KPNB1 inhibition may together contribute to the 
inhibitory effects on cancer cell biology.
DISCUSSION
The increased expression of KPNB1 has been shown 
to increase nuclear import efficiency in transformed cells 
[44]. This enhanced access of cargo into the nucleus is 
suggested to sustain the high metabolic and proliferative 
demands of cancer cells. Cancer cells have been found to 
require KPNB1 for their proliferation although the exact 
mechanism of action for this requirement is not fully 
understood. It could be attributed to either; the essential 
role of KPNB1 in mitosis or linked to the inability of 
certain cargoes to gain access into the nucleus and perform 
their jobs in promoting proliferation [45]. This led us 
to question whether other cancer phenotypes are also 
dependent on KPNB1.
In our study we have shown that inhibiting KPNB1 
reduced migration and invasion of cancer cells. As cancer 
cells require the activity of matrix-modifying enzymes to 
invade surrounding tissue, we looked at whether MMP 
activity was affected by KPNB1 inhibition. MMP activity 
was found to be significantly inhibited in cervical cancer 
cells following INI-43 treatment. Fan et al. (2016) found 
MMP-9 to be upregulated in cervical cancer tissue which 
correlated with a poor patient prognosis. Inhibiting MMP-
9 activity in SiHa and HeLa cervical cancer cells reduced 
their migratory and invasive ability [46]. Similarly, 
MMP-2 expression was also found to be decreased 
following KPNB1 inhibition while expression of the 
inhibitors of matrix metalloproteases, TIMP-1 and TIMP-
2, were significantly increased. TIMPs are known to be 
downregulated in a variety of cancer cell lines which is 
thought to contribute to the invasive properties of cancer 
cells. The overexpression of TIMP-2 in a highly metastatic 
melanoma cell line was able to inhibit metastasis [47, 48]. 
This work suggests that KPNB1 may play an important 
role in the migratory and invasive potential of cervical 
cancer cells. KPNB1 could be functioning as one of the 
key transporters of transcription factors associated with 
cancer cell migration, invasion and metastasis.
The transcription factors NFkB and AP-1 play a 
primary role in regulating MMP expression [14, 29, 49]. 
As both NFkB and AP-1 require access to the nucleus in 
order to be functional we hypothesized that inhibiting 
nuclear import via KPNB1 may lead to their inactivity 
and ultimately various downstream effects on cancer 
cell biology. We identified KPNB1 to be required for 
the subcellular translocation and activity of the NFkB 
transcription factor. A study by Liang et al. (2013) found 
KPNB1 to be responsible for the cellular translocation 
of NFkB p65 and inhibiting its function resulted in the 
retention of NFkB p65 in the cytoplasm leading to 
reduced NFkB transcriptional activity [23]. Our data is in 
support of these findings. NFkB is an important mediator 
of inflammation while other transcription factors such 
as AP-1 have also been known to initiate expression 
of inflammatory cytokines [26, 33]. In this study we 
questioned whether inhibiting NFkB and AP-1 activity 
via inhibiting KPNB1 associated with the inhibition of 
inflammatory gene expression. KPNB1 was inhibited 
using two approaches; RNA interference and drug-
mediated inhibition. The canonical NFkB pathway as well 
as c-JUN activation pathway was stimulated in cell culture 
using PMA which enhanced IL-1β, IL-6, TNF-α and 
GM-CSF expression. We show that stimulated cytokine 
expression could be blocked following inhibition of 
KPNB1 or through transcription factor specific inhibitors 
further confirming the reliance of NFkB and AP-1 activity 
on the nuclear importer. The pro-inflammatory cytokines; 
IL-1β, IL-6, TNF-α and GM-CSF have been implicated 
in cell biology changes required for tumour progression 
[11, 50–52]. These changes include increased migratory 
ability and invasive potential which are required for 
the epithelial-to-mesenchymal transition (EMT) that 
precedes metastasis [53]. On activation of the transcription 
factor, NFkB, target genes such as TNF-α and IL-6 can 
subsequently form a positive feedback loop further 
activating NFkB as well as other transcription factors such 
as AP-1. Together activation of these transcription factors 
has been associated with down-regulated E-cadherin 
expression and upregulation of matrix metalloprotease 
production ultimately promoting EMT [29, 54, 55].
To identify whether either NFkB or AP-1 are 
required for the migration of cervical cancer cells, each 
transcription factor was individually inhibited alongside 
INI-43 and the effect on migration analysed. Although 
inhibition of the AP-1 signaling pathway was able to 
significantly reduce migration, neither inhibition of AP-1 
or NFkB on their own were able to reduce migratory 
potential of cancer cells to the extent of the nuclear import 
inhibitor. Transcription factors of the FOS/JUN, CREB/
ATF and NFkB families are known to act synergistically 
to significantly increase the expression of the same target 
gene. It has therefore been proposed that inhibiting more 
than one transcription factor acting synergistically may 
be a more appropriate approach [56]. Darnell (2002) 
proposed that inhibiting nuclear import proteins may 
be a way of specifically targeting multiple overactive 
transcription factors [57]. Our data provides evidence 
that supports Darnell’s proposal, showing that inhibiting 
KPNB1 affects AP-1 and NFkB transcriptional activities 
required for cancer cell biology.
To our knowledge this study is a first to identify 
KPNB1 as a potential therapeutic target for inflammatory 
signaling in cancer associated with enhanced motility and 
invasiveness. Much research has been done on targeting 
individual transcription factors as a chemotherapeutic 
approach. This approach is often associated with broad-
range side effects given the diverse role of each transcription 
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factor in normal cellular functioning. Cancer cells however, 
have been reported to become “addicted” and highly 
dependent on the activity of certain transcription factors 
or oncogenes, hence inhibiting their function is thought 
to effect cancer cells to a greater extent than non-cancer 
cells [58]. Ideally a targeted approach would be required 
to limit such off-target effects. Targeting KPNB1 as a 
means of transcription factor inhibition may be a favorable 
approach as KPNB1 is overexpressed in cervical cancer 
tissue in comparison to normal cervical tissue and we have 
previously shown that normal cells are less dependent on 
KPNB1 for proliferation and survival [5]. Our research 
group has also previously shown that inhibiting KPNB1 
using INI-43 reduced tumour growth in a mouse model 
[37]. These results further characterize the nuclear import 
protein, KPNB1, as a potential anticancer target.
MATERIALS AND METHODS
Cell culture
Human cervical carcinoma cell line, HeLa and SiHa, 
were obtained from the American Type Culture Collection 
(ATCC). Cells were cultured under adherent conditions 
in Dulbecco’s Modified Eagle’s Medium (DMEM), 
supplemented with penicillin (100 U/ml), streptomycin 
(100 μg/ml) and 10% Fetal Calf Serum (FCS) (HiClone, 
Thermo Scientific, USA). Cells were incubated at 37°C 
in 95% air and 5% CO2. Cell lines were authenticated by 
DNA profiling using the Cell ID system (Promega, USA).
RNA interference & drug treatment
Short-interfering RNA (siRNA) was used to 
inhibit KPNB1 gene expression (sc-35736, Santa 
Cruz Biotechnology, USA). Control siRNA (SIC001, 
Sigma-Aldrich, USA) consisting of a scrambled RNA 
sequence was used as a non-silencing control. The 
cells were transiently transfected with 20 nM (35 mm 
plate)/ 52 nM (60 mm plate) siRNA using TransFectin 
Lipid Reagent (Bio-Rad, USA). Protein was extracted 
or cells assayed 30-48 hrs post transfection. The effect 
of KPNB1 knockdown was confirmed by Western Blot 
analysis. The nuclear import inhibitor, INI-43, was used 
at a concentration of 10 μM unless otherwise stated [37]. 
Other inhibitors include the NFkB inhibitor, JSH-23, used 
at 20 μM (Sigma-Aldrich, USA) and the JNK inhibitor, 
SP600125, used at 20 μM (Sigma-Aldrich, USA). The 
phorbol ester, phorbol-12-myristate-13-acetate (PMA) 
(Sigma-Aldrich, USA), was used to stimulate a cellular 
inflammatory response.
Migration and invasion assays
Cells were seeded into 35 mm dishes and treated 
accordingly before being trypsinized, resuspended in 0.1% 
FCS-containing DMEM and seeded in equal quantities 
into 12-well Transwell migration chambers (Greiner 
Bio-One, Austria) or 24-well matrigel covered Transwell 
invasion chambers (BD Biosciences, USA) with an 8 
μm pore size. The chambers were placed into a lower 
chamber containing 20% FCS-containing DMEM and the 
cells allowed to migrate/invade through the membrane or 
matrigel matrix over 24 hrs. The cells that were unable 
to move through the membrane were removed while 
the remaining cells were fixed in methanol, stained with 
crystal violet, counted and imaged using a Zeiss Primovert 
inverted phase microscope. Results were normalized to an 
MTT cell viability assay (according to the manufacturer’s 
protocol, Sigma-Aldrich, USA) and western blotting 
confirmed KPNB1 knockdown.
Gelatin zymography
Cells were seeded into 35 mm plates, treated and 
serum-free media placed onto the cells to condition for 
16 hrs. Conditioned media was collected and centrifuged 
to remove any cellular debris, combined with sample 
buffer, loaded into a gelatin gel and run at 125 V. The gel 
was removed and placed in a renaturing solution before 
being placed in the developing buffer and allowed to 
incubate at 37°C overnight to facilitate gelatinase activity. 
The staining solution was used to dye the gel while the 
destaining solution exposed areas of gelatinase activity.
Immunofluorescent microscopy
Immunofluorescent analysis of NFĸB p65 was 
performed on HeLa cells plated over glass coverslips 
and transfected with siRNA (48 hrs), treated with 10 μM 
INI-43 (3 hrs) and/or stimulated with 0.5 μM PMA for 1 
hour before being fixed in 4% paraformaldehyde. Cells 
on the coverslips were permeabilised using 0.25% Triton 
X-100 in PBS for 10 mins followed by three 5 min PBS
washes. Cells were blocked in 1% BSA in PBS-T + 0.3
M Glycine (for quenching) at room temperature for 30
mins. Cells were subsequently incubated with α-NFĸB
p65 primary antibody (1:200; sc-7151x, Santa Cruz
Biotechnology, USA) in 1% BSA in PBS-T for 1 hour at
room temperature, followed by three 5 min PBS washes.
Cy3-conjugated goat anti-rabbit secondary antibody
(1:300, Jackson ImmunoResearch, USA) in 1% BSA 
in PBS-T was applied for a further 1 hour. Cells were
washed three times for 5 mins in PBS, nuclei stained with
DAPI (100 ng/ml) and mounted onto glass slides with
Mowiol. Fluorescent images were captured at 100x in
oil immersion using a Zeiss Axiovert 200M fluorescent
microscope with AxioVision 4.8 Zeiss software and an
AxioCam HRm.
Protein harvest and western blot analysis
Following relevant treatment of cells, protein 
was either harvested on ice in RIPA buffer containing 
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a fresh mixture of complete protease inhibitors (Roche, 
Switzerland) and 0.1 M Sodium Orthovanadate to inhibit 
phosphatase activity or fractionated using the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents according 
to the manufacturer’s instructions (Thermo Scientific, 
USA). Protein concentrations were determined using 
the Bicinchoninic Acid (BCA) assay kit (Pierce, Thermo 
Scientific, USA). Western blot analysis was performed 
using rabbit anti-KPNB1 (H-300) (sc-11367, Santa Cruz 
Biotechnology, USA), rabbit anti-NFĸB p65 (H-286) 
(sc-7151x, Santa Cruz Biotechnology, USA), rabbit anti-
NFĸB p50 (H-119) (sc-7178x, Santa Cruz Biotechnology, 
USA), rabbit anti-p-c-Jun (Ser63/73) (sc-16312-R, 
Santa Cruz Biotechnology, USA), rabbit anti-c-Jun (D) 
(sc-44, Santa Cruz Biotechnology, USA), mouse anti-
GAPDH (0411) (sc-47724, Santa Cruz Biotechnology, 
USA), rabbit anti-β-tubulin (H-235) (sc-9104, Santa Cruz 
Biotechnology, USA) and rabbit anti-TBP (N-12) (sc-204, 
Santa Cruz Biotechnology, USA).
Electromobility shift assay (EMSA) and 
supershift assay
Nuclear protein was extracted from treated 
HeLa cells and concentrations quantified as 
before. The wild-type NFkB oligonucleotides; 
5’-AGTTGAGGGGACTTTCCCAGGC-3’ and 3’-TCA 
ACTCCCCTGAAAGGGTCCG-5’ were labelled using 
the Biotin 3’ End Labelling Kit (Thermo Scientific, USA) 
according to the manufacturer’s instructions. Equal parts 
of labelled probe were annealed under the following 
conditions; 3 mins- 95°C, 10 mins- 65°C, 60 mins- 37°C 
and 1 min- 25°C. The binding reaction contained; 5 μg 
protein, incubation buffer, poly DI/DC and 5 μl biotin-
labelled double-stranded NFĸB oligonucleotide. For the 
supershift analysis, 2 μl NFĸB p65/p50 antibody was 
added to the binding reaction. For the controls 1 μl 50 
μM unlabeled double-stranded wild-type oligonucleotide 
or unlabeled double-stranded mutant oligonucleotide, 
5'-AGTTGAGGCGACTTTCCCAGGC-3' and 3’-GCC 
TGGGAAAGTCGCCTCAACT-5’, was added to 
the binding reaction. Samples were electrophoresed 
on a polyacrylamide gel and detected using the 
Chemiluminescent Nucleic Acid Detection Module 
(Thermo Scientific, USA).
Luciferase reporter assays
HeLa cells were cultured in 24-well plates and 
transfected with 50 ng of the NFĸB p65 luciferase reporter 
construct (containing 5 copies of the p65 binding site, 
Promega, USA), the AP-1 luciferase reporter construct 
(containing four copies of the AP-1 binding site, [28]) 
or the full-length IL-6 promoter construct in the pXP2 
luciferase vector (Gifted by Assoc Prof Luiz Zerbini, 
ICGEB, Cape Town) [59] and 5 ng of the pRL-TK plasmid 
(encoding Renilla luciferase) to normalize for transfection 
efficiency. Thereafter cells were transfected with siRNA 
(48 hrs), treated with 10 μM INI-43 (3-24 hrs), 20 μM 
JSH-23 (24 hrs) and/or stimulated with 0.5 μM PMA for 
1-8 hours before being lysed in 100 μl 1x Passive Lysis
Buffer (Promega, USA). Luciferase firefly activity was
assayed using the Dual Luciferase kit (Promega, USA) on
the Glomax 96 microplate luminometer (Promega, USA).
Promoter activity was normalized to Renilla luciferase
activity.
Quantitative real time PCR
Quantitative real-time PCR was performed 
using the StepOne Real-time PCR system (Applied 
Biosystems, USA). RNA was isolated from treated 
cells using Qiazol (Qiagen, Netherlands), according 
to the manufacturer’s instructions. Synthesis of 
complementary DNA used 2 μg RNA and 2-4 μl of this 
was amplified using the KAPA SYBR Fast mastermix 
(KAPA Biosystems, South Africa) for qRT-PCR 
analysis. The sequence of qRT-PCR primers were as 
follows; MMP-2 F: 5’ TGGCGATGGATACCCCTTT 
3’, R: 5’ TTCTCCCAAGGTCCATAGCTCAT 3’, 
TIMP-1 F: 5’ AGAGACACCAGAGAACCCA 3’, R: 
5’ TGATGACGAGGTCGGAATTG 3’, TIMP-2 F: 5’ 
CATGATCCCGTGCTACATCTC 3’, R: 5’ TTGATGC 
AGGCGAAGAACT 3’, IL-1β F: 5’ CCACCTCCAGG 
GACAGGATA 3’ and R: 5’ TGGGATCTACACTCTC 
CAGC 3’, IL-6 F: 5’ GGATTCAATGAGGAGACTTGCC 
3’ and R: 5’ CAGGCTGGCATTTGTGGTTG 3’, TNF-α 
F: 5’ GTAGCCCATGTTGTAGCAAACC 3’ and R: 5’ TGA 
TGGCAGAGAGGAGGTTG 3’, GM-CSF F: 5’ GAC 
ACTGCTGCTGAGATGAATG 3’ and R: CAGTGC 
TGCTTGTAGTGGCT 3’, GAPDH F: 5’GGCTCT 
CCAGAACATCATCC 3’ and R: 5’ GCCTGCTTC 
ACCACCTTC 3’. Samples were standardized to the 
house-keeping gene, GAPDH. Analysis was carried out 
using the comparative threshold cycle (CT) method.
Statistical analysis
Experiments were performed in triplicate and 
represented as mean ± SD and repeated at least two 
independent times unless stated otherwise. The student’s 
t test was performed in GraphPad Prism V5.0 for all 
comparisons. A p value of p<0.05 was considered 
statistically significant.
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Abstract
The Karyopherin superfamily is a major class of soluble trans-
port receptors consisting of both import and export proteins.
The trafficking of proteins involved in transcription, cell signal-
ling and cell cycle regulation among other functions across
the nuclear membrane is essential for normal cellular function-
ing. However, in cancer cells, the altered expression or local-
ization of nuclear transporters as well as the disruption of
endogenous nuclear transport inhibitors are some ways in
which the Karyopherin proteins are dysregulated. The value of
nuclear transporters in the diagnosis, prognosis and treatment
of cancer is currently being elucidated with recent studies
highlighting their potential as biomarkers and therapeutic tar-
gets. VC 2016 IUBMB Life, 68(4):268–280, 2016
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Introduction
Protein trafficking is fundamental to cellular function and cell
survival. Of the protein trafficking systems found in cells,
access into the nucleus through the nuclear pore complex
(NPC) is essential for the functioning of many proteins. Pro-
teins smaller than 20–40 kDa can passively diffuse through the
NPC while larger proteins require active facilitated transport
to gain access in or out of the nucleus.
Facilitated transport of numerous proteins is achieved via
the action of the Karyopherin proteins. The Karyopherin
superfamily consists of both the Karyopherin beta/Importin
beta family and the Karyopherin alpha/Importin alpha family
of adaptor proteins. The Karyopherin beta family forms the
major class of soluble transport receptors. Its members inter-
act with and import and/or export cargo proteins and certain
RNAs across the nuclear envelope. Thus far there have been
20 genes encoding Karyopherin beta family members identi-
fied in the human genome including 10 proteins involved in
nuclear import, seven proteins involved in nuclear export,
two bidirectional transporters and one transporter that
remains uncharacterised (Table 1) (40). The Karyopherin
alpha family of adaptor proteins bind the nuclear localisation
signal (NLS) of cargo proteins and link them to the Karyo-
pherin beta transport protein, hence playing the role of an
adaptor. Seven Karyopherin alpha isoforms are currently
characterised, which are grouped into three subfamilies: A1,
A2 and A3. The A1 subfamily comprises Karyopherin A2 and
Karyopherin A7, the A2 subfamily includes Karyopherin A3
and Karyopherin A4 and, finally, the A3 subfamily consists of
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Karyopherin A1, Karyopherin A5 and Karyopherin A6
(Table 1) (41).
The classical nuclear import pathway involves a Karyo-
pherin alpha isoform recognising and binding a cargo contain-
ing a classical nuclear localisation signal (cNLS), which is then
bound by Karyopherin beta 1 (KPNB1). This trimeric complex
is then shuttled through the NPC. An alternative path of
nuclear import involves the cargo protein bypassing the need
for an adaptor and binding KPNB1 directly. Cargo proteins
such as parathyroid hormone-related protein (PTHrP) and ste-
rol regulatory-related protein (SREPB2) use this mode of
nuclear import (2). Passage through the NPC is mediated by
the interactions between Phe-Gly repeat-containing nucleopor-
ins of the NPC and KPNB1. Upon arrival in the nucleus, a key
event is the binding of RanGTP to the KPN/cargo complex,
which promotes dissociation of the import complex, allowing
the cargo to remain in the nucleus and the transport proteins
to be recycled (42,43). The nuclear export protein, CSE1L, is
responsible for recycling the Karyopherin alphas back into the
cytoplasm. XPO1, the most well-characterised export protein,
binds cargoes containing a leucine-rich nuclear export signal
(NES). RanGTP stabilizes the XPO1-bound NES–cargo complex
that can then pass through the NPC towards the cytoplasm.
When in the cytoplasm, the hydrolysis of RanGTP to RanGDP
allows the dissociation of the export protein and the cargo
(Fig. 1) (44).
Although the best described role of the Karyopherin pro-
teins is the nuclear import and export of cargo proteins, they
also play an important role in mitosis and other cell cycle-
regulated functions including regulating the assembly of the
NPC and nuclear membrane at mitotic exit as well as DNA
replication in S-phase (45,46). During normal cellular homeo-
stasis, the nuclear transport system is regulated through vari-
ous mechanisms including signal transduction, cell cycle,
immune response, development and stress (42). Dysregulation
of nuclear transport has been associated with carcinogenesis
and poor prognosis in a multitude of cancers. This review
aims to discuss recent work revolving around the role of key
nuclear transport receptors in cancer. It will cover the dysre-
gulation of nuclear transport pathways and focus on the poten-
tial of targeting these transporters in the diagnosis, prognosis
and treatment of cancer.
Proposed dysregulation of nuclear–cytoplasmic transport of cargo proteins in cancer cells in comparison to normal. (a) In nor-
mal cells protein cargo containing a nuclear localisation signal (NLS-cargo) is recognised and bound by a Karyopherin alpha
(A) transport protein after which this complex is bound by Karyopherin beta 1 (KPNB1) and allowed passage through the
nuclear pore complex (NPC). Upon association with RanGTP the cargo protein dissociates and the nuclear transport proteins
are recycled back into the cytoplasm. Recycling of the Karyopherin alpha protein occurs through binding to CSE1L and in asso-
ciation with RanGTP is transported back through the NPC into the cytoplasm. Nuclear protein cargo containing a nuclear export
signal (NES-Cargo) is recognised and bound by XPO1 where again in association with RanGTP is transported through the NPC
into the cytoplasm. (b) In cancer cells it is proposed that the overexpression of nuclear transporters (green 1), including
KPNB1, XPO1 and CSE1L leads to an increased rate of transport through the NPC. As a result their respective cargoes poten-
tially accumulate in the cytoplasm or nucleus. Nuclear transporters can also be mislocalized (red 2) rendering them non-
functional and inhibiting transport through the NPC which causes accumulation of cargo proteins in their compartment of ori-
gin. Both overexpression of nuclear transporters and their mislocalization have been seen in cancer and associated with
increased proliferation and increased survival.
FIG 1
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Dysregulation of Nuclear Transport
in Cancer
The Karyopherin superfamily of proteins play a fundamental
and indispensable role in normal cell physiology by providing
the means of trafficking between the cytoplasm and the
nucleus as well as in other cellular processes such as mitosis.
As intracellular localization of many proteins as well as the
nuclear transporters themselves has an impact on their activ-
ity status and/or function, the correct spatial arrangement of
proteins at the correct time is critical. It is therefore no sur-
prise that impaired regulation of nuclear–cytoplasmic trans-
port associates with pathogenesis. A well-researched area is
the association of nuclear transport dysregulation and cancer,
which most commonly leads to the mislocalization of cancer-
associated cargo proteins (Fig. 1). For example, the nuclear
accumulation of the DNA repair protein, NBS1, has been
shown to correlate with gastric cancer progression, while the
cytoplasmic accumulation of Wilms’ tumour protein, Wt1, was
observed more frequently in malignant tissues than normal
(11,47). There are many junctions in the nuclear transport
pathways at which dysregulation can occur; here we discuss
mechanisms that are more frequently observed and are known
to be linked to cancer. These include: (i) the altered expression
of the nuclear transporters, (ii) altered localization of nuclear
transporters, (iii) the disruption of endogenous nuclear trans-
port inhibitors and (iv) the mechanistic implications of nuclear
transporters in mitotic division and genetic instability.
Altered Expression of the Nuclear Transporters
The elevated expression of the Karyopherin proteins associates
with the global dysregulation of protein transport and this has
been observed in various types of cancer. Amongst all mem-
bers of the Karyopherin family, XPO1, KPNB1, KPNA2 and
CSE1L are the most frequently reported to be overexpressed in
cancer (Table 1). Kuusisto et al. found that the increased
expression of these Karyopherin proteins in transformed cells
correlates with enhanced nuclear import and export efficien-
cies in transformed cells (48). The increased expression and
thus transportation across the nuclear membrane is possibly a
mechanism devised by cancer cells to cope with the increased
metabolic and proliferative demands. The increased expres-
sion of import proteins, in particular, might allow for
increased nuclear entry of proteins that have oncogenic
tumour-promoting functions, for example, ERK1/2, c-Myc and
E2F1 (49–51).
Whilst the link between Karyopherin overexpression and
cancer has been the subject of numerous studies, few
researchers have addressed the underlying mechanism leading
to their overexpression. Using molecular and bioinformatics
approaches, van der Watt et al. showed that the overexpres-
sion of both KPNB1 and KPNA2 is primarily due to dysregu-
lated E2F/Rb activity in cancer cells. The constitutive activa-
tion of E2F in, e.g., cervical cancer cells was found to
associate with increased expression of both KPNB1 and
KPNA2 (7). It is well known that HPV infection in cervical can-
cer results in E2F dysregulation and thus elevated KPNB1 and
KPNA2 in this cancer. The E2F/Rb pathway is disrupted in a
remarkably high proportion of human cancers through other
mechanisms leading to the same overexpression phenotype
(52). Interestingly, Kuusisto et al. showed that the extent of
overexpression of KPNB1 correlates with disease state in the
MCF10 human breast tumour progression system, suggesting
that its overexpression not only correlates with E2F dysregula-
tion but can vary according to tumour progression state (5).
Other mechanisms for altered Karyopherin expression have
been reported. A recent study showed elevated KPNA2 expres-
sion resulting from decreased expression of microRNA-26b in
epithelial ovarian carcinoma. MicroRNA-26b directly targets
KPNA2 by repressing its translation and thus reduced
microRNA-26b resulted in elevated KPNA2 expression (53).
Quan et al. used bioinformatic approaches to predict tran-
scription factors that bind the promoter regions of Karyo-
pherin beta genes and identified Sp1, NRF-2, HEN-1, RREB-1
and NFY as potential regulators of Karyopherin beta expres-
sion (54). In line with this, van der Watt et al. found that
increased NFY and Sp1 expression in cervical cancer and
transformed are both potential contributors to XPO1 overex-
pression in these cells (7). Interestingly, Kahle et al. found that
NFY-A is imported into the nucleus by KPNB1 where it acts to
transcribe its downstream targets (55). This finding could
explain why the elevated expression of KPNB1 has been
observed concomitant with elevated XPO1 in cervical and gas-
tric cancer (3, 4, 22). van der Watt et al. also showed that
under DNA damage conditions the elevated p53 level plays a
repressive role in the transcription of the xpo1 gene (3). It is
not surprising then that XPO1 overexpression is commonly
observed in cancer as p53 is often expressed at low levels or
contains mutations in many cancers (56). Interestingly, XPO1
has also been shown to be involved in p53 nuclear export (3),
suggesting that a possible feedback regulatory mechanism
may exist. Under DNA damage conditions p53 expression
increases and enters the nucleus, thereby repressing XPO1
expression. The reduced XPO1 expression will in turn enhance
p53 retention in the nucleus further repressing XPO1 expres-
sion. In p53-deficient or -mutant cells the repression of XPO1
expression is relieved, likely leading to XPO1 overexpression.
The CSE1L protein, also a member of the Karyopherin
family involved in recycling the KPNA adaptors into the cyto-
plasm, is another member commonly reported to be overex-
pressed in cancer including bladder, leukaemia, breast, colon,
ovarian and non-Hodgkin’s lymphoma (28, 31, 34, 35). Its
overexpression has been attributed to gene amplification (31).
More recent work by Winkler et al. demonstrated a repressive
role of p53 in CSE1L and KPNA2 transcription in hepatocellu-
lar carcinoma mediated through p21 (57). As p53 loss-of-
function is a frequent occurrence in cancer it is not surprising
to observe overexpression of CSE1L in cancer.
The altered expression of nuclear transporters associated
with cancer more often involves elevated expression; however,
IUBMB LIFE
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downregulation of nuclear transporters has also been linked to
cancer. Exportin 4 (XPO4) is an example although the exact
underlying mechanism driving its downregulation is still
unknown (39).
Altered Localization of Nuclear Transporters
The ability of nuclear transporters to efficiently execute their
functions depends on their ability to interact correctly with
other members of the transport cycle. A truncated KPNA lack-
ing part of the cargo-NLS-binding domain has also shown fail-
ure to interact with and transport p53 into the nucleus in
breast cancer cells. Despite the KPNB1-binding domain
remaining intact in the mutant KPNA, it was localized predom-
inantly in the cytoplasm and perinuclear region as opposed to
the even distribution observed in wild-type KPNA (58). This
suggests that cargo recognition and binding by KPNA is a pre-
requisite for nuclear entry, and that pairing with KPNB1 alone
is not sufficient. A similar observation was made by Melo
et al., where an inactivating mutation in Exportin 5 (XPO5)
found in a subset of human tumours rendered it unable to
export itself as well as its precursor microRNA cargoes out of
the nucleus (36). As a result, the pre-microRNA processing
efficiency was decreased leading to defects in microRNA pro-
duction. Ultimately, failure to generate mature microRNA
leads to the impairment of the post-translational regulation of
target genes and altered expression profile.
Post-translational modification can also regulate protein
localization, which is well demonstrated by the CSE1L protein.
CSE1L is involved in more than one function inside the cell, but
its role in nuclear transport is specifically carried out when
localized to the nucleus (59). Its localization is phosphorylation-
dependent, while AKT-mediated phosphorylation is required for
its nuclear localization in ovarian cancer; MEK-1-mediated
phosphorylation retains it in the cytoplasm (60,61). Further-
more, siRNA-mediated inhibition of CSE1L expression in ovarian
cancer cells which exhibited predominant nuclear localization of
CSE1L showed increased sensitivity to cisplatin treatment com-
pared to breast and colon cancers which showed predominant
cytoplasmic localization (60). This suggests that the nuclear
CSE1L plays an oncogenic role and could contribute to the
resistance against cytotoxic agents. The aberrant function of the
upstream kinases can thus result in the incorrect localization of
CSE1L and resultant pathogenesis.
Disruption of Endogenous Nuclear
Transport Inhibitors
Cells also use endogenous nuclear transport inhibitors to regu-
late nuclear trafficking. The two most well-known endogenous
inhibitors are Complement Component 3 (CC3/TIP30) and
Aplasia Ras Homolog Member 1 (ARH1/NOEY2). Both proteins
were found to have reduced expression or absence in a wide
range of cancers. Knockdown studies concluded that these
proteins function to suppress the cancer phenotype, while res-
toration of their expression was unfavourable to cancer devel-
opment. Their ability to negatively regulate nuclear transport
was only recognised about a decade later (62,63). Both pro-
teins have been reported to interfere with nuclear import by
physically interacting with members of the Karyopherin fam-
ily. Binding of CC3 to the Karyopherins was RanGTP-
independent and also associated with nucleoporins in vivo.
Alternatively, ARH1 is thought to interact with Karyopherins
through the NLS domain, thereby preventing NLS-cargo bind-
ing, and also competed with the binding of Karyopherin to Ran
(64). Both inhibitors have the ability to prevent nuclear trans-
location of NLS-cargoes while CC3 was also able to prevent
transport of M9 signal-bearing cargoes (62).The alleviation on
nuclear transport and the subsequent altered cellular localiza-
tion of cargo proteins has several advantages in tumour devel-
opment and survival.
Mechanistic Implications of Nuclear Transporters in
Mitotic Division and Genetic Instability
When nucleo-cytoplasmic transport ceases, virtually all trans-
port factors take on new roles in mitosis, acting in the func-
tional organisation of the mitotic spindle and in the reconstitu-
tion of the interphase nucleus at mitotic exit. Modelling studies
have indicated that subtle dysregulation of the expression of
transport factors readily affects mitotic division and can cause
significant abnormalities in chromosome segregation, whereas
nucleo-cytoplasmic transport is a more robust process (65,66).
Dysregulation of nuclear transport factors can therefore cause
the onset of genetic instability, a cancer hallmark (Fig. 2).
The role of KPNB1 as a regulator of spindle formation and
function is well described. KPNB1 generally acts by preventing
the premature localisation or activity of spindle regulatory fac-
tors (67). Factors, with spindle assembly functions, regulated
by KPNB1 include: the spindle pole-organizing protein NuMA
Role and implications of nuclear transporters in mito-
sis. Under normal conditions upon cessation of
nuclear transport, nuclear transport factors take on
new roles in mitosis. They contribute to the stabiliza-
tion of mitotic factors and regulated mitotic division.
Dysregulation of the expression of nuclear transport
factors has been shown to contribute to the altered
localization of key spindle regulatory factors that
associate with the onset of genetic instability, which
is considered one of the hallmarks of cancer.
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(68), the microtubule-regulatory protein HURP (69), Rae1/
Nup98 (70), a regulator of the Aurora-A kinase maskin (71)
and APC (72), among others. KPNB1’s physical association and
regulation of the Adenomatous polyposis coli (Apc) oncogene,
itself a microtubule-promoting and mitotic spindle-associated
factor, may be of particular relevance to the onset of colon
cancer (72). A novel function through which KPNB1 can glob-
ally regulate the mitotic apparatus has recently emerged and
concerns its ability to regulate, in concert with the APC/C
ubiquitin ligase, the stability of mitotic spindle regulatory
factors (73).
Transportin 1 (TNPO1) has documented effects on the
mitotic apparatus and on post-mitotic reorganization of the
interphase nucleus, a critical process that is evidently crucial
for resuming transcription and replication via the cell cycle
(74,75). Disruption of this process by altered TNPO1 function
will also affect the genetic identity of the newly formed daugh-
ter cells after mitosis.
The CSE1L protein has predominant roles in the regulation
of apoptosis, as recalled above, most probably mediated by the
mislocalization of Karyopherin alpha members. It also has the
ability to associate with the mitotic apparatus; altered activity
of CSE1L can confer resistance to taxol but not to other che-
motherapeutic drugs (76). This effect is mediated through Mek
proteins, and it is particularly interesting in the light of design-
ing new potential therapeutics (76,77).
Karyopherin alpha family members, although difficult to
discuss collectively, share a common functional feature that
their downregulation induces substantial levels of apoptosis
(78). They contribute to mitotic control by interacting with key
spindle regulatory factors such as TPX2 (79). In addition, kar-
yopherin alpha 3 has a global role in mitosis. It interacts spe-
cifically with RCC1, the guanine exchange factor for Ran, and
this interaction is inhibited by mitotic phosphorylation
(78,80,81). This inhibition results in an increased concentra-
tion of free RCC1 and hence increased RanGTP production in
mitosis.
The nuclear export protein, XPO1, has well-defined mitotic
effects exerted at various levels of mitosis. These include the
mitotic spindle (82); kinetochores, stabilizing microtubule/
kinetochore interactions essential for chromosome segregation
(83) and centrosomes, preventing chromosome reduplication
that constitutes a major threat to genome stability (84,85).
These effects are mediated through several mitotic targets that
contain NES sequences. The interplay between XPO1 and
mitotic cyclin B is interesting to note. XPO1 contributes to
cyclin B localization and in turn cyclin B phosphorylates XPO1
to finely regulate its mitotic functions (86). It has also been
reported that XPO1’s interaction with survivin is important to
target the chromosomal passenger protein to kinetochores
(87).
Nuclear transport plays a critical role in the functioning of
many cellular processes. Because of this, cells have developed
elegant systems to tightly control the nuclear transport proc-
esses. Unfortunately, within each junction in the regulatory
pathway lies an opportunity for errors to occur, and indeed
many of these alterations have been associated with cancer.
Role of Nuclear Transporters in the
Diagnosis of Cancer
Late diagnosis of cancer is a major contributing factor to poor
patient outcome. Often, by the time patients present at clinics,
the cancer has already progressed to later stages and the
chances of the primary tumour having already metastasised
are relatively high. This highlights a need for effective tools for
the early detection of cancer. The ideal biomarker would be
unique to cancer and present in easily obtainable patient sam-
ples such as serum or urine. Nuclear transporters have
already been shown to be upregulated at the protein level in
many cancer tissues but few studies recognise these proteins
as potential diagnostic biomarkers. Wang et al. investigated
potential biomarker targets that were both significantly upreg-
ulated in lung cancer tissues and secreted/released from lung
cancer cells. They achieved this by integrating two lung adeno-
carcinoma cell line secretome datasets with one adenocarci-
noma microarray dataset. Using this strategy they identified
KPNA2 as a potential diagnostic biomarker for adenocarci-
noma. Elevated KPNA2 serum levels were confirmed in a
cohort of non-small-cell lung carcinoma patients (n 5 126) in
comparison to healthy individuals (n 5 64) (17). Similar to
what was observed in lung cancer patients, KPNA2 levels in
serum were also significantly upregulated in oesophageal
squamous cell carcinoma patients (n 5 86) versus healthy con-
trols (n 5 60) validating the potential of KPNA2 as a diagnostic
biomarker (88). KPNA2 has also been identified as a potential
diagnostic biomarker that can differentiate between grades of
astrocytoma. This, however, still requires immunohistochemi-
cal validation. The conventional criteria for differentiating
between WHO grade II and III astrocytomas is particularly dif-
ficult to define. Gousias et al. found that patients diagnosed
with WHO grade II astrocytoma showed little/no nuclear
KPNA2 immunostaining, whereas half of the patients diag-
nosed with anaplastic astrocytoma (WHO grade III) showed
5% KPNA2 staining in the nucleus (89).
The nuclear transporter, CSE1L, has also shown diagnostic
potential in bladder cancer and metastatic colorectal cancer
(29, 33). It is upregulated in bladder cancer and has been
found to be secreted into the urine of these patients while it is
not detected in the urine of healthy individuals (29). CSE1L has
also been found to be secreted into the sera of patients with
metastatic colorectal cancer (33). Thus far, no data have been
published regarding the serum levels of other nuclear trans-
port proteins in cancer. As previously mentioned, other mem-
bers of the Karyopherin superfamily such as KPNB1 and XPO1
have also been shown to be upregulated in various cancers. It
is thus possible that these proteins might also be secreted
from cancer cells and have potential as diagnostic markers.
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Nuclear Transporters as Prognostic
Markers
A study by van der Watt et al. found that KPNB1, KPNA2 and
XPO1 are all upregulated in cervical cancer patient samples in
comparison to normal tissue. KPNB1 and XPO1 but not KPNA2
were found to be essential for the survival of cervical cancer
cells. The nuclear importer, KPNB1, and exporter, XPO1, both
show promise as a cancer biomarker but have not as yet been
correlated to patient prognosis in cervical cancer (3). More
recently, Zhu et al. found that KPNB1 was also upregulated in
gastric cancer patient tissue and cells in comparison to their
normal counterparts. Interestingly, Zhou et al. found XPO1
protein levels to be significantly upregulated in gastric cancer
patient tissues as well, indicating that both import and export
machinery is upregulated in gastric cancer. The upregulation
of KPNB1 correlated positively with Ki-67 immunostaining,
infiltration depth and tumour grade but not TNM stage and
lymph node metastasis. On the other hand, overexpression of
XPO1 positively correlated with TNM stage as well as metasta-
sis. Both increased KPNB1 and XPO1 expression have been
identified as independent prognostic factors to predict gastric
cancer patient survival (4, 22).
XPO1 has also been identified as a suitable independent
prognostic marker in ovarian cancer, pancreatic cancer, osteo-
sarcoma, brain cancer and acute myeloid leukaemia (10, 23–
26, 90). Studies on pancreatic cancer as well as osteosarcoma
revealed XPO1 overexpression to be associated with increased
tumour size as well as histological grade in osteosarcoma but
not pancreatic cancer. For both pancreatic cancer and osteo-
sarcoma there is evidence suggesting that increased XPO1
expression is an indicator of reduced overall and progression-
free survival (24,25). In contrast, decreased expression of the
nuclear export protein, XPO4, was associated with poor overall
survival in patients with liver cancer suggesting XPO4 has
tumour suppressor properties (39,91). Although expression
levels of nuclear transporters often enhances their prognostic
value, in some cases so does their localisation within the cell.
While the localisation of XPO1 between the nucleus and the
cytoplasm showed no significant differences among gastric
cancer samples, the cellular localisation of XPO1 in ovarian
cancer has been correlated with different aspects of cancer
progression (22). Enhanced cytoplasmic XPO1 has been associ-
ated with advanced ovarian tumour stage, poor differentiation
and higher mitotic rate. Nuclear XPO1 levels have been associ-
ated with enhanced Cox-2 expression leading to poor overall
patient survival (23). Nuclear XPO1 has also been correlated
with pathological stage in gliomas (90). XPO1 localisation is
also altered during oesophageal tumourigenesis, where it
shifts from predominantly nuclear in normal tissue to nuclear
and cytoplasmic in cancer tissue. This appears to occur in the
early stages of disease progression (27).
The nuclear export protein, CSE1L, has been reported to
have prognostic potential in bladder, liver and ovarian cancers
(30, 32, (34)). Chang et al. found urothelial carcinoma patient
samples to have differing cytoplasm and nuclear CSE1L stain-
ing. While cytoplasmic CSE1L staining showed no correlation
to clinical manifestations, nuclear CSE1L closely correlated
with poor overall survival (30). In liver cancer, CSE1L was
found to be upregulated particularly in the cytoplasm of cells
in comparison to normal tissue, but the association to patient
outcome was not further investigated (32).
The value of nuclear transporters such as KPNB1, XPO1
and CSE1L as prognostic tools is still under investigation and
data supporting this are only available for a select few can-
cers. In contrast, KPNA2 has been well established as a prog-
nostic marker in various cancers including: breast cancer,
brain cancer, gastric cancer, prostate cancer, ovarian cancer,
bladder cancer, liver cancer, melanoma, lung cancer and
oesophageal cancer (8–11,14,15,92,93). Dahl et al.’s research
in breast cancer was the first to identify KPNA2 as a prognos-
tic marker (94). Since then high nuclear KPNA2 expression
has been linked to poor patient outcome. Numerous studies
have shown that KPNA2 expression correlates with overall
and progression-free survival in patients and established
KPNA2 as an independent prognostic marker when compared
to other clinical data (10, (11,13–15,89,93,95,96)). Interest-
ingly, KPNA2 expression also predicted the chances of metas-
tasis as well as histological grade and clinical stage of
tumours. High KPNA2 expression in non-invasive bladder can-
cer increased the risk of progression to a more invasive
form (13).
Some malignancies have a high recurrence rate following
therapeutic or surgical intervention and it is important to iden-
tify risk factors in these patients that might predict recurrence.
KPNA2 expression has been identified as a marker of both
early and more frequent recurrence in liver cancer while it is
also a marker of PSA recurrence in prostate cancer (9,97,98).
In meningioma, elevated KPNA2 and XPO1 expression was
observed in recurrent tumours in comparison to primary
tumours and this correlated with increased recurrence
rates (10).
The evidence presented here highlights that KPNA2 serves
as a valuable prognostic marker throughout the progression of
cancer from early-stage recurrence to chances of metastasis,
as well as overall survival. While there is evidence that
KPNB1, XPO1, CSE1L and XPO4 have shown potential as prog-
nostic markers, this requires further investigation and valida-
tion. Evidence from the study by Gousias et al., which shows
KPNA2 expression levels correlating with XPO1 expression lev-
els in meningioma, suggests that other nuclear transporters
may too have prognostic value in cancer (10).
Targeting Nuclear Transporters
as Cancer Therapeutics
The upregulation of nuclear transporters and their association
with poor prognosis in cancer highlights their potential as
therapeutic targets. Challenges may arise though when
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targeting cellular machinery that is active in both normal and
cancer cells. However, studies have shown that cancer cells
are more sensitive to nuclear transport inhibition than non-
cancer cells which remain viable (3, (5,99)). Specific knock-
down using siRNA for nuclear import proteins, KPNB1 and
KPNA2, and export proteins, XPO1 and CSE1L, in cancer cells
frequently results in reduced proliferation and increased apo-
ptosis (50,57,78,96,98,100–102). This suggests that cancer
cells may have an enhanced dependence on nuclear transport-
ers for their increased proliferative and metabolic demands
(referred to as tumour cell “addiction”).
Targeting Nuclear Export via XPO1
Among the Karyopherin family members, the nuclear
exporter, XPO1, has so far been the most successful chemo-
therapeutic target already being tested in clinical trials (Table
2). Several natural products were first described as inhibitors
of XPO1 with Leptomycin B being the most potent. Unfortu-
nately, Leptomycin B showed severe cytotoxic effects in phase
I clinical trials and was no longer pursued for use in patients.
Following that several Leptomycin B derivatives such as
Anguinomycin and Kos-2464 have been synthesized in an
attempt to reduce the cytotoxity while retaining the ability to
inhibit nuclear export via XPO1, but have as yet not entered
clinical trials. A recent review by Ishizawa et al. outlines the
history of XPO1 as a chemotherapeutic target in more detail
(21). In 2012 the SINE (selective inhibitors of nuclear export)
series of drugs were discovered through an in silico molecular
modelling strategy and synthesized by Karyopharm Therapeu-
tics (Karyopharm Therapeutics, Boston, MA) (110). These com-
pounds are water-soluble and irreversibly modify a cysteine
(Cys528) in the NES-binding groove of XPO1, thereby inhibiting
the function of the protein. KPT-185 is the most potent of the
series and is most commonly studied in vitro; however, KPT-
330/Selinexor, while nearly as potent, has more acceptable
pharmacokinetics and has shown promise in phase I and II
clinical trials in both haematological and solid tumours (111).
More recently, combination treatment strategies using
XPO1 inhibitors and currently available chemotherapeutic
agents have proven to be effective in enhancing the treatment
of cancer. Nuclear export inhibitors alone, while effective in
causing cell death in vitro, in animal models these inhibitors
while inhibiting tumour growth were less often likely to elimi-
nate existing tumours. The combination therapy is thought to
use the XPO1 inhibitor to sensitise cancer cells to chemothera-
peutic agents. A review by Turner et al. extensively discusses
Nuclear transport inhibitorsa
Nuclear transporters Inhibitor Nature of the compound Experimental status
KPNB1 cSN50.1 (103) Peptide Cell culture
KPNA/B1 Ivermectin (104) Antibiotic
cSN50.1 (103) Peptide Cell culture
Bimax1 (105) Peptide Cell culture
Bimax2 (105) Peptide Cell culture
Karystatin 1A (106) Small molecule Cell culture
Importazole (107) Small molecule Cell culture
TNPO1 M9M (108) Peptide Xenopus model
XPO1 Leptomycin B (109) Antibiotic Phase I clinical trials (discontinued)
Ratjadone analogs (21) Antibiotic Cell culture
Anguinomycin (21) Antibiotic Cell culture
Goniothalamin (21) Organic molecule Cell culture
Kos-2464 (21) Small molecule Xenograft mouse model
N-azolylacrylate analogs (21) Small molecule HIV model
CBS9106 (21) Small molecule Xenograft mouse model
SINE series (110) Small molecule Phase I–II clinical trials
aAs published until December 2015.
TABLE 2
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a range of studies providing evidence for the efficacy of XPO1
inhbitors in combination with alkylating agents, anthracy-
clines, BRAF inhibitors, platinum drugs, protease inhibitors
and tyrosine-kinase inhibitors against both haematological and
solid tumours (112). SINE compounds, KPT-185, KPT-249 and
KPT-330, were able to sensitize myeloma cells to doxorubicin,
bortezomib and carfilzomib and phase I/II clinical are cur-
rently underway (112,113). A combination therapy using KPT-
330 and gemcitabine has also been found to synergistically
enhance cell death in vitro and in vivo in pancreatic cancer
(114).
Targeting Nuclear Import via KPNB1 and KPNA
The field of nuclear import inhibitors, while not as advanced
as that of nuclear export inhibitors at present, is growing
(Table 2). Most commonly, KPNB1 and the KPNA isoforms
work together to transport cargoes into the nucleus, although
KPNB1 can also transport cargo independently. Therefore, tar-
geting KPNB1 may have a broader spectrum of import inhibi-
tion while targeting a single KPNA isoform would considerably
increase specificity. Pioneering work in the search for Karyo-
pherin alpha/beta 1 inhibitors was started by Lin et al. in
1995. They, among others, found that a cell-permeable peptide
containing the NLS of the NFjB p50 subunit was able to inhibit
the nuclear import of transcription factors containing a NLS,
such as NFjB, NFAT, AP-1 and STAT1 (115,116). The peptide
became better known as cSN50.1 and more recently has been
found to target both SREBP/KPNB1- and KPNA/NLS-cargo-
mediated import through two separate mechanisms. The inhi-
bition of SREBP/KPNB1-mediated import is thought to be
through the binding of the peptide’s SSHR motif with KPNB1.
The peptide is also able to bind all KPNA isoforms, except
KPNA6, with the highest affinity for KPNA1 and in that way
plays a role in the import inhibition of transcription factors
containing a NLS (103). Kosugi et al. also used peptide inhibi-
tor design to target the KPNA/B1 import pathway which
yielded two high-affinity peptides namely; Bimax1 and Bimax2.
They were found to specifically target the KPNA-mediated
import pathway and had no effect of KPNB1-only mediated
import although they showed no specificity for Karyopherin
alpha isoforms in mammalian cells (105). Unfortunately, the
chemotherapeutic ability of these import inhibitors remains
unknown. A peptide, M9M, has also been designed to inhibit
nuclear import but rather by targeting TNPO1 which recog-
nises a PY-NLS (108). M9M was used to elucidate the role of
TNPO1 in mitosis but its role in cancer has not been explored
(75). An antiparasitic antibiotic, Ivermectin, already on the
market, has also been found to bind non-specifically to
KPNB1/KPNA preventing binding to the cargo proteins (104).
Although Ivermectin has been shown to have anticancer
effects this seems to be through a mechanism of action unre-
lated to nuclear import inhibition (117).
Karyostatin 1A was the first small-molecule inhibitor of
KPNB1-mediated nuclear import to be described. Its mecha-
nism of action is thought to be through blocking the binding of
RanGTP to KPNB1 disrupting the KPNA/B1 import pathway
(106). The potential of this compound including its anticancer
effect has not been explored to date. Another small-molecule
inhibitor of nuclear import, Importazole, developed by Soder-
holm et al., was found to interfere with the interaction
between RanGTP and KPNB1 and specifically disrupts KPNB1-
mediated import without affecting Transportin or XPO1-
mediated transport (107). Importazole successfully inhibited
NFjB p65 nuclear localisation in myeloma cells and induced
apoptosis without affecting normal plasma cells, showing
promise as an anticancer compound (118). Although no studies
have been published using nuclear import inhibitors in combi-
nation with currently available chemotherapeutic agents it
may be an area of interest following the potential success of
combination therapies with nuclear export inhibitors.
Although other members of the Karyopherin family, such
as CSE1L, show promise as cancer therapeutic targets, no
inhibitors are available for any of the other transport proteins
as yet. The targeting of other nuclear transport proteins that
have a more limited selection of cargoes may have value as
anticancer strategies. For this to occur, their association with
cancer requires further investigation.
Conclusions and Perspectives
Nuclear transport proteins play an essential role in cellular
functioning. Hence, the increased reliance, of transformed and
cancer cells, on the nuclear transport proteins for their
increased metabolic demands warrants their usefulness as
chemotherapeutic targets. More recently, the potential of
nuclear transporters as cancer biomarkers has been investi-
gated. For example, the secretion of certain Karyopherin pro-
teins into the urine or serum of cancer patients shows diag-
nostic potential, while the differential expression of
Karyopherin proteins in cancer tissue in comparison to normal
tissue suggests that these proteins have potential as prognostic
markers as well. Further research is required to elucidate the
clinical potential of nuclear transport proteins as diagnostic,
prognostic and therapeutic targets.
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